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ABSTRACT OF DISSERTATION 
 
 
MICRONEEDLE-ASSISTED TRANSDERMAL DELIVERY OF NALTREXONE 
SPECIES: IN VITRO PERMEATION AND IN VIVO PHARMACOKINETIC STUDIES 
 
 
Naltrexone (NTX) is a drug used primarily in the management of alcohol dependence 
and opioid dependence. Based on several drawbacks associated with the oral and 
injectable intramuscular dosage forms of naltrexone currently available on the market, 
there is substantial interest in delivering naltrexone transdermally. Although naltrexone 
does not permeate skin at the rate sufficient to reach therapeutic plasma concentrations 
in humans, novel flux enhancement methods such as microneedles help address this 
challenge. Earlier work in humans has demonstrated that the use of microneedles 
achieves plasma concentrations in the lower end of expected therapeutic values. Further 
flux enhancement is desired to decrease the patch area while increasing drug transport 
rates. In the present work, several strategies aiming at in vitro flux maximization were 
employed including: formulation optimization, naltrexone salt screening, and naltrexone 
prodrug design. While naltrexone prodrugs did not reveal any improved permeation 
characteristics formulation optimization through decrease in vehicle microviscosity 
allowed a 5-fold increase in the percutaneous transport rates, and naltrexone glycolate 
salt selection provided an additional 1.5-fold enhancement in flux. One of the key 
observations was a good correlation (R2 = 0.99) between vehicle microviscosity and 
drug transport rates across the microchannel pathway. This finding alone allowed for 
formulation optimization and, at the same time, provided a potential explanation for the 
low permeation of high-concentration naltrexone salts and prodrugs. In vivo studies were 
carried out in Yucatan minipigs using a ―poke and patch‖ microneedle method to deliver 
NTX•HCl. These studies demonstrated that initial plasma concentrations spiked to 2.5 
ng/ml but rapidly dropped to a plateau of below 1 ng/ml. This pharmacokinetic profile 
could be explained by the use of a mathematical model which identified the importance 
of microchannel closure kinetics on drug transport. Also, an estimate of diffusional 
resistance of the viable tissue associated with percutaneous NTX•HCl delivery through 
microchannels was obtained. Its relatively large value suggests that the effect of 
diffusional resistance of the dermis in vivo should not be ignored and must be accounted 
for in order to obtain a good in vitro-in vivo correlation. 
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Chapter 1 
Statement of the Problem  
 
Alcohol and narcotic addiction are serious societal problems. Over 20 million Americans 
needed treatment for either alcohol or illicit drug abuse in 2009. Of these, only about 
11% received adequate therapy, showing no change in treatment trends as compared to 
those needing treatment in previous years [1]. Apart from the direct impact on health, 
illicit drug abuse alone costs society an estimated $181 billion in lost productivity, 
criminal justice and related areas [2]. Modern approaches to alcohol and opioid addiction 
treatment usually combine psychotherapy and counseling with medication.  A variety of 
different treatment categories are broadly used including: medical detoxification, long-
term and short-term residential programs, outpatient drug-free treatment, agonist 
maintenance treatment for opiate addicts (methadone) or narcotic antagonist treatment 
(naltrexone), to name a few. Methadone use is limited due to serious cardiotoxicity, 
which has been linked to a high number of sudden deaths [3].  
From a drug delivery point of view, naltrexone presents several challenging 
characteristics. Naltrexone (NTX) is a drug used primarily in the management of alcohol 
dependence and opioid dependence [4]. Our interest in delivering naltrexone 
transdermally is well-founded and based on several drawbacks associated with the oral 
and injectable intramuscular dosage forms of naltrexone currently available on the 
market. These include: significant first-pass effect, gastrointestinal side effects and poor 
patient compliance [5]. Although NTX does not permeate skin at the rate sufficient to 
reach therapeutic plasma concentrations in humans, novel flux enhancement methods 
such as microneedles (MN) can address this limitation [6]. The use of MN can 
substantially increase the rate of drug delivery through skin and create a great potential 
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for more effective delivery of drugs, including compounds that previously could not be  
delivered via this route of administration [7, 8]. Naltrexone‘s mode of action results in 
attenuation of euphoric effects of opioids and its effectiveness is well-established [4, 9-
13]. The rationale behind NTX treatment is that the repetitive lack of desired 
alcohol/opiate effects will, over time, result in the decrease of craving thereby breaking 
the dependence.  NTX itself, being an antagonist, does not present a problem of 
potential misuse [14, 15]. 
In the United States, naltrexone is currently available under three brand names: ReVia®, 
Depade® and Vivitrol®. The first two are available in the form of naltrexone hydrochloride 
50mg tablets with a daily dosing regimen, the latter is a naltrexone 380mg extended-
release intramuscular injection administered monthly. Additionally, low-dose naltrexone 
is prescribed for other therapeutic indications such as auto-immune disorders (multiple 
sclerosis). The oral dosing regimen is less than optimal and one of the main issues 
related to the NTX therapy is poor patient compliance. Moreover, gastrointestinal (GI) 
tract side effects as well as low and varied interpatient bioavailability (5-40 %) are further 
disadvantages of this route of administration [5]. In 2004, the Food and Drug 
Administration (FDA) approved Vivitrol®, which is an injectable formulation that can be 
used as an alternative. Vivitrol® injection overcomes some of the limitations associated 
with the oral formulations including the lack of compliance, pharmacokinetics with large 
daily fluctuations in plasma concentration, and GI toxicity. However, this formulation 
requires patients to come to a healthcare center to obtain a painful intramuscular 
injection. Moreover, in August 2008 FDA released an alert notifying healthcare 
professionals of the risk of adverse injection site reactions in patients receiving Vivitrol®. 
Serious injection site reactions including abscesses and drainage and cases of tissue 
necrosis needing surgical intervention have been reported [16]. Additionally, in case of 
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an emergency pain treatment, when medical opiate administration is necessary patients 
on Vivitrol® require very high opioid doses to counteract the presence of NTX. Hence, 
intramuscular injections are not an optimal route of NTX administration either. In general, 
the major problem associated with naltrexone therapy is noncompliance. A favorable 
treatment outcome requires effective counseling and careful monitoring of medication 
compliance. 
Transdermal drug delivery represents a novel and alternative route of naltrexone 
delivery to the existing NTX formulations. Among potential benefits related to this 
method of drug administration are: elimination of the first-pass effect, lack of pain, 
prolonged zero-order delivery, transdermal patch self-application and better patient 
compliance [8, 17]. Typically, drug molecules delivered across skin at desired rates 
possess a range of favorable physicochemical properties that allow fast passage 
through the skin barrier. The overall barrier properties of skin (diffusional resistance) 
towards most xenobiotics can be well approximated by the barrier properties of the 
stratum corneum (SC) alone [18]. This outermost layer of skin, due to its structure and 
composition, greatly limits the pool of molecules that can be delivered percutaneously. 
Low molecular weight (<500 Da), logKo/w value about 2 and low melting point are usually 
evoked as critical parameters for a good transdermal delivery candidate [19]. Previous 
studies in our lab showed that NTX does not possess the necessary physicochemical 
properties for transdermal delivery at satisfying rates to achieve therapeutic 
concentrations in vivo [20]. Modifying NTX‘s physicochemical properties by the synthesis 
of its prodrugs and salts can significantly alter transdermal flux values. A prodrug is an 
inactive precursor of a drug, converted into its active form in the body by normal 
metabolic processes or chemical hydrolysis. It was shown that some straight-chain ester 
3-O-NTX prodrugs afforded superior flux values over the parent drug [21]. These flux 
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however, were below values that would result in desired plasma levels in humans. 
Nonetheless, recourse to a new microneedle flux enhancement method proved to 
significantly improve percutaneous NTX delivery [6]. Microneedle use relies on the 
creation of transient disruption in the stratum corneum. As a result, the skin barrier 
properties are compromised and drug permeation is facilitated.  
Microneedles offer several advantages over other enhancement methods and can be 
seen as a hybrid between a traditional transdermal delivery and subcutaneous 
injections. A great variety of microneedle types have been reported in scientific literature 
and the increasing number of publications suggests a great potential and interest in this 
particular technique [22-28]. Typically, ―microneedles‖ denote an array of 200-1000 µm 
long protrusions fixed on a surface able to perforate the stratum corneum. Among 
popular types of microneedles are stainless steel solid microneedles [29]. In the most 
basic mode of application, MN are used to perforate SC and removed; subsequently a 
transdermal patch is applied – also referred to as a ―poke and patch‖ method. In this 
way, microchannels (pores) are created in the skin allowing drug molecules to bypass 
the formidable barrier of SC and diffuse freely through deeper layers of the skin and into 
the microcirculation. Microneedles offer an advantage of simplicity over other physical 
enhancement methods and their application is painless [25, 30, 31]. In the case of MN-
enhanced transdermal drug delivery, the traditional limitations on the lipophilicity and 
molecular size of a permeating molecule don‘t seem to hold. This creates great potential 
for the delivery of either hydrophilic and/or large molecules. The lack of optimal 
lipophilicity requirement brings about the option of using ionized, and therefore more 
water-soluble, molecules. In consequence, the driving force for diffusion can be 
increased by raising the drug concentration gradient across skin [6]. It has been reported 
that the application of MN in conjunction with NTX•HCl-containing transdermal patches 
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on humans afforded plasma concentrations in the lower end of expected therapeutic 
values [32]. It is the goal of this project to further increase the transdermal delivery of 
naltrexone (NTX) from a transdermal patch and gain a better understanding of 
microneedle-enhanced transdermal drug delivery, in terms of critical parameters 
governing the transport. The development of a mathematical model describing in vivo 
drug transport would facilitate optimization of future drug delivery systems.  
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Chapter 2 
Research hypotheses 
 
The thesis project is based on two major objectives. The first, narrower in scope, is to 
increase the transdermal delivery rate of naltrexone from a transdermal patch through 
microneedle-treated (MN-enhanced) skin. The second, wider in scope, is to gain better 
understanding of microneedle-enhanced transdermal drug delivery in terms of critical 
parameters governing the transport.  
The major hypotheses that have driven this research project are as follows: 
 
Hypothesis 1: Charged naltrexone species with high aqueous solubility and low 
molecular weight will increase the percutaneous flux through MN-treated skin. 
It is commonly recognized that the physicochemical properties of the permeant affect its 
ability to cross the stratum corneum membrane in traditional passive transdermal drug 
delivery. Properties such as ionization, molecular weight, lipophilicity as measured by 
logKo/w, hydrogen bonding potential, heat of fusion or melting point determine the 
solubility and permeability of a given drug. The solubility and permeability, in turn, will 
determine the maximum flux across skin. With respect to MN-enhanced permeant 
transport, the critical physicochemical parameters that would allow maximizing the flux 
have not been explicitly described. It is hypothesized that the presence of molecular 
charge and low molecular weight will provide high aqueous solubility resulting in high 
driving force for diffusion. Also, low molecular weight is anticipated to translate into high 
permeability through microchannel pathway due to its effect on NTX diffusivity in the 
microchannels. 
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Hypothesis 2: Non-rate-limiting transdermal formulation of low microviscosity will 
increase the naltrexone percutaneous flux through MN-treated skin. 
Although many literature reports focused on the microneedle effectiveness in the 
percutaneous drug delivery area, one aspect that lacks extensive examination is the 
influence of the formulation on the drug transport rates across MN-enhanced skin. In 
passive transdermal drug delivery the use of permeation enhancers in the formulation 
has been shown to substantially increase percutaneous flux. However, in the presence 
of microchannels in the skin it is anticipated that the major diffusional barrier of the 
stratum corneum will be bypassed and the formulation characteristics may have a 
radically different effect.  It is hypothesized that the selection of a low-microviscosity 
aqueous-based formulation will provide high mobility for naltrexone and a non-rate-
limiting environment for permeation across MN-treated skin. Additionally, it is 
hypothesized that the elimination of formulation excipients, which can permeate into 
dermis increasing its diffusional resistance, will allow further improvement of flux. 
 
Hypothesis 3: The analysis of in vitro-in vivo correlation in the naltrexone 
permeation data will elucidate the effect of in vivo microchannel closure on the 
MN-assisted drug delivery and allow calculation of diffusional resistance of 
dermis separating microchannel from dermal microvasculature. 
Typically, in traditional passive transdermal drug delivery the establishment of in vitro-in 
vivo correlation is based on the fact that stratum corneum constitutes the major barrier 
for drug diffusion. Therefore, accounting for the different skin surface area involved in 
diffusion alone allows, in many cases, for providing a reasonable link between in vitro 
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and in vivo conditions. In the case of MN-assisted transport, several additional factors 
must be taken into account. The contribution of flux through microchannels as compared 
to flux across the skin around the microchannels, the diffusional resistance of the dermis 
and the kinetics of microchannel closure are expected to play a substantial role in 
establishment of the vitro-in vivo correlation. It is hypothesized that the development of 
mathematical model accounting for the above phenomena will allow for assessment of 
the role of microchannel closure on drug transport. Specifically, it is hypothesized that 
the time-dependent changes in microchannel electrical impedance will be mimicked by 
corresponding changes in microchannel permeability to NTX. Also, it is hypothesized 
that it will be possible to assess the diffusional resistance of the dermis separating 
microchannel from dermal microvasculature . 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Mikolaj Milewski 2011 
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Chapter 3 
Research plan 
 
3.1. Development of a mathematical model for in vitro microneedle-assisted drug 
delivery 
MN-assisted drug permeation can be analyzed without the use of any mathematical 
model by comparison of drug apparent permeability coefficients for MN-treated and 
untreated skin. Such approach allows quick estimation of the ―enhancement ratio‖, which 
represents the fold-increase in flux (permeability coefficient) as a result of the MN skin 
treatment. However, this simple analysis lacks insight and is not easily transferable to 
different experimental conditions. Hence, a mathematical model which accounts for 
existence of two parallel routes of permeation and individual diffusional resistance of 
skin layers will be introduced. This model will accommodate the change in the number of 
microchannels created by microneedles, assign the permeability coefficients to 
unionized and ionized species permeating through either MN-treated or untreated skin, 
and account for different skin thickness used in the in vitro diffusion experiments.  
 
3.2. Characterization of the formulation physicochemical properties and their 
influence on the flux of naltrexone hydrochloride across microneedle-enhanced 
Yucatan minipig skin 
The field of transdermal formulation optimization for MN-assisted drug delivery is not 
well developed and an abundance of literature in the area does not exist. In the 
presence of microchannels the diffusional resistance of the skin decreases substantially 
and transdermal formulation is expected to exert an even more pronounced effect on the 
overall drug transport rate than in passive percutaneous transport. Hence, the effect of 
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parameters such as micro- and macro-viscosity of the formulation, as well as its osmotic 
pressure and pH will be examined. A Brookfield DV-III LV programmable cone/plate 
rheometer with a CPE-40 spindle will be used for measuring viscosity of the donor 
solutions. All determinations will be carried out at 32°C using a circulating water bath 
TC-102. Osmotic pressure will be determined through use of a freezing-point osmometer 
(Micro-Osmette™ from Precision Systems, Inc.). Additionally, pH measurements will be 
carried out using a pH-meter (Sentron Titan benchtop meter). 
 
3.3. Characterization of the physicochemical properties and determination of in 
vitro microneedle-enhanced transdermal flux of naltrexone prodrugs across 
Yucatan minipig skin 
Physicochemical parameters of the permeant such as ionization, molecular weight, 
lipophilicity as measured by octanol-water partition coefficient (logKo/w), and melting 
points play an important role in the design of a successful transdermal drug candidate. 
These parameters affect permeability coefficients and solubility, which in turn determine 
flux. Additionally, in the case of prodrugs, the chemical and enzymatic stability are 
critical. A prodrug should possess adequate stability in the formulation but be quickly 
metabolized to the active form either by chemical or enzymatic processes in vivo.  The 
objective of this study is to investigate the stability, solubility and permeation of various 
groups of naltrexone prodrugs. Prodrug stability studies in donor (0.3M acetate buffer pH 
5.0) and receiver solutions (25mM HEPES-buffered Hanks‘ balanced salt solution pH 
7.4) will be initiated by charging a 10 ml volume of hydrolysis media thermostated at 32 
°C with ≈1 mg of prodrug, filtering the solution through a 0.45µm nylon syringe filter 
(Acrodisc® Premium 25mm Syringe Filter) and taking samples of the filtrate over a period 
of 120 h. Samples will then be diluted with acetonitrile ACN-water 70:30 (v/v) for high-
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performance liquid chromatography HPLC analysis. Apparent pseudo-first-order 
hydrolysis rate constants will be estimated from the slope of the log-transformed amount 
of prodrug remaining in the medium over time. Prodrugs, which possess adequate 
stability, will be further tested in in vitro permeation studies using MN-treated skin. A 
PermeGear flow-through (In-Line, Riegelsville, PA) diffusion cell system will be used for 
permeation studies through MN-enhanced Yucatan minipig skin. The flow rate of the 
receiver fluid will be set at 1.5 ml hr-1 in order to provide sink conditions as well as mimic 
physiological conditions. HEPES-buffered Hanks‘ balanced salts solution will be used as 
receiver solution to preserve tissue viability [33]. The temperature of the diffusion cells 
will be maintained at 32 °C (the temperature of the skin) with a circulating water bath. 
The diffusion experiment will be initiated by charging the donor compartment with 250-
400 μl of donor solutions. Samples will be collected every six hours and analyzed by 
HPLC. The cumulative quantity of drug collected in the receiver compartment will be 
plotted as a function of time. The flux value for a given experiment will be obtained from 
the slope of the steady-state portion of the cumulative amount of drug permeated vs. 
time data. In addition, the concentration of the drugs in the skin will be determined after 
the 48h experiment. Transepidermal water loss (TEWL) will be used to determine the 
barrier integrity of the skin. 
 
3.4. Characterization of the physicochemical properties and determination of in 
vitro microneedle-enhanced transdermal flux of naltrexone salts across Yucatan 
minipig skin 
In the passive transdermal delivery, the physicochemical parameters of the permeant, 
such as: ionization, molecular weight, lipophilicity as measured by logKo/w, and melting 
points, play an important role in the design of a successful transdermal drug candidate. 
These parameters affect permeability coefficients and solubility, which, in turn, 
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determine flux.  The objective of this study is to investigate the pH-dependent solubility 
and permeation of various naltrexone salts. A naltrexone salt, which possesses the 
highest aqueous solubility at pH 5.0 will be further tested in in vitro permeation studies 
through MN-treated skin. pH-solubility profiles of naltrexone salts will be determined at 
25 °C. At first, excess solids (NTX salts) will be added to glass vials containing 2 ml of 
water. Solubility at different pH values will be determined by stepwise titration with HCl 
or NaOH solutions. At each addition of HCl or NaOH, the suspension will be equilibrated 
for 24 h, the pH value will be recorded, and an aliquot will be removed and spin-filtered 
for 1 min in VWR centrifugal filters (0.2 µm membrane) at 25 °C. The filtrate will be 
diluted with an adequate amount of acetonitrile (ACN):water 70:30 (v/v), and resulting 
solution analyzed by high pressure liquid chromatography (HPLC).  A PermeGear flow-
through (In-Line, Riegelsville, PA) diffusion cell system will be used for permeation 
studies through MN-enhanced Yucatan minipig skin. The flow rate of the receiver fluid 
will be set at 1.5 ml hr-1 in order to provide sink conditions as well as mimic physiological 
conditions. HEPES-buffered Hanks‘ balanced salts solution will be used as receiver 
solution to preserve tissue viability. The temperature of the diffusion cells will be 
maintained at 32 °C (the temperature of skin) with a circulating water bath. The diffusion 
experiment will be initiated by charging the donor compartment with 250-400 μl of donor 
solutions. Samples will be collected every six hours and analyzed by HPLC. The 
cumulative quantity of drug collected in the receiver compartment will be plotted as a 
function of time. The flux value for a given experiment will be obtained from the slope of 
the steady-state portion of the cumulative amount of drug permeated vs. time data. In 
addition, the concentration of the drugs in the skin will be determined after the 48h 
experiment. Transepidermal water loss (TEWL) will be used to determine the barrier 
integrity of the skin. 
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3.5. Development of a mathematical model for in vivo microneedle-assisted drug 
delivery 
The mathematical model for in vitro-in vivo correlation will include the following three 
components: a diffusion through the MN-treated skin module, a microchannel closure 
module, and a compartmental pharmacokinetic module. The first module will be 
analogous to the mathematical model for in vitro microneedle-assisted drug delivery 
(3.1). This module will account for existence of two parallel routes of permeation and 
diffusional resistance of skin layers. The second module will account for the kinetics of 
microchannel closure, which has been shown to follow approximately exponential 
behavior. Finally, the third module, will be a typical compartmental pharmacokinetic 
model with systemic clearance as a major parameter.  
 
3.6. Determination of plasma pharmacokinetic parameters and in vivo MN-
enhanced transport of naltrexone hydrochloride in Yucatan minipig 
Yucatan minipig skin has been recognized as a good model for human skin [34-36]. 
Additionally, due to its size Yucatan minipig is expected to be an approximate model of  
human pharmacokinetics. The pharmacokinetic (PK) parameters of I.V. NTX•HCl will be 
determined. Data analysis will be carried out using compartmental modeling 
(WinNonLin, Pharsight®). After gathering the I.V. data, 3-day transdermal studies with a 
formulation optimized for MN-enhanced transdermal delivery of naltrexone (3.2) will be 
performed. The plasma concentrations of naltrexone will be evaluated with a LC-MS-MS 
method. In the sample preparation procedure, all standards and samples of volume 200 
µl will be extracted with 1ml of acetonitrile:ethyl acetate (1:1, v/v), resulting in protein 
precipitation. The mixture will be vortexed for 15 s and centrifuged at 12000xg for 20 
min. The supernatant will be transferred to a glass tube and evaporated under nitrogen. 
Then, the residue will be reconstituted in 100 µl acetonitrile, sonicated for 10 min and 
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vortexed for 15 s. Samples will be transferred into low volume inserts in HPLC vials and 
injected into the LC-MS-MS system. Positive mode atmospheric pressure chemical 
ionization will be used for detection of naltrexone (APCI+). The analysis of the in vivo 
data will provide evidence regarding the critical factors involved in MN-assisted drug 
transport in Yucatan minipig. The focal points of interest include: estimating the 
diffusional resistance of the dermis in vivo, kinetics of microchannel closure and the use 
of the mathematical model (3.5) to predict the potential of delivering other drugs via a 
MN-enhanced skin route. 
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Chapter 4 
Background and literature review 
 
4.1. Introduction 
Skin has evolved to provide an efficient barrier at the interface of the external 
environment and the body. The formidable skin barrier properties greatly limit the 
permeation of xenobiotics [18, 37]. This protection against toxicological agents makes 
life in a terrestrial environment possible. However, the same skin structure that is 
advantageous in terms of the protection against harmful stimuli is also a drawback from 
the perspective of percutaneous drug delivery. As compared to the traditionally 
employed oral route of drug delivery, transdermal drug administration can offer several 
advantages, e.g. avoidance of hepatic first-pass metabolism, time-independent 
approximately zero-order delivery, the ease of administration, and the possibility of 
immediate termination of the treatment when needed [8]. However, the aforementioned 
formidable barrier properties of the skin limit the pool of drugs that can be effectively 
delivered to the systemic circulation. One of the drugs that does not permeate the skin at 
a sufficiently high rate to provide therapeutic plasma concentrations in vivo is naltrexone. 
To address this obstacle, permeation enhancement methods can be used [17, 38]. It 
was demonstrated that with the help of microneedles, which create transient 
microchannels through the skin barrier, naltrexone transport rates can be increased 
significantly [6, 32, 39]. 
In the following paragraphs the structure of the skin will be discussed in more detail and 
the potential challenges of traditional transdermal drug delivery will be presented. Then, 
the prevalence of the alcohol and opioid addiction in the U.S.A. will be described and the 
need for better drug therapies emphasized. Finally, current naltrexone dosage form 
limitations will be addressed and the employment of transdermal enhancement methods 
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to overcome the insufficient permeation rate of naltrexone across skin will be discussed 
further. 
 
4.2. Structure and function of the skin 
The skin is the largest organ in the human body. Its primary functions are related to the 
protection against harmful external conditions and containment of bodily fluids. In an 
average adult human skin surface area is close to 1.8 m2 and is the largest organ of the 
human body [40]. The thickness of skin varies with anatomical site and can be as low as 
approximately 1 mm up to 4 mm. Typically, it weighs 15 % of the total body weight [41, 
42]. The primary protective function is exerted through stratum corneum which provides 
an interface of significant barrier properties between the organism and its external 
environment. Not less important is skin‘s role in preventing water loss and ensuring 
proper water homeostasis, protecting against ultraviolet radiation, and microbial 
infection. In one‘s lifetime skin suffers from multiple physical and chemical insults, 
however, skin possesses a formidable ability for self-repair. Small flaws in the continuum 
of the barrier, such as scratches and minor surface wounds, are healed quickly and 
without any permanent loss of the skin function at the affected site. The rate of wound 
healing is an area of active research as it is of major clinical and scientific interest [43-
46]. Skin‘s ability to recover from minor insult is of substantial importance for the current 
work as the viability of the microchannels created by microneedles determines the time 
window of MN-enhanced drug delivery through a ―poke and patch‖ method and will be 
briefly addressed in Chapter 10. On the other hand, after suffering from a major insult, 
the skin does not possess the ability to fully restore the original functional state of the 
barrier. It manifests itself as scar formation – not only the skin‘s mechanical properties 
are permanently impaired but also appendages such as hair follicles are never 
regenerated [18]. Another important function of the skin is related to the temperature 
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regulation. Under conditions of very cold weather, the peripheral blood flow through skin 
is diminished with the aim of protection of body organs such as brain and heart that are 
vital for survival. Conversely, under hot weather conditions peripheral blood flow is 
increased and eccrine glands produce significant amount of sweat to reduce the body 
temperature. This temperature regulation exerted by skin is an important contributor to 
overall body homeostasis. Additionally, biochemical metabolites are also excreted with 
eccrine glands. The mechanical strength of the skin is a necessary prerequisite for 
proper functioning in the natural environment and enables to resist physically harmful 
stimuli [37]. The typical cross-section of human skin reveals the existence of two distinct 
layers: epidermis and dermis as shown in Figure 4.1. The top-most epidermis can be 
further divided, from outside inward, into stratum corneum, stratum lucidum, stratum 
granulosum, stratum spinosum and stratum basale. At the interface between epidermis 
and dermis the basement membrane provides adhesion of the two strata. The dermal 
layer lies directly above the subcutaneous fat layer. 
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Figure 4.1. A cross-sectional diagram of human skin 
Reprinted with permission from Nature 445, 874-880 (22 February 2007) 
 
4.2.1. Stratum corneum 
The stratum corneum (horny layer) is the outermost layer of the epidermis. It is also the 
most distinct layer of the skin in the sense that its composition imparts the barrier 
properties to the whole skin. The anatomy of stratum corneum is substantially different 
from all other skin layers. The bulk of this stratum is built of large, flat, and hexagonal 
cells. At this stage of final differentiation, the cells are dead and fully keratinized. The 
horny layer undergoes constant renewal through upward migration of the cells from the 
underlying viable epidermis and shedding off of the topmost cells in the process called 
―desquamation‖. The complete turnover of the horny layer takes around two weeks in 
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healthy humans [37]. An individual corneocyte is composed of keratin which fills up the 
inside of the cell together with so called ―natural moisturizing factor‖ – a mixture of 
compounds, amino acids and α-hydroxy acids, that provide the adequate water sorption 
potential of the stratum corneum. This assures the proper level of hydration (under 
normal conditions around 20% water) [47]. The outside of the corneocyte forms a 
cornified envelope and is built of insoluble proteins loricirn and involucrin. Cornified 
envelopes of neighboring cells are linked together by corneodesmosomes. These 
structures must be degraded first in order for the outer stratum corneum cells to slough 
off the surface [48, 49]. The exact thickness of the stratum corneum varies depending on 
the region of the body. For example, at the friction surfaces of the body such as palm 
and soles stratum corneum can be up to several hundreds of micrometers thick. 
Typically, however, around 15-20 corneocytes stacked vertically one upon each other to 
form the thin layer around 10-20 µm-thick [50]. The overall structure of the horny layer is 
often referred to as a ―brick and mortar‖ arrangement, with keratinized corneocytes 
corresponding to bricks and intercellular lipids corresponding to mortar [51, 52]. Stratum 
corneum possesses a very dense structure that makes its physicochemical properties 
stand out as compared to all other skin strata. The exceptional lipid composition of the 
―mortar‖ built of long chain ceramides, free fatty acids, and cholesterol in approximately 
equimolar ratio imparts unique lipid phase behavior. Unlike in the phospholipid-based 
membranes, the horny layer lipids are mainly present in the crystalline phases, with 
smaller subpopulation of lipids in the liquid phase [53]. Both the crystalline nature and 
the presence of a 13 nm lamellar strata of lipids between corneocytes are believed to be 
critical for the proper functioning of the skin barrier. The intercellular lipids are organized 
in the lipid bilayers with alternating hydrophilic and hydrophobic strata as demonstrated 
in Figure 4.2.  
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Figure 4.2. Electron micrograph showing the stacked and patterned lamellar 
membrane sheets in a single intercellular space in mouse SC postfixed with 
ruthenium tetroxide. The cornified envelope of the lower corneocyte is clearly 
visible (arrows); ICS, intercellular space; K, keratin contents of the corneocytes 
bordering the intercellular space. Original magnification x 200,000. 
Reprinted with permission from J. Invest. Dermatol. 2003 Aug;121(2):231-41. 
 
Thanks to the unusual composition of the horny layer it is often distinguished as a 
unique layer of different and very high diffusional resistance as compared to any other 
portion of the skin. From the drug delivery perspective it means that the horny layer 
represents the rate-determining step in the diffusion across skin process. In other words, 
the rate of permeation through the skin can be well-approximated by the permeation 
across stratum corneum alone. [54]. In its dry state, the intercellular space is filled mostly 
by lipid matrix accounting for 20 % of the mass while the intracellular space is 
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predominantly composed of fibrous, 65-70 %, and non-fibrous, 5-10 %,  protein [50]. 
While under normal humidity conditions the stratum corneum absorbs water from the 
environment to the extent of around 20% of its dry mass, under humid or aqueous 
conditions the amount of water retained in the stratum corneum may increase several-
fold affecting its physical state – skin becomes more pliable – and facilitating the 
permeation of hydrophilic xenobiotics. On the other extreme, ultra dry conditions cause 
the dehydration of the stratum corneum and render it more brittle which may manifest 
itself as chapped lips or windburned skin. It used to be thought that stratum corneum 
was metabolically inert, and it was treated like a thin lipoidal sheet covering more active 
viable layers of the epidermis. More recently, however, discoveries illustrating that the 
biological and chemical activity of the stratum corneum is very intricate and complex 
have been made [48]. The desquamation involves several enzymes that degrade 
corneodesmosomes in a specific pattern to facilitate the exfoliation process. Although 
the exact nature of those processes is not known, it was suggested that water content 
and pH play a significant role in the activity of these enzymes [55, 56].  
 
4.2.2. Viable epidermis 
Viable epidermis is sandwiched between the dead stratum corneum layer and the 
dermis. It is composed of living cells forming, from outside inward, stratum lucidum, 
stratum granulosum, stratum spinosum and stratum basale. The thickness of this layer is 
around 100-200 micrometers [42, 57]. The stratum basale is the bottom-most layer of 
the epidermis in direct contact with the underlying dermis. This layer of undifferentiated 
cubical cells constantly proliferate producing new cells through mitosis. This constant 
production of cells provides basis for turnover of the skin layers. The complete migration 
of an undifferentiated keratinocyte from the stratum basale to the terminally differentiated 
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corneocyte of the stratum corneum takes around 30-40 days. Cells that migrate upward 
across spinosum layer to stratum granulosum and to stratum lucidum undergo gradual 
differentiation. The processes involved in their differentiation are: elimination of cell 
nuclei, intensive synthesis of keratin, lamellar bodies development [53], and successive 
flattening of the cells. At the flat (non-interdigitated) interface of stratum granulosum and 
stratum corneum the extrusion of lamellar bodies takes place. Polar lipid precursors are 
enzymatically converted into nonpolar products which then form lamellar structures and 
become the intercellular ―mortar‖ surrounding corneocytes [57]. On the other hand, the 
interface between dermis and viable epidermis is highly interdigitated forming many 
ridges and rivets that increase the interaction surface and provide better adhesion of the 
these layers. Chemically, keratinocytes of the stratum basale are attached to the 
basement membranes by proteinaceous hemidesmosomes, which enable anchoring of 
the cells to the dermal layer. From the histological perspective keratinocytes are 
predominant and form the bulk of cells present in the viable epidermis. Additionally, 
Langerhans cells of leukocyte origin are present and exert immunological functions by 
presenting antigens on their surface [47]. Also, melanocytes can be found at the 
epidermal-dermal junction. Their role is the production of melanin, the pigment 
responsible for the darkening of the skin under the control of melanocyte-stimulating 
hormone and ultraviolet light [18]. Other cells, such as lymphocytes and macrophages 
are present in smaller quantities and are also involved in immune response. The 
epidermis is avascular in nature and, in consequence, nutrients and waste products 
must diffuse across the dermal-epidermal junction in order to provide the necessary 
exchange for the living epidermal cells. Similarly, xenobiotics applied to the skin must 
cross the whole epidermis thickness and through the epidermal-dermal junction to be 
finally swept away by the blood flow in the microvasculature and delivered systemically. 
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4.2.3. Dermis 
The dermis is a skin layer situated between the epidermis and subcutaneous fat. The 
typical thickness of this layer is around 1 millimeter, although it varies greatly with 
anatomical site [42, 53, 58]. It may be as thin as 300 micrometers on eyelids and up to 3 
millimeters on the back. The dermis, unlike the epidermis, lacks typical lamellar structure 
although there are fine differences between upper (papillary) dermis and lower (reticular) 
dermis. The structure of the dermis is composed of a complex meshwork of structural 
fibers: collagen and elastin, located in a ground substance made out of a 
mucopolysaccharidic gel. From the perspective of transdermal drug delivery, dermis is 
often viewed as an aqueous gel-like structure with drug molecular mobility being not less 
than 1/10 of that seen in water [18]. Krestos et al. suggested that the diffusivity of free 
drug in dermis is around 3.7-fold lower than in water showing no selectivity with respect 
to physicochemical properties of the drug [59]. For most drugs this skin layer provides 
minimal diffusional resistance, although it may change for highly lipophilic drugs, which 
may experience low solubility in the aqueous environment of the dermis [60]. A variety of 
structures are present in the dermis, most notably, sensory nerve endings, skin 
appendages such as hair follicles, sebaceous glands, eccrine glands, and apocrine 
glands. Eccrine (sweat) glands produce sweat, a slightly acidic dilute salt solution of pH 
5, believed to play a crucial role in the protection against the excess microbial growth on 
the skin surface. These glands are stimulated in response to heat and emotional stress. 
The sebaceous glands, colocalized with hair follicles, secrete sebum; a lipophilic 
substance composed mainly of free fatty acids, waxes, and triglycerides, which lubricate 
the skin surface and help maintain the surface pH at around 5. Although dermis is mostly 
acellular, fibroblasts responsible for the production of structural fibers and mast cells 
synthesizing the ground substance can be found. It is noteworthy that skin appendages 
such as hair follicles and sweat ducts, which extend to the surface of the skin across 
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stratum corneum, can be seen as offering an alternative permeation pathway for 
molecules permeating the skin. These shunt routes are thought to play some role in the 
early times of the permeation process for some polar molecules, but their contribution to 
the overall permeation is typically negligible because of the very limited area of around 
0.1% of total skin surface available for this route [61, 62]. 
 
4.2.4. Microvasculature 
Cutaneous vasculature originates from deeper-residing arterial vessels and muscles. It 
forms two separate horizontal plexuses in the dermis, which are connected through 
vertical vessels [42] as demonstrated in Figure 4.3. The superficial (papillary) plexus is 
located at the interface of the papillary and reticular dermis and nourishes papilla 
through vertical vascular loops. The arterioles and venules in the hairpin-like loop are 
connected through dermal capillaries. In the papillary plexus the vessels are represented 
by 25-µm-in-diameter arterioles and venules to 5-15-µm-in-diameter capillaries. The 
capillaries are built of a single fenestrated endothelial cell layer followed by a 
discontinuous outer layer of pericytes and a basement membrane [42]. The deeper 
(reticular) plexus is located close to the dermal-hypodermal junction and provides 
nutrients to hair follicles and eccrine glands. Dermal arterioles and venules of the 
reticular plexus are larger - 50-100 µm in diameter.  
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Figure 4.3. Dermal vasculature 
Reprinted with permission from Reprinted with permission from Dermatology Nursing. 
2005;17(1):62  
 
 
Capillaries of the superficial plexus are located within approximately 0.1 - 0.2 mm of the 
skin surface.  The lymphatic system is also present in the dermis and plays an important 
role in controlling the pressure of the interstitial fluid, removal of excess fluid and eliciting 
immune responses. It originates from blind lymphatic capillaries and forms two plexuses, 
similar to the blood vasculature, one superficial and another deep. Lymphatic system 
may play a role in the percutaneous transport of large molecules such as interferon [63] 
 
4.3. Transdermal drug delivery 
Transdermal drug delivery offers distinct advantages over more ubiquitous oral drug 
delivery. Some of the most notable features of this route of systemic delivery are the 
avoidance of drug stability issues in the gastrointestinal tract and the first-pass effect, the 
ease of application, and approximately zero-order delivery rates that result in steady-
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state drug plasma levels [18]. The major challenge often encountered in the field of 
percutaneous drug delivery is the slow permeation rate across skin [64]. The overall 
therapeutic effect of the therapy mainly relies on the ability to achieve and maintain the 
drug plasma levels in the relevant therapeutic window providing desired pharmacological 
action. The drug plasma levels are controlled by the rate at which the drug is transported 
into the systemic circulation and the rate at which it is removed. Therefore, there is no 
general ―minimum‖ permeation rate that would guarantee the therapeutic success as 
different drugs will possess not only different skin penetration rates, but are also 
characterized by varied systemic clearance values. While the systemic drug clearance 
values are determined by a myriad of complex physiological processes typically 
including renal and hepatic contributions, the drug skin absorption relies mainly on 
passive diffusion. 
 
4.3.1. Routes of penetration 
Upon application of drug formulation to the skin, the permeant must first passively 
diffuse out of the vehicle.  When released from the formulation, it partitions into one of 
the permeation routes available through the stratum corneum. The main permeation 
pathway is a function of the physicochemical properties of the drug in question [54]. The 
pathways available include: appendageal, transcellular, and intercellular. For a 
moderately lipophilic compound (logKo/w around 0.5 - 3.5) the preferred permeation 
pathway is the tortuous intercellular route via intercellular lipids, or stratum corneum 
―mortar‖ [65]. After diffusing along the preferred stratum corneum permeation pathway 
the drug molecule partitions into an effectively aqueous milieu of the viable epidermis, 
which it needs to traverse to ultimately reach the upper portion of the dermis where the 
microvasculature is located. Next, the drug enters the blood capillaries and is swept 
away by the bloodstream into the systemic circulation. The driving force for passive 
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diffusion is the drug concentration (or more precisely activity) gradient across the barrier. 
It has been shown that for typical, small and moderately lipophilic drugs, that the stratum 
corneum presents the major diffusional barrier. As mentioned earlier, the horny layer is 
not homogeneous in nature; rather, its heterogeneity can be represented by a simplified 
―brick and mortar‖ model. In this analogy, the lipid domain, or ―mortar‖, was identified as 
the barrier to drug diffusion across the stratum corneum. Therefore, the rate-determining 
step in skin permeation would be the permeation through the horny layer alone. The 
diffusional resistance of the viable epidermis and dermis is typically negligible. 
Exceptions to this common scenario are known and are dependent on the 
physicochemical properties of permeants. For very hydrophilic compounds the 
partitioning into the stratum corneum‘s lipid domain becomes unfavorable and 
permeation through a ―polar‖, possibly appendageal, pathway must be taken into 
account to explain the skin permeation [66]. Also, high molecular weight permeants 
possess very low diffusion coefficients within the lipid domain and the existence of an 
alternate permeation route must be accounted for to satisfactorily explain the 
experimental data. The existence of the ―polar‖, possibly appendageal, permeation 
pathway is supported by experiments, which showed no dependence of the permeation 
of hydrophilic and large compounds on their lipophilicity and small dependence on the 
size of the permeant. Both of these observations suggest a permeation pathway distinct 
from the intercellular route. On the other hand, for very lipophilic compounds, the low 
aqueous solubility becomes the limiting factor and the transport through the aqueous 
layers of the skin such as viable epidermis and dermis is rate determining [66].  
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Figure 4.4. A schematic depiction of permeation across stratum corneum via 
intercellular and transcellular routes. Appendageal route is not depicted. 
Reprinted with permission from Eur. J. Pharm. Sci. 14, 101-114 
 
Overall, the three distinct permeation pathways across the horny layer: intercellular, 
transcellular and appendageal are not mutually exclusive, and xenobiotics may pass 
through the stratum corneum by a combination of these routes. The schematic depiction 
of intercellular and transcellular routes is presented in Figure 4.4. The relative 
contribution of each of these pathways to the total flux will depend on the 
physicochemical properties of the drug. The brief characterization of the three pathways 
is presented below. 
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4.3.1.1. Intercellular  
The intercellular pathway is commonly believed to be the main pathway by which the 
low-molecular weight and moderately lipophilic compounds traverse the stratum 
corneum [58, 67].  It is the only continuous phase of the stratum corneum [51]. The 
intercellular lipids form large sheets stacked one upon another forming multiple bilayers. 
The intercellular volume is estimated to be 5 – 30% of the total stratum corneum volume 
[52] with the thickness of a single bilayer around 13 nm [68]. There are between 4 and 
20 such bilayers between two adjacent corneocytes. The permeants diffuse within the 
lipid domain around corneocytes through a tortuous route, which implies that the actual 
length of the permeation pathway is not equal to the stratum corneum thickness, but 
rather is a multiple of it [69]. 
 
4.3.1.2. Transcellular 
The transcellular pathway involves permeants‘ diffusion through the transcellular 
proteinaceous, keratin-filled corneocytes as well as across transcellular lipid domains. 
This is due to the non-continuous nature of the transcellular environment.  Hence, a drug 
that traversed the stratum corneum by this route would experience multiple partitioning 
between the aqueous in nature corneocyte interior and the intercellular lipid domain. It is 
believed that such process would be generally unfavorable and the contribution of this 
pathway to the overall transport of drugs across the horny layer is minimal with some 
exceptions [70, 71]. 
 
4.3.1.3. Appendageal  
The appendageal pathway (shunt pathway) refers to the transport through hair follicles 
and sweat ducts. Due to the anatomy of skin these appendages can be seen as 
providing a permeation pathway that bypasses the barrier of the stratum corneum. The 
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upper portions of hair follicles and sweat ducts extend over the thickness of the horny 
layer and don‘t allow the permeant to diffuse across the highly resistive ―brick and 
mortar‖ structure. Instead, a permeation pathway of lower diffusional resistance 
becomes available. While in most cases the importance of this route is overridden by the 
intercellular one there are examples suggesting otherwise for certain hydrophilic 
compounds. It has been proposed that the appendageal transport is important for large 
polar molecules and ions that would exhibit low permeation rates across the lipid domain 
of the horny layer [61]. Shunt pathway transport is characterized by minimal diffusion lag 
time relative to transport across the stratum corneum lipid domain [72] as can be 
anticipated based on the lack of shunt tortuosity and higher permeability of the sebum 
and sweat as compared to the SC‘s lipid domain. These observations are in agreement 
with expected high drug diffusivity values in the shunts as compared to the horny layer 
lipids. 
Overall, the significance of this route is, however, limited by the fact that the fractional 
area of skin area covered by shunts (hair follicles and sweat ducts) is only around 0.1% 
[61]. Hence, the contribution of this pathway to the total drug flux at steady state is 
typically minor [62].  
 
4.3.1.4. Clearance by the microvasculature 
The presence of the microvascular bed in the dermis is critical from the perspective of 
transdermal drug delivery. Since the epidermis is an avascular tissue, a xenobiotic to be 
absorbed systemically must permeate through the whole thickness of the epidermis and 
top portion of the dermis to reach the blood circulation. The blood flow in the dermis is 
around 0.05 ml/min per g of skin and the surface area of vasculature available for drug 
exchange is approximately the same as the surface area of skin subjected to drug 
permeation (1-2 cm2/cm2 skin) [18]. These characteristics typically are sufficient to 
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provide sink conditions at deeper skin layers. The approach which assumes the 
existence of an absolute dermal clearance at the skin depth of about 0.2 mm, 
corresponding to the superficial plexus, has proven to be adequate for a variety of 
permeants [73]. The cases in which this approach may be unsatisfactory include the use 
of vasoconstrictive agents [74], pathological states of skin [75], or serious compromise of 
the stratum corneum barrier [76, 77]. The presence of the lymphatic system may also 
play a role for absorption of certain xenobiotics. It was shown that the lymphatic flow was 
a significant factor for the clearance of large molecules such as interferon [63].  
 
4.3.1.5. Mathematics of skin diffusion 
The anatomy of human skin is complex, yet in many cases a simple mathematical model 
for studying drug permeation through skin has been successfully employed [54].  In the 
modeling of drug absorption across skin in vitro several assumptions are typically made. 
Generally, during permeation experiments drug concentration in the donor solution is 
maintained constant and receiver solution provides sink conditions throughout the 
duration of the experiment. Moderately lipophilic solutes permeate SC across lipophilic 
domain – intercellular pathway. Assuming that steady-state diffusion across a 
homogenous membrane can approximate steady-state diffusion across stratum corneum 
the Fick‘s first law can be employed: 
 
1
𝐴
𝑑𝑀
𝑑𝑡
= 𝐽𝑆𝑆 = 𝑃𝐶 
 
where Jss is the steady state flux. It is apparent from the above equation that the 
permeability coefficient can be treated as a proportionality constant between the drug 
concentration in the vehicle and flux. Therefore, in an ideal situation, P is a 
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concentration-independent constant describing the intrinsic ability of a molecule to 
traverse the stratum corneum barrier. Additionally, P, having units of distance over time 
can be further broken down into the product of a dimensionless drug partition coefficient 
between the stratum corneum lipid domain and the vehicle Km, and drug diffusivity in the 
lipid domain D divided by the diffusion path length: 
 
𝑃 =
𝐾𝑚𝐷
𝑕
 
 
The introduction of the dimensionless partition coefficient Km is necessary due to the 
difficulty in the direct estimation of the drug concentration in the top layers of the stratum 
corneum lipid barrier. The product of the vehicle drug concentration and the partition 
coefficient Km provides this estimate [66].  
Additionally the steady-state permeation can be also analyzed in terms of the cumulative 
amount of drug permeating across stratum corneum. The amount appearing at the 
receiver side of the membrane as a function of time can be expressed as: 
 
𝑀 = 𝑃𝐴𝐶(𝑡 − 𝑡𝑙𝑎𝑔 ) 
 
where M is the cumulative amount of drug absorbed, P is permeability coefficient, A is 
the area involved in the diffusion, C is the drug‘s concentration in the vehicle, t is time 
and tlag is the lag time. For a simple, homogeneous membrane the lag time can be 
related to the diffusivity of the drug in that membrane D, and the membrane thickness h, 
as follows: 
 
𝑡𝑙𝑎𝑔 =
𝑕2
6𝐷
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The cumulative amount of drug permeated M, plotted against time is shown in Figure 
4.5. In this permeation profile, at any time, the flux equals numerically the slope of the 
line. At late time points, when steady-state is achieved, the slope of the terminal portion 
of the profile corresponds to the steady-state flux. By back-extrapolation of the steady-
state flux to the time axis the estimate for the lag time is obtained. 
 
Figure 4.5. A typical permeation profile of a drug diffusing through human skin 
 from a transdermal formulation. Drug concentration remains constant throughout 
the experiment.  
 
Besides the abovementioned simple, steady-state, conditions the Fick‘s second law of 
diffusion can be employed to solve for the time dependence of flux of cumulative amount 
of solute permeated: 
 
𝛿𝐶
𝛿𝑡
=
𝛿2𝐶
𝛿𝑥2
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where C is permeant concentration in barrier, x is a spatial coordinate, and t is time. In 
other words, the rate of change in drug concentration with time at a point within a 
diffusional field is proportional to the rate of change in the concentration gradient at that 
point. After imposition of the relevant initial conditions and boundary conditions this 
equation serves as a starting point for resolution of many diffusion problems [78]. For 
example, the amount of drug leaving the vehicle taken up by the stratum corneum and 
permeating as a function of time can be calculated as shown in Figure 4.6 [79].  
 
 
Figure 4.6. Normalized cumulative amount of solute penetrating Q/M∞ (curve 2); 
taken up by the stratum corneum (curve 3); and leaving vehicle (curve 4) with 
normalized time. Curves 1 and 5 represent steady state approximations of the 
cumulative amount penetrating the stratum corneum and leaving the vehicle with 
normalized time. 
Reprinted with permission from ―Percutaneous absorption: drugs-cosmetics—
mechanisms-methodology‖ edited by Robert L. Bronaugh, Howard I. Maibach, 1999 
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4.4. Naltrexone  
Naltrexone is used along with counseling and social support to treat alcohol addiction 
and opioid addiction. Pharmacologically, naltrexone belongs to opiate antagonists and 
competes for opioid receptor binding with opiate agonists. The drug exerts its action 
through decreasing the craving for opiates/alcohol. Naltrexone is reported to be of 
greatest use in opioid addicts and motivated alcoholics who participate in psychosocial 
therapy or other compliance-enhancing protocol [80]. 
 
4.4.1. Alcohol and opioid addiction prevalence 
Opiate and alcohol addiction are societal problems. The scale of the problem is best 
presented through statistics. A recent National Survey on Drug Use and Health: Volume 
I. Summary of National Findings [1] showed that: ―Slightly more than half of Americans 
aged 12 or older reported being current drinkers of alcohol in the 2009 survey 
(51.9 percent). This translates to an estimated 130.6 million people, which is similar to 
the 2008 estimate of 129.0 million people (51.6 percent). Nearly one quarter 
(23.7 percent) of persons aged 12 or older participated in binge drinking at least once in 
the 30 days prior to the survey in 2009. This translates to about 59.6 million people. The 
rate in 2009 is similar to the rate in 2008 (23.3 percent). In 2009, during their most recent 
treatment in the past year, 2.9 million persons aged 12 or older reported receiving 
treatment for alcohol use, and 1.2 million persons reported receiving treatment for 
marijuana use. Accordingly, estimates on receiving treatment for the use of other drugs 
were 787,000 persons for cocaine, 739,000 for pain relievers, 517,000 for stimulants, 
507,000 for heroin, 443,000 for hallucinogens, and 421,000 for tranquilizers. In 2009, 
23.5 million persons aged 12 or older needed treatment for an illicit drug or alcohol use 
problem (9.3 percent of persons aged 12 or older). Of these, 2.6 million (1.0 percent of 
persons aged 12 or older and 11.2 percent of those who needed treatment) received 
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treatment at a specialty facility. Thus, 20.9 million persons (8.3 percent of the population 
aged 12 or older) needed treatment for an illicit drug or alcohol use problem but did not 
receive treatment at a specialty substance abuse facility in the past year. These 
estimates are similar to the estimates for 2008 and for 2002. 
 
Figure 4.7. Current, Binge, and Heavy Alcohol Use among Persons Aged 12 or 
Older, by Age: 2009 
Substance Abuse and Mental Health Services Administration. (2010). Results from 
the 2009 National Survey on Drug Use and Health: Volume II. Technical 
Appendices and Selected Prevalence Tables (Office of Applied Studies, NSDUH 
Series H-38B, HHS Publication No. SMA 10-4856Appendices). Rockville, MD. 
 
In 2009, there were 180,000 persons aged 12 or older who had used heroin for the first 
time within the past 12 months. The number of heroin initiates was significantly higher 
than the average annual number of heroin initiates during 2002 to 2008 (slightly over 
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100,000). Estimates during 2002 to 2008 ranged from 91,000 to 118,000 per year. The 
average age at first use among recent initiates aged 12 to 49 was 25.5 years in 2009, 
similar to the average age in 2008. Between 2002 and 2009, the percentage of youths 
aged 12 to 17 perceiving great risk declined for the following substance use patterns: 
using heroin once or twice a week (from 82.5 to 81.0 percent), trying heroin once or 
twice (from 58.5 to 57.0 percent), using cocaine once or twice a week (from 79.8 to 
78.5 percent), trying LSD once or twice (from 52.6 to 48.4 percent), and using LSD once 
or twice a week (from 76.2 to 71.8 percent). 
 
Figure 4.8. Substance Dependence or Abuse in the Past Year among Persons 
Aged 12 or Older: 2002-2009 
Substance Abuse and Mental Health Services Administration. (2010). Results from 
the 2009 National Survey on Drug Use and Health: Volume II. Technical 
Appendices and Selected Prevalence Tables (Office of Applied Studies, NSDUH 
Series H-38B, HHS Publication No. SMA 10-4856Appendices). Rockville, MD. 
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Of the 20.9 million persons aged 12 or older in 2009 who were classified as needing 
substance use treatment but not receiving treatment at a specialty facility in the past 
year, 1.1 million persons (5.1 percent) reported that they perceived a need for treatment 
for their illicit drug or alcohol use problem. Of these 1.1 million persons who felt they 
needed treatment but did not receive treatment in 2009, 371,000 (34.9 percent) reported 
that they made an effort to get treatment, and 693,000 (65.1 percent) reported making 
no effort to get treatment. These estimates remained stable between 2008 and 2009.” 
The alarming magnitude of the problem related to the alcohol and illicit drug abuse calls 
for better treatment options. The introduction of wider in scope and more effective 
treatments could help recovering addicts could carry out a more productive and drug-
free life. A variety of treatment approaches are used in the management of addictions. 
While some rely solely on drug-free educational and behavioral programs, others 
combine them with pharmacotherapy. The pharmacology of addiction is related to the 
endogenous opioid system. 
 
4.4.2. Endogenous opioid system 
Endogenously, the opioid receptor system is involved in signaling of aversive and 
reinforcing effects. Several receptors have been identified in the central nervous system. 
Generally, the activation of μ- and δ-receptors is associated with reinforcing effects. 
Contrarily, selective κ-agonists are typically associated with aversive responses [81]. 
There are three major classes of endogenous opioid ligands including β-endorphins, 
dynorphins, and enkephalins, which exert their pharmacological action via binding with 
the aforementioned μ, δ, and κ opioid receptors [82]. Each class of ligand is 
characterized by different affinity to the receptors. β-Endorphins have a high affinity for 
the μ-opioid receptors and, to a lesser extent, for the δ-opioid receptors. Enkephalins 
have a high affinity for the δ-opioid and, to a lesser extent, for the μ-opioid receptor. 
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Dynorphins show selectivity mainly for the κ-opioid receptors, although a dynorphin 
degradation pathway has been described, which generates enkephalin-like peptides that 
may interact with δ- and μ- receptors  [82]. Opioid receptors respond to the 
administration of exogenous opioids such as heroin. It has been shown that the μ-opioid 
receptor is involved in the reinforcing effects of heroin and alcohol  [11] [83]. The overall 
mechanisms of craving are not fully elucidated, however, there is evidence implying that 
the dopamine system is involved in the control of alcohol intake and craving. Both 
alcohol and opioids seem to induce dopamine release in the nucleus accumbens, 
through activation of the μ-opioid receptors in the ventral tegmental area, which triggers 
a cascade of biochemical reactions involved in the brain reward system  [11, 13]. In 
consequence, the potential of substances behaving as opioid receptor antagonists was 
recognized in the addiction therapies. Multiple studies have shown that opioid receptor 
antagonists such as naltrexone, naloxone, and nalmefene reduce alcohol consumption 
in animals and humans. The pharmacological mode of action is believed to be related to 
the decrease of alcohol-reinforcing effects by inhibiting alcohol-induced dopamine 
release [84]. It has been suggested that μ-opioid receptors play a major role in this effect 
[14, 15].  
 
4.4.3. Therapeutic indications 
Naltrexone was discovered in the 1970s. In 1984 it was FDA-approved for the purpose 
of helping heroin or opium addicts. In 1994, after a successful clinical study with an 
alcohol-dependent population, it was approved for the treatment of alcohol dependence 
[4]. Since then, several clinical studies have confirmed the effectiveness of naltrexone 
therapy [10, 12]. Of note, a large multicenter study carried out in 2001-2004 with over 
1300 patients evaluated the efficacy of medication, behavioral therapies and their 
combinations. The outcomes for patients receiving naltrexone, either with or without a 
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combined behavioral intervention, were significantly better as compared to the placebo 
group [9]. Currently naltrexone is available in two dosage forms, as an oral 25, 50 and 
100 mg tablet (hydrochloride salt) and a 380 mg monthly depot injection (base form). 
Additionally, low-dose naltrexone is used off-label for treatment of HIV/AIDS, cancer, 
autoimmune diseases, and central nervous system disorders [85]. 
 
4.4.4. Limitations of the current naltrexone dosage forms 
Oral 50 mg tablets of naltrexone (ReVia® and Depade®) are, however, related to several 
limitations. Orally administered, naltrexone is extensively metabolized by the liver 
through the first pass effect with an estimated bioavailability ranging from 5% to 40% [5]. 
At high doses, naltrexone causes hepatotoxicity, which limits its use in the alcoholic 
population often characterized by impaired hepatic function in the first place. Hence, 
some patients who could benefit from a dose higher than 50 mg, cannot increase the 
dose due to possible hepatic injury. Additionally, naltrexone is known to cause 
gastrointestinal side effects such as nausea, vomiting and stomach pain [86]. It has been 
established that NTX‘s usage in opioid and alcohol addiction is most effective in highly-
motivated individuals [83]. Poor compliance with the daily regimen is a major issue 
related to NTX therapy [83, 87, 88], which lead to the development of sustained-release 
injectable Vivitrol® formulation. Vivitrol® was FDA-approved in 2004 as an alternative to 
oral dosing. Indeed, the new dosage form addressed some of the drawbacks of the oral 
dosage form. Vivitrol® is a once-per-month, 380 mg, extended-release injectable 
suspension of naltrexone base. It has been used to treat both alcohol and heroin 
addiction [89-91]. A clinical study testing two doses of 190 mg and 380 mg injectable 
NTX has demonstrated a dose-dependent, marked decrease in alcohol consumption 
[92]. Although the depot injection of NTX eliminates the patient compliance issue, which 
limited the practical usefulness of the oral dosage form, it creates the necessity of a visit 
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to a healthcare professional to obtain the injection. Moreover, in 2008, FDA issued a 
postmarket drug safety warning related to the use of Vivitrol®. A risk of adverse injection 
site reactions in patients receiving naltrexone was observed including cellulitis, 
hematoma, and necrosis. Some of the worst injection site reactions required surgical 
interventions [16]. Other shortcomings related to the depot injectable form include 
inconsistent drug release from the depot, patients overcoming the narcotic blockade with 
high doses of opiates and in emergency situations painful surgery to remove a depot in a 
hospital setting [93, 94].  
An alternative to the aforementioned oral and injectable delivery forms is the transdermal 
route of drug delivery. The potential benefits of designing a transdermal form of NTX are 
as follows: the convenience of application of a once-per-week transdermal patch, easily-
adjustable dose, decreased hepatotoxicity potential (avoidance of the first-pass effect), 
and the possibility of immediate discontinuation of therapy, if needed. However, NTX 
does not possess the physicochemical properties to achieve of therapeutically-relevant 
plasma levels in the presence of high systemic clearance in humans [20, 95, 96]. 
However, several delivery enhancement strategies have been investigated. 
 
4.5. Enhancement methods in transdermal drug delivery   
The following discussion is vastly based on a publication section entitled ―Challenges & 
solutions for overcoming the skin permeation barrier‖ by M. Milewski in ―Challenges and 
opportunities in dermal/transdermal delivery‖ by K. Paudel et al. [97]. The microneedle 
section is partly based on the publication entitled ―Current aspects of formulation efforts 
and pore lifetime related to microneedle treatment of skin‖ by M. Milewski et al. [98]. 
Overcoming low skin permeability to xenobiotics is an active field of research and can be 
achieved by a variety of approaches. Their effectiveness and applicability depends on 
the physicochemical nature of the compound. Here, a brief overview of the enhancement 
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methods including chemical methods, physical methods and a prodrug approach will be 
provided. Their applicability to the maximization of percutaneous naltrexone delivery will 
also be discussed.  
 
4.5.1. Chemical methods  
Chemical permeation enhancement is synonymous with the use of chemical permeation 
enhancers. These substances have the ability to transiently compromise the barrier 
properties of the horny layer, thus enabling increased transport rates of xenobiotics 
through skin.  
 
4.5.1.1. Permeation enhancers 
Chemical permeation enhancers facilitate drug permeation across the skin by increasing 
drug partitioning into the barrier domain of the stratum corneum, increasing drug 
diffusivity in the barrier domain of the stratum corneum or the combination of both [99]. 
The heterogeneous SC is composed of cross-linked keratin ―bricks‖ and transcellular 
continuous lipid ―mortar‖ organized in multilamellar strata [51, 100, 101]. Depending on 
the nature of the drug either of these two environments may be the rate-limiting milieu 
(barrier domain) of percutaneous transport. As a consequence, it is anticipated that the 
magnitude of permeation improvement obtained with a given permeation enhancer will 
vary between lipophilic and hydrophilic drugs. Several mechanisms of action are known: 
increasing fluidity of SC lipid bilayers, extraction of transcellular lipids, increase of drug‘s 
thermodynamic activity, increase in SC hydration, alteration of proteinaceous corneocyte 
components, and others [102, 103]. Permeation enhancers are conventionally divided 
into several groups based on their chemical structure rather than the mechanism of 
action. This is partially due to the difficulty determining a primary or mixed mode of 
action for many of them. Also, compounds from the same group can exert their effect 
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through different mechanisms. More than 300 substances have been shown to have skin 
permeabilization potential and this number is still growing. Most known enhancers fall 
into the following categories: alcohols (ethanol, pentanol, benzyl alcohol, lauryl alcohol, 
propylene glycols, glycerol), fatty acids (linoleic acid, valeric acid, lauric acid), amines 
(diethanolamine, triethanolamine), esters (isopropyl palmitate, isopropyl myristate, ethyl 
acetate), amides (1-dodecylazacycloheptane-2-one - Azone®, urea, dimethylacetamide, 
dimethylformamide, pyrrolidone derivatives), hydrocarbons (alkanes, squalen, mineral 
oil), surfactants (sodium laureate, cetyltrimethylammonium bromide, Brij, Tween, sodium 
cholate), terpenes (D-limonene, carvone, anise oli), sulfoxides (dimethyl sulfoxide) and 
phospholipids (lecithin). The importance of water, or hydration of SC, is not to be 
underestimated. A fully hydrated SC (under occlusion) presents lesser diffusional 
resistance to xenobiotics than its dehydrated counterpart. However, a common 
drawback of permeation enhancers is that their efficacy is often closely mimicked by skin 
irritation. In general, the same mechanisms that are responsible for enhanced drug 
transport such as disrupting ordered SC lipid bilayers or corneocyte structural 
organization are also responsible for skin irritation [104]. A possible solution to this 
concern is to identify mixtures of permeation enhancers that exhibit synergistic effects 
[105]. Such mixtures allow decreased irritation potential while maintaining high 
effectiveness. Although the identification of such combinations a priori is difficult, 
Karande et al. successfully used a screening approach to test 5000 binary mixtures of 
chemicals [106, 107]. Several types of synergistic mixtures were identified such as 
sodium laureth sulfate (0.35%) and phenyl piperazine (0.15%) or a 1:1 mixture of 
ethanol and phosphate-buffered saline. Most of the products on the transdermal market 
rely on the effect of occlusion, which is defined as an enhancement technique acting 
through the hydration of the SC. Additionally, drugs such as nitroglycerin (Nitro-Dur®, 
Nitro Disc®, Transderm-Nitro®) use fatty acid esters, and lidocaine (Lidoderm®) urea and 
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propylene glycol as chemical enhancers. Traditionally, chemical enhancers have been 
used to increase the delivery of small molecules and showed only limited success in 
permeation enhancement of macromolecules. Overall, chemical methods, although 
effective, cannot compete with physical enhancement methods, which provide greater 
magnitude of skin permeabilization.  
 
4.5.2. Physical methods  
The oldest and most by far the most popular way of overcoming the skin barrier 
physically is the use of hypodermic needles. In many cases it is the only viable method 
of delivery of poorly absorbable and highly unstable agents. Typically, drug solution is 
forced under piston pressure directly into bloodstream or tissue (skin and muscle). Such 
drug administration results in quick delivery of large amounts of drug. If controlled drug 
delivery over longer periods of time is desired indwelling catheters are used. However, 
both require mechanical perforation of skin with a needle which causes pain and trauma. 
According to Hamilton needle phobia is a medical condition that affects at least 10% of 
the population [108]. This condition is a serious problem in the health care system in the 
sense that people with needle phobia tend to avoid medical care. To address these 
drawbacks, several alternative physical skin enhancement methods such as jet 
injections, dermabrasion, thermal ablation, laser, microneedles, iontophoresis, 
electroporation, ultrasound and combinations of the above are investigated. These 
methods aim at developing more user-friendly and flexible delivery systems able to 
produce bolus-type as well as sustained drug delivery profiles. 
 
4.5.2.1. Jet injections 
Jet injections involve the delivery of liquid or solid particles driven by high pressure 
accelerators across the SC [109]. The concept of drug-delivering jets is not new as first 
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reports date back to the 1940‘s; however, first attempts of using this technology 
translated into limited success. Technology advances in the later decades enabled the 
construction of more reliable and effective devices based on the compressed helium 
[110]. It proved its potential in the delivery of insulin to diabetic patients [111]. This 
method, similar to the hypodermic injection in that it enables rapid delivery of large 
amounts of drug, has resulted in improved patient compliance [112]. Shortcomings of jet 
injections include inability to deliver drugs over longer periods of time; however, they 
seem to be well-suited for vaccination delivery [113]. 
 
4.5.2.2. Dermabrasion 
Dermabrasion has been traditionally used to treat acne, scars and other dermatologic 
and cosmetic conditions [114]. Recently the potential of this technique for transdermal 
drug delivery has been recognized. Mechanistically, crystal microdermabrasion use 
microcrystals blown onto the skin surface to perform the exfoliating process. Several-fold 
improvement in the flux of small molecular weight drugs was shown by various 
researches using this technique [115, 116]. Recent study by Gill et al. investigated the 
effect of microdermabrasion on SC removal in rhesus macaques and human volunteers 
in vivo. The effectiveness of the skin barrier removal correlated with number of passes of 
the mobile dermabrasion device and selective removal without damage to the viable 
epidermis was possible [117].  
 
4.5.2.3. Thermal ablation 
Thermal ablation takes advantage of the external source of thermal energy, which 
propagates into the SC to create microchannels. Heating of the skin surface to hundreds 
of degrees for a very short period of time allows the thermal damage to be limited to the 
SC alone without further heat propagation to live epidermal layers. An interesting 
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publication by Park et al. discussed the effect of heat in skin permeability. Authors 
pointed out skin permeability changes to a model hydrophilic compound at different 
temperature ranges. While an intermittent increase in the skin temperatures to 100-150 
°C causes moderate increase in the flux of a hydrophilic compound, 150-250 °C 
translates into one to two-orders of magnitude increase and temperature of over 300 °C 
add yet another tenfold augmentation in the transdermal flux. Different mechanisms are 
postulated to be responsible for such change at each temperature range [118]. Althea 
Therapeutics developed a PassPortTM system that is comprised of a single-use 
disposable patch and a re-useable handheld applicator. Phase I and II clinical trials have 
been completed for the delivery of insulin via this enhancement system.  
 
4.5.2.4. Laser ablation 
A laser can also be used to thermally ablate parts of the SC creating pores. These pores 
allow drug molecules applied to the surface of the skin to bypass the diffusional barrier 
and gain easy access to the vascularized deeper layers of the skin. This method has 
been able to extract of interstitial fluid to measure glucose levels in diabetic patients as 
well as effective in augmenting transdermal flux of hydrophilic and hydrophobic 
molecules [119-121]. A transdermal laser system P.L.E.A.S.E.® (Pantec Biosolutions) 
has been developed and was granted a European patent in 2009. Furthermore, laser-
assisted drug delivery (Norwood Abbey) was developed and the device has been 
cleared for marketing by the FDA for the delivery of a topically applied local anesthetic. 
The pitfalls of the laser approach are relatively complicated technology and cost. 
 
4.5.2.5. Iontophoresis 
There are several methods that use electric current as means to permeabilize the skin. 
Iontophoresis relies on the continuous electric current to drive charged drug molecules 
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across the skin via electrophoresis and electroosmosis [122]. It is commonly stated that 
iontophoresis mainly provides additional electrochemical driving force for drug transport 
across skin, rather than increases permeability of the skin. First in vivo animal 
investigation showing effectiveness of this approach was carried out at the beginning of 
the 20th century. Since then many drug delivery systems were tested for small 
molecules such as pilocarpine [123] or lidocaine [124], zolmitriptan [125] and large 
molecules such as calcitonin, insulin, parathyroid hormone or vasopressin [126-130]. 
Clinical studies, however, have been limited to the small agents such as lidocaine, 
cortisone or fentanyl [131-133]. Although there have been reports indicating the 
presence of erythema under electrode application site [134] the irritation correlates well 
with the current and as long as the current is low adverse effects are not substantial. 
Both continuous and intermittent delivery of drugs is feasible. A couple of drug delivery 
systems using iontophoretic devices were approved by the FDA in the past, for example, 
lidocaine HCl with epinephrine (Iontocaine® and Lidosite® topical system) and fentanyl 
HCl (IONSYS™) [135]. IONSYS, however, was never marketed in the USA. These 
products have now been listed as discontinued by the FDA (Iontocaine since 2005, 
Lidosite topical system since 2006 and IONSYS since 2008). The discontinuation of 
IONSYS in the USA was affected primarily by the European Medicines Agency‘s recall 
of the product and suspension of marketing because of corrosion of a component in the 
system, which can lead to release of fentanyl without patient activation. The limitations of 
this delivery method include the relatively high cost of the iontophoretic device. 
 
4.5.2.6. Electroporation 
Another method – electroporation – is based on the use of short (micro- to mili-second), 
high-voltage electrical pulses to create transient disruptions in the structure of the SC  
[136]. Such disruptions, or pores, facilitate the transport of small and large molecules 
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otherwise unable to permeate at all. Drug molecules are believed to be transported 
through skin by electrophoretic movement and diffusion. Examples proving in vitro 
effectiveness of electroporation include small molecules such timolol [137] as well as 
larger molecules such as oligonucleotides, heparin and IgG antibodies [138]. 
 
4.5.2.7. Sonophoresis 
Ultrasound skin enhancement (sonophoresis) is achieved by the use of high (MHz) or 
low (kHz) frequency devices, the latter showing greater percutaneous drug flux 
improvement. At low frequencies the ultrasound applied to the skin results in the 
production of cavitational bubbles which by oscillation disrupt the SC structure. In vitro 
experiments have shown substantial increase in the skin permeability to small molecules 
such as estradiol, aldosterone or lidocaine [139] as well as macromolecules such as 
insulin, erythropoietin or γ-interferon [140-144]. In 2004 FDA approved an ultrasound 
system SonoPrep® to accelerate the action of lidocaine for local dermal anesthesia. The 
same system is intended to be used for delivering vaccines, insulin delivery, blood 
glucose monitoring, and antibiotic delivery in the future. An interesting feature of the 
device is real-time skin impedance feedback which stops the sonication procedure when 
the desired level of conductance has been achieved. This method does not cause pain 
or irritation when used within certain limitations. A ViaDerm system (TransPharma) has 
been developed and preclinical trials demonstrated effectiveness of this method of skin 
enhancement. Moreover, clinical trials involving the ViaDerm system coupled with 
human parathyroid hormone (1–34) and human growth hormone are underway. 
 
4.5.2.8. Microneedles 
Microneedles became one of the major enhancement techniques in the transdermal 
drug delivery field after advancements in the micro-fabrication techniques in recent years 
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had been made. Microneedles are a minimally invasive means of assisting the transport 
of drug molecules across the skin, and several reports have demonstrated that MN 
treatment is painless and well-tolerated by most patients [30, 31, 145].  There are 
various ways that microneedles can assist in the transdermal delivery of drugs across 
the SC, and currently 4 major types of microneedle systems have been described [146].  
Solid microneedles pierce the skin and create pores (also referred to as microchannels) 
in the SC, which can be utilized to increase delivery of a variety of compounds by 
applying a gel formulation or transdermal patch over the MN-treated skin; this is called 
the ―poke and patch‖ method [7, 147].  Figure 4.9 presents two designs of solid steel 
microneedles. 
 
  
Figure 4.9. Solid steel microneedles: A) “in-plane” row with five microneedles; C) 
“out-of-plane” microneedle array with 50 microneedles 
Reprinted with permission from Journal of Controlled Release 117 (2007) 227–237 
 
 
Microneedles can be coated with various drug formulations, which has been used to 
deliver DNA, proteins, and virus particles; this is referred to as the ―coat and poke‖ 
approach [7, 147].  Polymeric microneedles have been prepared with encapsulated drug 
to be inserted, detached and left in the skin, which can be used for either rapid or 
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controlled release into the skin [146].  Lastly, hollow microneedles have been utilized to 
deliver drug compounds (insulin, vaccines) by diffusion or pressure-driven flow through 
the bore of the needle [7, 146, 147].  All of these applications are inherently different and 
it can be expected that each technique requires separate optimization. There are many 
factors that affect drug delivery and permeability of the skin with respect to MN 
application.  These include parameters such as mechanical properties of the MN arrays, 
formulation of drugs to be delivered, and lifetime of the pores following MN application.  
To date, the mechanical properties of microneedle arrays have been well described in 
the literature, including parameters such as length, bore, geometry, force of application, 
and number of microneedles [30, 148-151].  The optimization of these factors affects the 
strength of the microneedles, the amount of pain associated with application, and the 
overall permeability of the skin (and therefore efficiency of drug delivery) [146, 151].  
Beyond the mechanical properties of the MN arrays, the other factors affecting drug 
delivery via this route remain largely unexplored, specifically drug formulation and pore 
lifetime following MN treatment. When it comes to the effectiveness of MN in enhancing 
the permeability of the skin, Henry et al. showed an increase in the transdermal flux of 
calcein up to four orders of magnitude [152]. A multitude of other studies proved that 
microneedles effectively permeabilize skin to drugs [6, 29, 153, 154]. With respect to 
NTX delivery it has been shown that although the creation of microchannels in the skin 
after MN treatment did not have a substantial effect on the delivery rates of the neutral 
(free-base) form of NTX or 6-ß-naltrexol, an improvement in the delivery of positively 
charged (salt-form) species of these drugs was possible [6]. It was proposed that higher 
NTX and 6-ß-naltrexol water-solubility at the lower pH range, rather than the presence of 
a positive charge, was responsible for the observed increase in the transport rates of the 
salt forms of these drugs [6]. In vitro and in vivo animal studies proved the utility of the 
MN method of enhancement showing approximately an order-of-magnitude increase in 
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the transdermal flux of highly water soluble species via MN-assisted delivery over that 
through untreated skin [6, 155]. Subsequently, a first-in-human MN study demonstrated 
that the combination of MN skin pretreatment and application of four NTX•HCl patches 
afforded drug plasma levels in the lower end of the targeted therapeutic range [32]. 
Currently, several systems based on microneedles are being investigated such as 
Microstructured Transdermal Systems (3M), Macroflux® (Zosano), MicroCorTM (Corium), 
or SoluviaTM (Becton-Dickenson) and have shown efficacy in preclinical trials.  
 
Combinations of enhancement techniques have a potential of showing synergistic 
effects [156]. Some combinations that have been studied include electroporation-
ultrasound [157], electroporation-iontophoresis [158, 159] and microneedle–
iontophoresis [160]. The observed synergistic effects may be rationalized by different 
mechanisms by which enhancement methods work, e.g. electroporation disrupts SC 
barrier structure increasing its permeability to drugs while iontophoresis provides 
additional driving force for diffusion of charged particles above that of just passive 
diffusion.  
 
4.5.3. Prodrugs  
The design of prodrugs for increasing transdermal delivery must consider: permeation 
across skin, chemical and enzymatic stability as well as skin irritation potential. While all 
of these factors need to be considered for a design of a successful prodrug, usually the 
main reason to recur to this approach is to modify the physicochemical properties of a 
parent drug so that the flux of the prodrug is increased over that of the parent molecule. 
A chemical modification of the compound of interest presents great opportunity to alter 
its ability to cross the SC barrier. In the most conventional case, when the diffusional 
barrier is represented by the lipid domain of the SC and parent drug is relatively 
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hydrophilic, increasing its lipophilicity can result in the improved percutaneous flux. 
However, a penalty is paid for the increase in the size of the permeant [60]. By contrast, 
it has also been possible to improve the flux of extremely hydrophobic compounds 
(which undergo viable tissue controlled diffusion, in comparison to stratum corneum 
controlled diffusion) by creating more hydrophilic prodrugs. With respect to NTX, several 
studies evaluated the potential of employing various prodrug classes to enhance its 
percutaneous flux [21, 96, 161-164]. Prodrug moieties based on short aliphatic chains in 
conjunction with carboxylic acid esters proved to be successful in increasing transdermal 
flux up to 6-fold. More recent literature reports of use prodrugs in transdermal drug 
delivery include the delivery of ketorolac piperazinylalkyl prodrugs [165], a pilot clinical 
trial involving prodrugs of levodopa [166], effects of PEGylation on transdermal flux of 
acetaminophen [167], naltrexone prodrugs [96] and bupropion prodrugs [162]. Currently, 
there are no transdermal prodrugs available on the market. 
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Chapter 5 
Development of a mathematical model for maximum flux estimation of nonionized 
drugs across untreated skin 
 
5.1. Introduction 
Although the main research objectives of this thesis are related to MN-enhanced 
transdermal drug delivery (Chapter 2 and 3) it is important to develop a general 
understanding of the drug transport across skin in the absence of microchannels. Not 
only does drug delivery through intact skin provide a basis for comparison against MN-
assisted transport, but it also is an integral part of the delivery through MN-treated skin. 
This is true because after formation of microchannels the vast majority of the skin 
surface is still covered with intact stratum corneum. Hence, as long as the formulation is 
applied on the MN-treated skin area, the intact skin surface will also participate in the 
overall drug transport. More detailed description of the parallel drug transport across 
microchannels and intact skin will be presented in Chapter 6. Moreover, the relative 
contribution of either of the parallel pathways to the total flux will be further discussed in 
Chapter 7. In the current chapter the emphasis is placed on the recognition of basic 
physicochemical characteristics of nonionized permeants that influence the maximum 
percutaneous flux through untreated skin. The following discussion has been submitted 
for publication in Molecular Pharmaceutics, and a revision has been requested. 
Skin has evolved to provide an efficient barrier at the interface of the external 
environment and the body. The formidable skin barrier properties greatly limit the 
permeation of xenobiotics [18, 37]. An advantage in terms of the protection against 
environmental toxicological agents is also a drawback from the perspective of 
percutaneous drug delivery. In both respects, the ability to identify the key 
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physicochemical properties of xenobiotics that determine their skin permeation potential 
is very attractive.  
A large body of literature has been published about skin permeability to drugs. The 
description of percutaneous transport across skin usually comprises several 
assumptions about the nature of the barrier and the nature of the drug penetrating this 
barrier. The barrier properties of the skin for a moderately lipophilic drug are typically 
well-described by accounting for the barrier properties of stratum corneum (SC) lipid 
domain alone [49, 57]. While some studies focused on the investigation of the 
permeability coefficient (P), others emphasized the maximum transdermal flux (Jmax). 
From the therapeutic and toxicological point of view it is often the maximum transdermal 
flux that is of critical importance. Such flux is normally attained by the use of a drug-
saturated vehicle. 
The purpose of this study is to develop a simple and easy-to-use predictive 
mathematical model for estimation of the maximum transdermal flux of xenobiotics 
based on three easily accessible molecular descriptors: logarithm of octanol-water 
partition coefficient (logKo/w), molecular weight (MW) and melting point (MP).  
Additionally, the usefulness of this model was evaluated using a permeation database 
comprised of 64 compounds. The model is based on two previously-reported, predictive 
models estimating drug skin permeability coefficients [168] and aqueous solubility of 
nonionic compounds (Sw) [169, 170]. 
 
5.2. Models estimating permeability coefficients 
The permeability coefficient is often seen as a parameter describing the intrinsic, 
concentration- independent, ability of a molecule to cross the SC barrier. The majority of 
mathematical models used to estimate drugs‘ permeability coefficients recognize the 
importance of drug partitioning into the SC lipids and drug molecular size. 
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Physicochemical properties frequently used to estimate the permeability coefficients of 
drugs include MW, logKo/w and hydrogen bonding potential [58, 168, 171-178]. The direct 
measurement of a drug concentration in the lipid domain of the SC is not easily obtained 
and often replaced by a product of a drug aqueous-vehicle concentration and a partition 
coefficient between the SC lipids and the vehicle (KSC/w).  In turn, this partition coefficient, 
can be related through a linear free energy relationship [179-181] to a drug partition 
coefficient between octanol and water (Ko/w) e.g. logKSC/w = a logKo/w. In this equation, ―a‖ 
stands for a coefficient accounting for the difference in the drug solubilities in SC lipids 
and bulk octanol, and usually is found to be in the range of 0.7 – 0.9 indicating a 
somewhat more hydrophilic nature of the anisotropic SC lipids as compared to the 
isotropic bulk octanol [58, 168, 172, 175]. Additionally, the diffusivity of a drug molecule 
in the SC lipid domain (D) can be linked to its size through an inverse power function 
[182, 183] or a free volume theory [60, 184-186]. In the free-volume theory, molecular 
volume is habitually substituted with MW for simplicity and without loss of prediction 
accuracy e.g. D = D0*10
-β*MW, where D0 is the diffusivity of a hypothetical molecule 
having MW of zero, and β is a coefficient relating the MW to a drug‘s diffusivity in the SC 
lipid domain. This relationship predicts a sharp drop in the drug diffusivity within the SC‘s 
lipid bilayers with increasing molecular size, where β values typically vary in the range of 
0.006-0.012 [58, 168, 171, 173]. The accessibility and ease of interpretation of the 
logKo/w and the MW makes them very popular determinants in skin permeability 
equations. The number of equations estimating permeability coefficient based, among 
others, on logKo/w and MW is above 20 and still growing [187]. It is worth noting that 
most models strive to use a single equation to describe the skin permeability for 
molecules spanning a broad range of physicochemical properties which implicitly 
assumes that the same permeation pathway across the SC is involved and no shift in 
the rate-limiting step in drug transport across skin occurs. One of them, arguably the 
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most widely used, was derived by Russel Potts and Richard Guy (P&GE) [168]. These 
authors used a multiple regression analysis of the Flynn permeation database [65] 
containing human epidermal permeability data of about 90 compounds to obtain the 
following relationship: 
 
logP = -2.72 + 0.71 logKo/w – 0.0061 MW [cm/h]    (5.1) 
 
This model explained 67% of the variability in the dataset [168]. The popularity of this 
model can be, at least to some extent, explained by the choice of just two easily-
accessible determinants: logKo/w and MW. 
 
5.3. Models estimating aqueous solubility of nonelectrolytes  
According to Fick‘s first law of diffusion the maximum flux can be achieved by using a 
drug-saturated vehicle. Since the P estimates are often obtained with the use of the 
logarithm of octanol and water partition coefficient (as it is in the P&GE), the knowledge 
of the drug‘s aqueous solubility becomes important for finding the maximum 
percutaneous flux. A number of equations predicting solubility of nonelectrolytes in non-
aqueous [188-191] and aqueous media have been published [169, 170, 192-195]. Many 
of them take a theory-based approach to the solubility estimation and typically recognize 
the importance of determinants such as heat of fusion, experimental temperature, MP, 
heat capacity, cohesive energy density, molecular volume, dispersion forces, dipolar 
forces and hydrogen bonding potential. However, some of the above properties are not 
easily accessible and their estimation requires additional experimental or calculation 
work. One way to circumvent this hurdle is to introduce reliable assumptions about the 
solute‘s nature and simplify the model so that it is based solely on more readily 
accessible determinants. One of the most widely known semi-theoretical models 
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estimating aqueous solubility of nonelectrolytes which uses only two determinants, MP 
and Ko/w, is the General Solubility Equation (GSE) introduced by Samuel Yalkowsky 
[169, 170]. Parameter values obtained by a multiple regression analysis on the database 
of 580 nonelectrolytes were found to agree very closely with those derived theoretically 
and accounted for 97% of the variability in the dataset. The regression form of the model 
is as follows:  
 
logSw = -0.0102 (MP-25) – 1.031 logKo/w + 0.424 [mol/l]   (5.2) 
 
where logSw is solute aqueous solubility, MP is solute melting point [C] and logKo/w is 
the logarithm of the solute octanol-water partition coefficient. The first term is derived 
from the ideal solubility equation. The ideal solubility is solvent-independent and the 
solubility estimate relies on the knowledge of the enthalpy of fusion, MP of the solute 
and the experimental temperature [169]. The introduction of a molecular-independent 
estimate of enthalpy of fusion and a set temperature of 25⁰C allows a substantial 
simplification of the original equation and shows a negative dependence of the aqueous 
solubility on the MP of the solute. The second term addresses the non-ideality concerns 
by directly relating solute activity coefficient in water to solute Ko/w. This transformation 
reveals a strong inverse relationship between aqueous solubility of a nonelectrolyte and 
its logKo/w. 
 
5.4. Models estimating maximum percutaneous flux 
From the therapeutic and toxicological point of view the Jmax is usually of higher 
importance than the P because it correlates directly with the maximum dose deliverable 
over a given period of time. Relatively few mathematical models have been proposed for 
the purpose of Jmax estimation [60, 196, 197]. They employ parameters such as drug 
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solubility in octanol, Sw, solubility in isopropyl myristate, and MW. Kasting et al. proposed 
a semi-theoretical model for moderately lipophilic permeants based on the drug octanol 
solubility and MW [60]. Magnusson et al. found by statistical analysis that MW was the 
single major determinant of Jmax in the database tested by the authors. It was shown that 
the addition of extra determinants such as solute solubility in octanol, MP and hydrogen 
bonding potential only improved the predictive ability of the model marginally [196]. Also, 
Sloan et al. postulated a model using drug solubility in isopropyl myristate (or octanol), 
Sw and MW [197-199]. Each of those models showed reasonable performance in their 
Jmax predictive ability. However, drawbacks include the use of parameters that are not 
easily determined, such as octanol or isopropyl myristate solubility. Also, the statistical 
model based on MW alone, although extremely simple and user-friendly, lacks 
theoretical backing. We believe that the introduction of a new semi-theoretical model 
based solely on easily-accessible molecular descriptors will be useful for the quick 
estimation of Jmax. The model reported herein may be seen as a close relative to the one 
reported by Kasting et al. [60] in which the drug MP and logKo/w are surrogates for drug 
octanol solubility. Octanol solubility, in turn, approximates drug solubility in the SC lipid 
barrier. 
Generally, the maximum transdermal flux can be obtained by the use of a drug-saturated 
aqueous vehicle, as long as the aqueous solubility is sufficient to eliminate the possibility 
of dissolution rate-limited diffusion, and as long as the drug stability is sufficient: 
Jmax = P * Sw, or  
 
logJmax = logP + logSw        (5.3) 
 
The model we set forth is based on the combination of two semi-theoretical models – 
P&GE (Eq. 5.1) and GSE (Eq. 5.2). The P&GE uses two determinants, logKo/w and MW, 
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to estimate a compound‘s skin permeability. Similarly, the GSE uses two determinants, 
logKo/w and MP, to estimate the aqueous solubility of a nonionic compound. The direct 
substitution of Eq. 5.1 and 5.2 into Eq. 5.3 and the unit conversion gives: 
 
logJmax = 3.704 – 0.321 logKo/w – 0.0061 MW – 0.0102 (MP-25) [nmol h
-1 cm-2] (5.4)  
 
where logKo/w is the logarithm of the permeants‘s octanol-water partition coefficient, MW 
is the permeants‘s molecular weight, and MP is its melting point [C]. For liquid solutes 
the term (MP-25) is set equal to zero. Since the logKo/w is used by both Eq. 5.1 and 5.2, 
Eq. 5.4 relies on the total number of three determinants: logKo/w, MW and MP.  
To assess the predictive ability of this equation it was tested against the skin permeation 
database (Table 5.1) of 64 nonionized compounds (87 entries). The database was 
obtained from Magnusson et al. ―Molecular size as the main determinant of solute 
maximum flux across the skin‖ (supplement, originally named ―set t‖) [196] and is 
compiled in terms of the Jmax of various solutes obtained from aqueous vehicles. The 
inclusion criteria for this database were: the use of human SC or epidermal membrane, 
no organic liquids present either in donor or receiver solutions, no pure liquid permeants 
applied to the membrane, ionization less than 10% at the experimental pH, and the 
knowledge of MP, Sw and either Jmax or P. The compounds included in the database 
span over a large range of physicochemical properties, logKo/w (-4.67 – 4.52), MW (18 - 
477) and MP (liquids – 293 ºC). The maximum flux was either experimentally measured 
or calculated from the product of the reported drug aqueous solubility and its 
permeability coefficient. No theoretically estimated aqueous solubility was allowed for 
calculation of Jmax from P, which is critical for evaluation of this model. The database is 
not complete in the sense that it does not include extremely lipophilic solutes with Ko/w 
greater than 4.6. However, this is should not be seen as a major disadvantage since for 
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very lipophilic compounds the rate of percutaneous permeation is not SC-limited and 
they would not be expected to follow the relationship derived here. Additionally, the 
accurate estimation of the rate of transdermal permeation of such solutes could be very 
challenging due to limited aqueous solubility in the absence of cosolvents. The 
compounds included in Table 5.1 partly overlap with the entries included in the Flynn 
database [65]. 
Figure 5.1 shows the logJmax predicted by Eq. 5.4 plotted against the experimental 
logJmax reported in the database (Table 5.1). The straight line depicts ideal correlation 
and dashed lines enclose the region of ideal correlation ± 1 log unit. Generally, the 
predictions fall in a reasonable range of logJmax values, although a trend of 
overestimating Jmax in the low-flux region and underestimating Jmax in the high-flux region 
is apparent. It is noteworthy that Eq. 5.4 parameter values were obtained directly from 
Eq. 5.1 and 5.2 employing separate databases (training sets), and not through the 
regression analysis on the database reported here. In the next step, a multiple linear 
regression analysis on the database (Table 5.1) was carried out using the following 
model:  
 
logJmax = a + b logKo/w + c MW + d (MP-25)   [nmol h
-1 cm-2]  (5.5) 
 
The initial parameter (a,b,c, and d) estimates were taken directly from Eq. 5.4. Since the 
parameters c and d were found to be highly inversely correlated, the parameter d 
preceding the (MP-25) term was fixed at 0.0102, the value estimated a priori by the 
GSE. The least-square fitting (Scientist®) yielded the following equation: 
 
logJmax = 4.9109 – 0.1666 logKo/w – 0.0120 MW – 0.0102 (MP-25)  [nmol h
-1 cm-2] (5.6) 
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An improved correlation devoid of any systematic deviation between calculated and 
experimental logJmax is demonstrated in Figure 5.2. The coefficient of determination (R
2) 
indicates that the model accounts for 90% of the variability in the dataset with the 
standard deviation of 0.7145 log unit. The vast majority of the experimentally determined 
Jmax values fall in the range of the predicted Jmax values ± 1 log unit. Moreover, the 
difference between predicted and experimental logJmax‘s (residuals) plotted against 
individual determinants: logKo/w, MW and MP is shown in Figures 5.3, 5.4 and 5.5, 
respectively. As evident from these figures residuals oscillate around the value of zero 
and there are no apparent trends in residuals as the value of each determinant is varied.  
 
5.5. Discussion 
According to Eq. 5.6 a decrease in a drug‘s logKo/w, MW or MP implies higher maximum 
percutaneous flux. While the parameters c and d preceding MW and (MP-25) terms, 
respectively, retain their original meaning from Eq. 5.1 and 5.2, the parameter b 
preceding the logKo/w term reflects its influence on both P and Sw. All parameter 
estimates obtained here (mean ± 95% CI) agree well with previous literature reports. 
The negative dependence of logJmax on the MW (0.0120 ± 0.0015) is somewhat steeper 
than that reported by Potts and Guy but falls in the range of values previously reported, 
such as 0.012 [58], and is justified on the grounds of the free-volume theory. The 
increase in the MW of 100 Da translates, on average, into a 16-fold drop in the Jmax.  The 
negative dependence of logJmax on the drug‘s MP (0.0102, as estimated a priori by GSE) 
can be rationalized by its influence on the aqueous solubility, with an increase in the MP 
of 100°C translating, on average, into a 10-fold drop in the flux. Finally, the negative 
dependence of logJmax on the drug‘s logKo/w (0.1666 ± 0.0801) arises from its effect on 
both the drug‘s permeability coefficient and aqueous solubility. A unit increase in the 
logKo/w value causes roughly a 10-fold drop in the aqueous solubility of a nonionic drug. 
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On the other hand, it also causes around a 7-fold increase in the partitioning into the SC 
lipids. Overall, the permeant‘s concentration in the SC lipid barrier drops, on average, 
around 1.5-fold per unit increase in the logKo/w value. Therefore, the logKo/w effect on Jmax 
is opposite from its effect on P. It is also true that logKo/w influence on Jmax, as compared 
to MW and MP, is minor since its effects on P and Sw almost cancel out. It could be 
argued that the presence of the logKo/w parameter in the model is not necessary. 
However, both the non-zero parameter b estimate found here as well as a slight 
decrease in the Model Selection Criterion from 2.28 to 2.12, when logKo/w is excluded 
from the model, suggest otherwise. (Model Selection Criterion is a modified Akaike 
Information Criterion where larger value indicates more appropriate model). Physically, 
the non-zero parameter b estimate supports the notion of SC lipids being somewhat 
more polar in nature as compared to the bulk octanol [58, 168, 172, 175].  
Although the cosolvent-containing vehicles were excluded from the analysis reported 
here it is known that drug‘s solubility in any vehicle (not necessarily aqueous) can be 
related to its solubility in the SC lipids through a partition coefficient [200]. At saturation, 
the product of the drug solubility in that vehicle and the vehicle-SC lipids partition 
coefficient remains constant. Therefore, as long as the vehicle does not affect either 
drug‘s solubility or diffusivity in the SC barrier the Jmax from any saturated vehicle would 
be expected to be the same and the relationship (Eq. 5.6) derived here should hold. At 
present, however, any solvents other than water were not included in the database due 
to the concern of potential interaction with the SC barrier.  
Limitations of the model proposed here are related to the fact that it uses a single 
equation to predict the maximum transdermal flux. Therefore, it is implicitly assumed that 
all permeants cross the skin barrier by the same pathway and no shift in the rate-limiting 
step of the drug transport occurs. Also, the GSE predicts aqueous solubility of the 
nonionic compounds at 25°C while in vitro skin diffusion experiments are typically carried 
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out at higher temperature. However, given the different experimental conditions 
(temperature in the range 22 - 39°C) used by authors whose data is included in the 
regression database (Table 5.1) and for the sake of simplicity of the final model, the 
temperature difference was not explicitly considered.  
 
5.6. Conclusions 
There are several mathematical models that can be used to estimate maximum 
transdermal flux of xenobiotics. We believe that the major advantage of our model 
comes from the fact that it requires little or no experimental data. While many models 
estimating drug skin permeability coefficient use two determinants – logKo/w and MW, 
with the cost of one additional determinant – MP, the maximum percutaneous flux can 
be estimated. Also, all three parameters are typically easily accessible and their use can 
be rationalized based on scientific theory. The model provides simple mechanistic 
interpretation of the influence of each determinant on Jmax. When skin permeation 
measurements are not readily available or a quick screening of a database of 
compounds is required, this model can readily provide initial estimates of maximum 
transdermal flux. 
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Table 5.1. Skin permeation database comprised of 67 compounds, 87 entries. The 
database was obtained from Magnusson et al. “Molecular size as the main 
determinant of solute maximum flux across the skin” (supplement, originally 
named “set t”) [196]. 
 
# Compound 
logJmax 
[nmol h-1 cm-2] 
MW [Da] logKo/w MP [°C]* 
1 17-alfa-Hydroxyprogesterone -1.77 330.5 2.89 223 
2 2,3-Butanediol 2.75 90.1 -0.99 25 
3 2,4,6-Trichlorophenol 2.43 197.5 3.58 69 
4 2,4-Dichlorophenol 3.27 163 3 45 
5 2-Butanone 4.14 72.1 0.37 25 
6 2-Ethoxy ethanol 3.42 90.1 -0.27 25 
7 2-Phenylethanol 3.14 122.2 1.36 25 
8 3,4-Xylenol 3.17 122.2 2.4 61 
9 4-Hydroxybenzyl alcohol 2.03 124.1 0.3 120 
10 5-Fluorouracil   0.43 130.1 -0.78 283 
11 
alfa-(4-Hydroxyphenyl) 
acetamide 
1.63 151.2 -0.29 177 
12 Benzene 3.39 78.1 2.22 25 
13 Benzoic acid 3.1 122.1 1.9 122 
14 Benzoic acid 3.1 122.1 1.9 122 
15 Benzyl alcohol 3.38 108.1 1.04 25 
16 beta-Estradiol -0.89 272.4 4.13 176 
17 beta-Estradiol -2.88 272.4 4.13 176 
18 beta-Estradiol -1.2 272.4 4.13 176 
19 Betamethasone-17-valerate -1.65 476.6 3.98 184 
20 beta-Naphthol 2.29 144.2 2.71 123 
21 Butanol 3.41 74.1 0.88 25 
65 
 
22 Butanol 3.33 74.1 0.88 25 
23 Chlorocresol 3.28 142.6 2.89 67 
24 Chloroxylenol 2.05 156.6 3.35 116 
25 Cortexone -0.87 330.5 3.41 142 
26 Corticosterone -0.51 346.5 1.76 181 
27 Corticosterone -1.54 346.5 1.76 181 
28 Corticosterone -1.89 346.5 1.76 181 
29 Corticosterone 0.17 346.5 1.76 181 
30 Cortisone -2.19 360.5 1.24 222 
31 Decanol 1.27 158.3 4.06 25 
32 Estriol -2.23 288.4 2.94 282 
33 Estrone -1.76 270.4 3.69 255 
34 Ethanol 4.13 46 -0.19 25 
35 Ethyl ether 4.12 74.1 0.98 25 
36 Heptanol 2.73 116.2 2.47 25 
37 Heptanol 2.66 116.2 2.47 25 
38 Hexanol 2.87 102.2 1.94 25 
39 Hydrocortisone  -2.64 362.5 1.43 220 
40 Hydrocortisone -2.6 362.5 1.43 220 
41 Mannitol 1.95 182.2 -4.67 167 
42 Mannitol 1.74 182.2 -4.67 167 
43 Mannitol 2.07 182.2 -4.67 167 
44 m-Cresol 3.55 108.1 1.94 25 
45 Methanol 4.19 32 -0.72 25 
46 Methanol 4.7 32 -0.72 25 
47 Methyl-4-hydroxy benzoate 2.08 152.1 1.87 128 
48 m-Nitrophenol 2.72 139.1 1.93 97 
49 Nicotinate, ethyl 3.35 151.2 1.41 25 
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50 Nicotinate, methyl 3.03 137.1 0.88 43 
51 Nonanol 1.77 144 3.53 25 
52 o-Chlorophenol 3.75 128.6 2.04 25 
53 o-Cresol 3.56 108.1 1.94 30 
54 Octanol 2.33 130.2 3 25 
55 Octanol 2.4 130.2 3 25 
56 o-Phenylenediamine 2.26 108.1 0.05 104 
57 p-Bromophenol 3.5 173 2.49 64 
58 p-Chlorophenol 3.83 128.6 2.43 44 
59 p-Cresol 3.53 108.1 1.94 36 
60 p-Cresol 4.38 108.1 1.94 36 
61 Pentanol 3.18 88.2 1.41 25 
62 p-Ethylphenol 3.15 122.2 2.47 45 
63 Phenol 4.23 94.1 1.48 41 
64 Phenol 2.12 94.1 1.48 41 
65 Phenol 3.83 94.1 1.48 41 
66 p-Nitrophenol 2.75 139.1 1.57 114 
67 p-Phenylenediamine 1.91 108.1 -0.85 146 
68 Prednisolone -1.56 360.4 1.69 241 
69 Pregnenolone -1.09 316.5 4.52 193 
70 Progesterone -1.37 314.5 4.04 121 
71 Propanol 4.35 60 0.34 25 
72 Propanol 4.2 60 0.34 25 
73 Resorcinol 3.19 110.1 0.76 111 
74 Sucrose 1.76 342.3 -3.85 186 
75 Testosterone -1.46 288.4 3.48 155 
76 Testosterone -1.16 288.4 3.48 155 
77 Thymol 2.55 150.2 3.28 52 
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78 Toluene 3.68 92.1 2.68 25 
79 Triamcinolone -3.09 394.5 1.03 270 
80 Triamcinolone acetonide -3.01 434.5 2.6 293 
81 Urea 3.4 60.1 -2.11 133 
82 Urea 3.24 60.1 -2.11 133 
83 Urea 3.13 60.1 -2.11 133 
84 Water 4.94 18 -1.38 25 
85 Water 4.93 18 -1.38 25 
86 Water 4.68 18 -1.38 25 
87 Water 4.44 18 -1.38 25 
*For liquid permeants the MP was set to 25 °C 
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Figure 5.1. 
 
 
Maximum transdermal flux calculated from Eq. 4 (Jpred) plotted against the 
experimental maximum transdermal flux (Jexp) of solutes included in the 
permeation database (Table 5.1). The solid line indicates ideal correlation while 
dashed lines enclose the region of ideal correlation ± 1 log unit. 
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Figure 5.2. 
 
 
 
Maximum transdermal flux calculated from eq. (6) (Jpred) plotted against the 
experimental maximum transdermal flux (Jexp) of solutes included in the 
permeation database (Table 1). The solid line indicates ideal correlation while 
dashed lines enclose the region of ideal correlation ± 1 log unit. 
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Figure 5.3.  
 
 
Regression analysis residuals log(Jpred/Jexp) plotted against logKo/w of permeants 
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Figure 5.4.  
 
 
 
Regression analysis residuals log(Jpred/Jexp) plotted against MW of permeants 
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Figure 5.5. 
 
 
Regression analysis residuals log(Jpred/Jexp) plotted against MP of permeants 
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Chapter 6 
Development of a mathematical model for characterization of drug transport 
across microneedle-treated skin 
 
6.1. Introduction 
The aim of this chapter is to introduce a simple mathematical model for analysis of the 
drug permeation data across MN-treated skin in fulfillment of the research goal 3.1. 
Although permeation data can be analyzed without use of any mathematical model by 
comparison of drug apparent permeability coefficients for MN-treated and untreated skin, 
such analysis lacks insight and is not easily transferable to different experimental 
conditions. Therefore, a simple mathematical model, which accounts for existence of two 
parallel routes of permeation – microchannel pathway and intact skin pathway – and the 
diffusional resistance of individual skin layers will be introduced. This model will 
accommodate the change in the number of microchannels created by microneedles, 
assign the permeability coefficients to unionized and ionized species permeating through 
either MN-treated or untreated skin, and account for different skin thickness used in the 
in vitro diffusion experiments. Fragments of the following discussion related to 
conceptual model development have been published in Pharmaceutical Research [39]. 
 
6.2. Classical transdermal transport 
The description of percutaneous transport across untreated skin usually comprises 
several assumptions about the nature of the barrier and the nature of the drug 
penetrating this barrier. Often the barrier properties of the skin can be well-described by 
accounting for the barrier properties of SC alone. Despite its heterogeneous nature, the 
SC is frequently assumed to be a thin layer of skin that is lipoidal in nature. Current 
marketable drugs that are passively delivered through the skin into systemic circulation 
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are uncharged, small and moderately lipophilic compounds [8]. It is believed that these 
drugs traverse the SC mainly through continuous intercellular lipids, which becomes the 
rate-limiting step in transport across skin. Hence, the transdermal delivery of fairly 
lipophilic drugs through intact skin is usually described by the following equation: 
 
𝐽𝐼𝑆𝑃 = 𝑃𝐼𝑆𝑃 ∗ 𝛥𝐶 = 𝐾𝑆𝐶/𝑣𝑒𝑕 ∗
𝐷𝑆𝐶
𝑕𝑆𝐶
∗ 𝛥𝐶      (6.1) 
 
where JISP is flux, PISP is permeability coefficient, KSC/veh is partition coefficient between 
SC lipid domain and vehicle, DSC is the diffusivity of the drug in SC, hSC is effective 
thickness of the SC; and ΔC is the drug concentration difference across SC. The 
subscript ―ISP‖ refers to the ―intact skin pathway‖ or the only pathway available for drug 
diffusion across untreated skin. A good understanding of the above parameters and the 
role they play in transdermal delivery permits recognition of potential drug candidates 
and optimization of delivery systems. 
Many studies have found that the partitioning between SC lipids and aqueous vehicle, 
although relatively hard to be determined directly, can be estimated by use of the 
octanol-water partition coefficient Koct/w. The character of the octanol microenvironment, 
although isotropic in nature, was found to be similar to the microenvironment of 
anisotropic SC lipids and they can be correlated through a linear free energy relationship 
[179, 180]. On the other hand, the diffusivity of a drug molecule in SC lipids can be 
linked to its size through a free volume theory. Habitually molecular volume is 
substituted with molecular weight for simplicity and without large loss of prediction 
accuracy. This relationship predicts a sharp drop in the drug diffusivity within the SC‘s 
lipid bilayers with increasing molecular size [60, 168]. Also, the effective thickness of the 
SC differs from the real SC thickness. The microstructure of the SC shows keratinocytes 
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being surrounded by a continuous phase of lipid bilayers in a ―brick and mortar‖-like 
arrangement [51, 100, 101]. The actual pathway along which a drug molecule diffuses 
using intercellular lipid domain across the SC is longer than just its thickness [51, 201-
204]. Lastly, transdermal flux is affected by the concentration (more precisely activity) 
gradient across the SC. When sink conditions are maintained on the receiver side of skin 
then the concentration gradient is simply the drug concentration in the donor solution. 
Therefore, the upper limit of the transdermal delivery rate can be attained by using 
saturated donor solutions. Moreover, having the same drug saturated in different 
solvents corresponds to the same (maximum) activity of the drug in those solvents [205]. 
Thus, transdermal flux values obtained from such donor solutions should be the same, 
as long as the solvent does not significantly affect the permeability of the skin. This is the 
basis for a generalization that a certain percent solubility of a drug in different solvents 
will provide approximately the same percutaneous flux. This is expected to be true only if 
transport across skin is occurring through the intercellular lipid domain of SC and there is 
no effect of the solvent used on the barrier properties of SC. 
 
6.3. MN-enhanced transdermal transport 
Transdermal transport characteristics change dramatically when MN are used as an 
enhancement method. MN create transient aqueous channels through the upper skin 
layers thus providing a new route of transport. This new pathway bypasses the SC 
barrier and continues through microchannels directly into deeper layers of skin. 
Transport across microchannels, therefore, is not expected to be SC-limited. A diffusing 
drug molecule needs to traverse several layers in series before it reaches the receiver 
solution (in vitro experiments) or the microvascular bed (in vivo experiments). Although 
this scenario is analogous to delivery across intact skin, one important difference needs 
to be taken into account. For untreated skin, the diffusional resistance of the SC is 
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typically orders of magnitude larger and overrides that coming from vehicle, epidermis 
and dermis [18, 54, 59]. In the context of this thesis, MN-enhanced delivery was limited 
to the use of MN in skin pretreatment and subsequent application of the drug-containing 
formulation on the treated area resulting in zero-order drug delivery. Other applications 
of MN, such as hollow MN with drug, coating MN with drug, using self-dissolving drug-
containing MN etc. were not considered for development of this mathematical model. In 
the case of the microchannel pathway (MCP), corresponding to the channels and 
underlying dermis, the resistance from SC is eliminated and diffusional resistances from 
the microchannel and the dermis beneath the microchannel become important. Also, 
transport is not dependent on partitioning between two distinct hydrophilic and lipophilic 
phases. The relative contributions of individual layer resistances to the total resistance 
will determine a new rate-determining step in skin transport. The individual layer 
resistance depends on drug diffusivity in that layer as well as on its thickness. G. Flynn 
reported that drug diffusivities in viable tissue (epidermis and dermis) are typically no 
more than 10 times lower than in bulk water and are without great molecular selectivity 
[18] while Kretsos et al. calculated the free drug diffusivities in the viable tissue to be 
about 3.7-fold lower than their diffusivities in water [206]. The thickness of the viable 
tissue used in in vitro diffusion experiments can be controlled by using either different 
length MN or different thicknesses of skin. In the following studies the thickness of the 
microchannel layer was typically about half the thickness of the underlying dermis layer 
(0.6 mm and 1.2 mm, respectively). Hence, it is anticipated that the dermis layer would 
present a higher resistance to a diffusing drug molecule as compared to the 
microchannel itself. Nevertheless, the difference between these two layers is not 
expected to be anywhere close to that between SC and viable tissue seen in delivery 
through untreated skin. Another crucial difference in transport via the microchannel 
pathway is the absence of a lipoidal layer that separates vehicle from viable tissue. By 
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creating microchannels in the skin and bypassing the SC an aqueous pathway is formed 
for transport which connects an aqueous vehicle through interstitial fluid to the aqueous 
milieu of viable tissue. As expected, the partition coefficients between aqueous vehicle 
and dermis for a variety of drugs are close to 1 [18] (and authors unpublished data). 
Moreover, aqueous vehicles are miscible with interstitial fluid within the microchannels. 
These conditions sharply contrast those met in the delivery across intact skin. An 
equation that can describe the steady-state flux through the microchannel pathway is as 
follows: 
 
𝐽𝑀𝐶𝑃 = 𝑃𝑀𝐶𝑃 ∗ 𝛥𝐶 =  
1
𝑅𝑀𝐶 +𝑅𝑉𝑇
 ∗  𝛥𝐶 =  
1
𝑕𝑀𝐶
𝐷𝑀𝐶
+
𝑕𝑉𝑇 ′
𝐷𝑉𝑇
 ∗ 𝛥𝐶   (6.2) 
 
where JMCP is flux, DMC is diffusivity of the drug in the microchannel,  DVT is diffusivity of 
the drug in the viable tissue, hMC is thickness of the microchannel, hVT‘ is thickness of the 
underlying viable tissue, and ΔC is the drug concentration difference across skin. The 
terms in this equation no longer relate to SC as it is not involved in the transport. 
Instead, two individual resistance terms from the microchannel and the underlying viable 
tissue are included. One important realization is that, contrary to intact skin, transport 
through microchannels no longer revolves around SC-oriented optimization of the 
physicochemical parameters of a drug molecule. A commonly reported logKo/w value 
around 2 provided favorable drug partitioning into the lipid domain of the SC lipids and a 
small molecular volume assured that diffusivity of the drug across SC would be 
sufficiently high to provide desired transdermal flux. These physicochemical parameters 
of the drug molecule seem to be no longer critical.  
Drug diffusivity in the bulk solution doesn‘t follow the relationship described by the free 
volume theory used for SC. Rather, it obeys the Stokes-Einstein equation: 
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𝐷 =
𝑘𝑇
6𝜋𝜂𝑟
         (6.3) 
 
Where: k is the Boltzmann constant, T is the absolute temperature, η is the viscosity of 
the medium and r is the hydrodynamic radius of the solute. Although this equation 
predicts the decrease of diffusivity with increasing molecular size of the drug molecule, 
the magnitude of this effect is much smaller. It has been shown by McAllister et al. that 
MN-enhanced transdermal flux values for a variety of compounds of different sizes 
correlated well with prediction based on the Stokes-Einstein eq. [27]. It suggests that 
diffusivity of drug molecules in the microchannels will resemble that in the bulk solution 
rather than in the SC lipid bilayers. The thicknesses of layers that a diffusing molecule 
has to traverse in series in an in vitro diffusion experiment depend on several factors. In 
contrast to the SC, the effective thicknesses of the microchannel layer and underlying 
dermis layer are expected to resemble closely their real thicknesses. Dermis, for the 
purpose of diffusion studies, is a highly aqueous, gel-like phase with a meshwork of 
collagen fibers surrounded by a proteoglycan matrix. Molecular motion in this milieu is 
not restricted to a large extent, and drug molecules can diffuse relatively unhindered 
along the concentration gradient.  
Upon piercing the skin with MN, a new route of delivery is created. This new 
microchannel pathway (MCP) is in parallel with the intact skin pathway (ISP), which was 
originally the only route available before the MN treatment. Assuming independence of 
these two routes, percutaneous flux can be described according to the equation: 
 
𝐽𝑇𝑂𝑇 = 𝐽𝑀𝐶𝑃 + 𝐽𝐼𝑆𝑃 = (𝑓𝑀𝐶𝑃 ∗ 𝑃𝑀𝐶𝑃 + 𝑓𝐼𝑆𝑃 ∗ 𝑃𝐼𝑆𝑃 )𝛥𝐶   (6.4) 
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where JTOT is the total flux through MN-treated skin, JMCP is the microchannel pathway 
flux, JIS is the intact skin pathway flux, fMCP is the fractional skin surface area of the 
microchannel pathway, PMCP is the apparent permeability coefficient of the microchannel 
pathway, fISP is the skin surface fractional area of the intact skin pathway, PIS is the 
apparent permeability coefficient of the intact skin pathway and ΔC is the drug 
concentration difference across skin. In other words, the flux values coming from two 
independent parallel routes are additive. The relative importance of each pathway for a 
given drug molecule depends on that pathway‘s distinct features, reflected in the 
respective permeability coefficient, and the fractional area of skin each pathway covers. 
A MN treatment produces numerous microchannels; however, the fractional area 
occupied by them is typically very low. For example, McAllister et al. estimated that in 
their in vitro experimental set-up the fractional area of microchannel pathway was on the 
order of 0.001 or 0.1% [27]. Consequently, as a result of the MN-treatment the fractional 
area of intact skin pathway decreases only by 0.1% to 99.9% of the original value. In the 
in vitro diffusion experiments described in the following chapters of this thesis, typically a 
skin area of 0.95 cm2 was treated with MN to obtain the total of 100 microchannels. 
Assuming the diameter of a single microchannel opening is around 50 µm, 100 
microchannel openings translate into 0.2 % of the total skin surface area. This allows a 
simplification to be introduced. Since fISP ≈ 1 (100%) the fISP*PISP term can be well-
approximated by the value of PISP alone. Additionally, from a practical point of view, the 
exact knowledge of fMCP is not necessary as long as it remains very small.  
In the experiments involving MN, it is sometimes assumed that intact skin is 
impermeable to drug and flux is ascribed to the microchannel pathway exclusively. This 
premise may or may not be sound depending on the drug being used and particular 
experimental conditions and is further discussed in Chapter 7. Additional experiments 
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with untreated skin allow determination of the value of JISP (PISP) independently which 
then can be used to calculate JMCP (fMCP*PMCP) from JTOT (PTOT).  
MN-enhanced transport permits the use of ionized drug molecules and increases the 
maximum achievable driving force for diffusion through the use of highly water soluble, 
charged molecules. The question whether charged molecules can permeate through SC 
becomes important because the majority of skin surface area after MN-treatment is still 
intact SC and this pathway may contribute to the total flux. The area of transdermal 
research dealing with transport of charged molecules across SC is not extensively 
developed and less understood. There are reports that indicate that the transport of 
small charged molecules is possible through a polar route in SC [207, 208]. Transport 
via this polar route is not expected to obey the relationships discussed earlier for 
classical transdermal delivery. In most cases, the treatment of ionic equilibria in 
percutaneous transport evokes the pH-partition theory which states that the neutral form 
of a drug molecule traverses membranes far more readily than its ionized counterpart 
[66]. Therefore, the correction introduced to solutions containing partly ionized drug is to 
multiply the total drug concentration by the fraction of uncharged drug.  While this 
approach works, it is important to realize that although the SC permeability of charged 
species is low, their solubility might be much higher. Consequently, while working with 
saturated donor solutions at different pH‘s, the experimental results may be somewhat 
counterintuitive as evoked by Hadgraft showing higher transdermal flux of ibuprofen in 
its charged form through intact skin as compared to its uncharged form. These results 
suggest that, in this particular case,  lower permeability of the charged species is more 
than compensated for by its increased solubility [209]. Another relevant question is how 
the diffusivity of a molecule in bulk solution changes as its charge varies. It has been 
shown that the ionization of molecules typically doesn‘t change their bulk diffusivity 
much, if at all [54]. In the case of small molecules, the diffusivity of charged species may 
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drop slightly due to solvation effects and the resulting increase in the hydrodynamic 
radius. Those effects are not expected to play an important role with regard to larger 
molecules. Therefore, as long as the microchannel environment can be properly 
described by bulk solvent properties, one would expect that diffusional resistance of the 
microchannel should be similar for both charged and uncharged species. 
 
6.4. In vitro skin diffusion studies 
Full-thickness hairless guinea pig skin was harvested from the dorsal region of 
euthanized animals. Animal studies were approved by the University of Kentucky 
IACUC. Subcutaneous fat from skin samples was removed with a scalpel. Such skin 
samples were immediately placed in a plastic bag and frozen until use (-20 °C). Before 
the permeation study, skin samples were allowed to thaw for about 30 min. Skin used for 
MN treatment was placed on a wafer of polydimethylsiloxane polymer, which mimicked 
the naturally occurring mechanical support of underlying tissue because of its 
comparable structural elasticity. MN which were obtained from Dr. Prausnitz‘s laboratory 
were fabricated by laser cutting of stainless steel sheets as reported previously [210]. 
MN were solid metal, two-dimensional ―in-plane‖ rows each containing five MN oriented 
with their axis parallel to the steel sheet. This design is characterized by the following 
MN dimensions: 750 µm long, 200 µm wide and 75 µm thick.  The insertion of MN into 
skin was carried out manually by applying gentle finger pressure followed by their 
instantaneous removal. The diffusion area of skin (0.95 cm2) was pierced 20 times with a 
row containing five MN (i.e., to make a total of 100 individual and non-overlapping 
piercings) before mounting the skin in the diffusion cell. If any damage to MN was 
observed a new array was used. Untreated skin samples were placed directly into the 
diffusion cells. Three to four cells were used per donor solution composition per case 
(untreated or MN-treated skin) (n = 3-4). A PermeGear flow-through (In-Line, 
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Riegelsville, PA) diffusion cell system was used for the in vitro diffusion studies. Normal 
saline with 10% ethanol was used as the receiver solution. The flow rate of the receiver 
fluid was set at 1.5 ml/h to maintain sink conditions. Skin samples in the diffusion cells 
were kept at 32°C using a circulating water bath. The diffusion experiments were 
initiated by charging the donor compartment with 0.3 ml of the donor solution. Samples 
were collected from the receiver compartment in 6 h increments over 48 h. All samples 
were stored at 4°C until processed by HPLC. The permeation data were plotted as the 
cumulative amount of NTX•HCl collected in the receiver compartment as a function of 
time. The flux value for a given run was calculated from the terminal slope of the 
cumulative amount plotted vs. time. 
Quantitative analysis of indomethacin concentrations was carried out by HPLC. The 
HPLC system consisted of a Waters 717 Plus autosampler, a Waters 600 quaternary 
pump, and a Waters 2487 dual wavelength absorbance detector with Waters 
Empower™ software. A Brownlee (Wellesley, MA, USA) C-18 reversed phase Spheri-5 
μm column (220×4.6 mm) with a C-18 reversed phase guard column of the same type 
(15×3.2 mm) by Perkin Elmer® was used with the UV detector set at a wavelength of 254 
nm. The mobile phase consisted of 60% methanol and 40% 0.03 M KH2PO4 buffer (pH 
7.0). Samples were run at a flow rate of 1.5 ml/min with a run time of 8 min. The injection 
volume used was 100 µl. The retention time of NTX•HCl was 5.0 ± 0.1 min. Samples 
were analyzed within a linear range of the NTX•HCl standard curve from 100 – 10000 
ng/ml. 
The statistical analysis of data was carried out with student t-test at significance level α = 
0.05 using SIGMA-STAT (SPSS, Inc., Chicago, IL, USA) software.  
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6.5. Indomethacin permeation 
Indomethacin was chosen as a model drug for model testing due to its physicochemical 
characteristics. Its molecular weight 357.8 Da resembles that of naltrexone 341.4 Da. 
Indomethacin lipophilicity, as measured by logKo/w, is 3.1 and higher as compared to 
naltrexone‘s logKo/w of 1.8. Finally, indomethacin is an acid with pKa of 4.5 while 
naltrexone behaves as a base at acidic to neutral pH with pKa of 8.2. Hence, with careful 
selection of experimental conditions meaningful comparisons between the ionized and 
unionized species, their solubility and permeability through intact skin and through 
microchannels can be made. 
In the current experimental design two sets of in vitro diffusion experiments – with 
untreated and MN-treated skin – and at two pH values of 2.5 and 8.0 were performed. 
The absence or existence of microchannels in skin translated into the absence or 
existence of the microchannel pathway, respectively, in addition to the intact skin 
permeation pathway, according to Eq. 6.4. Next, the pH control allowed influencing the 
ionization state of indomethacin. At pH of 2.5 (2 units below pKa) the species 
predominantly present in the solution were unionized while at pH 8.0 (over 2 units above 
pKa) the predominant species were negatively charged. Also, the pH affects the total 
solubility of indomethacin. At pH 2.5 the saturation solubility in propylene glycol:water 
(PG:water) 1:3 solution was measured to be 5.1 mg/ml while at pH 8.0 it was 182.3 
mg/ml. By performing studies which employ untreated skin at two pH values it is possible 
to estimate JISP, and using the experimental drug concentration in the donor solution 
(equal to saturation solubility) calculate PISP according to Eq. 6.1. On the other hand, 
carrying out the studies with MN-treated skin provided estimates for JTOT and PTOT from 
which JMCP and PMCP can be calculated according to Eq 6.4. The permeation profiles of 
indomethacin are presented in Figure 6.1. The first striking feature of the comparison is 
that the flux of indomethacin from a pH 8.0 donor solution and through MN-treated skin 
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is by far the highest. All other cases resulted in much lower flux. In simple terms, the flux 
enhancement ratio as result of MN skin treatment at pH 8.0 is around 8-fold. However, at 
the same time at pH 2.5 this enhancement ratio is only about 1.4-fold. These 
enhancement ratios are a quick way to estimate the benefit of employing MN in drug 
delivery but do not provide much insight of the drug transport process. It is difficult to 
judge why such change in the enhancement ratio is observed as a function of pH. Also, 
it is difficult to predict what critical parameters govern the permeation through MN-
enhanced skin. On the other hand, by Eq. 6.1 and 6.4 the flux and permeability 
coefficients corresponding to the intact skin pathway and microchannel pathway can be 
calculated. The analysis of these parameters provides much more informative 
comparison. As presented in Figures 6.2 and 6.3 the total flux JTOT is composed of JISP 
and JMCP. However, at pH 2.5 the relative contribution of JMCP to the JTOT is small while at 
pH 8.0 the contribution of JMCP to the JTOT is overwhelming. To explain this experimental 
observation it is necessary to recall that at low pH indomethacin is predominantly 
unionized which makes it a relatively good transdermal permeant through untreated 
(intact) skin. Thus, the flux across intact skin around microchannels is relatively high and 
the formation of microchannels increases total flux only by around 40 %. Conversely, at 
high pH indomethacin is negatively charged which makes it a poor permeant across 
intact skin. In this scenario, the formation of microchannels in skin brings about a 
substantial increase in the total flux of around 800 %. Ionized species are not disfavored 
at permeation through microchannel pathway because there is no requirement of 
crossing highly resistive barrier of stratum corneum lipids. Thus, the recourse to the 
nature of the permeant and barrier of the intact skin pathway and microchannel pathway 
can satisfactorily explain experimental observations. Interestingly, it should be noted that 
in terms of indomethacin permeation through the intact skin alone, the highly soluble but 
poorly permeating ionized species provide higher flux over poorly soluble but highly 
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permeating neutral species. This demonstrates that the drop in the indomethacin 
permeability coefficient caused by ionization (Figure 6.4) is more than compensated for 
by the increase in the donor solution solubility. Even more interesting is the evaluation of 
ability of the ionized and neutral species to permeate through the microchannel pathway. 
Figure 6.4 shows that the permeability coefficients of negatively charged and neutral 
species are statistically equal (t-test p>0.05). This finding suggests that the intrinsic 
ability of indomethacin to permeate across microchannel pathway is independent of the 
molecular charge. Since the length of the microchannel hMC and underlying dermis hVT‘ 
are experimental constants, the comparisons of permeability coefficients can be 
interpreted as changes in drug diffusivity. Such observation is in good agreement with 
the fact that diffusivity of the molecule in bulk solution is independent of or barely 
affected by its electronic state [54]. Also, since the permeability coefficients of negatively 
charged and neutral species were found to be the same it implies that the drug diffusivity 
in the whole microchannel pathway – including underlying dermis – is independent of the 
molecular charge. This bears an important consequence on the overall understanding of 
drug delivery through MN-treated skin. First, the current data suggests that high 
aqueous solubility, irrespective of the permeant‘s charge, will result in the elevated flux 
though microchannel pathway. In reality, for many permeants high aqueous solubility is 
achieved through the presence of molecular charge. Second, the apparent enhancement 
ratios obtained as a consequence of MN skin treatment at different pH values will 
primarily depend on the permeant‘s ability to cross the untreated (intact) skin as its 
ability to permeate through the microchannel pathway remains the same irrespective of 
the ionization state. Finally, the direct comparison of total permeability coefficients PTOT, 
which can be done without use of the mathematical model presented herein (Figure 
6.4), is meaningless because PTOT contains confounded information about overall 
permeation and does not discriminate between intact skin and microchannel pathways. 
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Hence, no differences in the nature of the barriers are recognized and properly 
addressed by such comparison. 
Furthermore, Figure 6.4 reports the PMCP values multiplied by fraction of skin surface 
area available for microchannel pathway fMCP. This approach allows a direct comparison 
between the magnitude of indomethacin flux between 100 microchannels used in the 
present study (microchannel pathway) and 1 cm2 of intact skin. To obtain a comparison 
between the relative ease at which indomethacin permeates the same area of 
microchannel pathway and intact skin pathway a correction accounting for the surface of 
the area taken by the microchannel pathway fMCP needs to be made. Assuming a 50 µm 
opening of a single microchannel a fMCP of 0.2 % can be calculated. Numerically, PMCP is 
expected to closely mimic the permeability coefficient that would be obtained by 
employing SC-devoid skin in in vitro diffusion experiments. At pH 2.5, unionized 
indomethacin has a PMCP of 8.77 10
-3 cm h-1 and PISP of 4.07 10
-5 cm h-1. This translates 
into approximately 200-fold increase in the ease of permeation through microchannel 
pathway as compared to the intact skin pathway. On the other hand, at pH 8.0, ionized 
indomethacin has a PMCP of 1.71 10
-2 cm h-1 and PISP of 4.93 10
-6 cm h-1. This translates 
into approximately 3500-fold increase in the ease of permeation through microchannel 
pathway as compared to the intact skin pathway. The difference in these values, again, 
is reflective of the change in the ability of ionized and unionized species to permeate 
through intact skin pathway and not their ability to permeate through microchannel 
pathway which remains unchanged. Also, the influence of number of microchannels 
present in the skin on the flux is accounted for by fMCP. It was found that flux increases 
proportionally with the increase in the number of microchannels in accordance with Eq. 
6.4 (unpublished data). Lastly, the influence of the thickness of the microchannel layer 
(its length) and the thickness of the underlying dermis on steady-state flux is also 
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incorporated in the model. An increase in the barrier thickness causes inversely 
proportional drop in the flux. This topic will be further discussed in the Chapter 10. 
A reasonable doubt can be expressed about the statistical equivalency of the 
microchannel pathway permeability coefficients presented in Figure 6.4. The error 
related to the PMCP estimate at pH 2.5 is large and makes the power of comparison with 
PMCP at pH 8.0 less than desirable. However, it should be noted that the attainment of 
PMCP estimate at pH 2.5 with narrow margin of error is extremely difficult. This is due to 
the fact that it is calculated from the difference of PTOT and PISP which is numerically very 
small. Despite of the reasonable errors associated with both PTOT and PISP estimates the 
error associated with the difference between these values becomes large. The only way 
to address this issue is the collection of extremely precise estimates of PTOT and PISP. At 
present, the comparison reported herein between PMCP at pH 2.5 and 8.0 is deemed 
acceptable, however, more precise estimates would be very helpful in strengthening the 
conclusions.  
 
6.6. Naltrexone and 6β-naltrexol permeation 
The permeation of naltrexone and 6β-naltrexol across MN-treated skin had been 
extensively studied [6, 32, 155, 211]. In vitro diffusion experiments of similar design to 
these described above for indomethacin showed that the highly water-soluble ionized 
species in combination with microneedle skin treatment afforded the highest transdermal 
flux. On the other hand, the effect of microchannels on the permeation of unionized 
species was much less pronounced. In other words, the overall behavior of naltrexone 
and 6β-naltrexol seems to follow the trend seen for indomethacin [6]. Noteworthy, the 
ionized species of naltrexone and 6β-naltrexol possess positive charge unlike negatively 
charged indomethacin. 
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6.7. Conclusions 
A simple mathematical model was developed for analysis of steady-state permeation 
data through MN-treated skin. The distinct feature of the model is that it recognizes the 
microchannels as a separate permeation pathway in parallel to the intact skin 
permeation pathway. Since the fractional skin surface area taken by the microchannel 
openings is very small the formation of microchannels does not significantly affect the 
intact skin pathway. Hence, MN-treatment can be seen as a method of providing an 
additional permeation pathway through skin without affecting an already existing one. In 
vitro diffusion studies with indomethacin demonstrated that the formation of 
microchannels increases percutaneous drug transport. The magnitude of flux 
enhancement depends on the drug donor solution solubility and permeability through 
both: intact skin pathway and microchannel pathway. The interplay between these 
factors determines the overall benefit of using MN. Former studies carried out with 
naltrexone and 6β-naltrexol provided similar results. This mathematical model provides a 
simple framework for analysis of in vitro permeation data presented in Chapters 7,8 and 
9. 
 
 
 
 
 
 
 
 
 
 
89 
 
Figure 6.1. 
 
Permeation of indomethacin across untreated and MN-treated guinea pig skin at 
two different pH values 2.5 and 8.0. Mean ± SD (n = 3-4). 
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Figure 6.2. 
 
Indomethacin flux at pH 2.5 across MN-treated guinea pig skin (JTOT), intact skin 
pathway (JISP) and microchannel pathway (JMCP). Mean ± SD (n = 3-4). 
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Figure 6.3. 
 
Indomethacin flux at pH 8.0 across MN-treated guinea pig skin (JTOT), intact skin 
pathway (JISP) and microchannel pathway (JMCP). Mean ± SD (n = 3-4). 
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Figure 6.4. 
 
Indomethacin permeability coefficients at pH 2.5 and 8.0 across MN-treated guinea 
pig skin (PTOT), intact skin pathway (PISP) and microchannel pathway (PMCP). Mean ± 
SD (n = 3-4). PISP at two pH values is statistically different (t-test p<0.05), while 
fMCP*PMCP at two pH values is not statistically different (t-test p>0.05). 
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Chapter 7 
Formulation effects on the in vitro permeation of naltrexone hydrochloride across 
untreated and microneedle-treated skin 
 
7.1. Introduction 
The purpose of this chapter is to present the formulation optimization efforts to maximize 
the delivery of naltrexone hydrochloride through MN-treated skin. As stated in the 
research plan 3.2 there is a literature gap with respect to examination of preferred 
formulation characteristics for MN-enhanced drug transport. Oftentimes, diffusion studies 
involve a direct application of an aqueous drug solution to the treated skin area. This 
approach works well in in vitro conditions. However, in in vivo studies the application of 
drug-containing aqueous solution although not impossible [212], is highly inconvenient 
and without prospect of being ultimately developed into a practical transdermal patch. It 
is the intent of this chapter to first analyze the influence of the propylene glycol, a 
ubiquitous thickening cosolvent excipient in percutaneous drug delivery, on the flux of 
NTX•HCl in an aqueous system. Then, the application of other cosolvents will be 
examined. Finally, gel systems will be investigated and the application of gels and 
hydrocolloids in in vivo studies will be briefly discussed. Fragments of the following 
discussion related to the use of propylene glycol have been published in Pharmaceutical 
Research [39]. 
The SC possesses formidable barrier properties that prevent most xenobiotics from 
permeating through the skin. Since the pool of molecules possessing necessary 
physicochemical properties to cross this barrier is limited, the amount of drugs that can 
be delivered percutaneously at therapeutically relevant rates is also low [17, 18, 141]. 
Increasing drug permeation rates across skin represents a great challenge. MN offer a 
method of substantially increasing the transdermal delivery of drugs by transiently 
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compromising the barrier properties of SC. The use of MN enables the formation of 
microchannels that extend over upper layers of skin and allow drug molecules to diffuse 
directly into deeper layers of skin. In general, this process results in up to several orders-
of-magnitude enhancement of transdermal transport of drugs [6, 27, 152, 213]. 
Naltrexone is a potent, competitive opioid receptor antagonist. It is used to treat opioid 
and alcohol addiction [83]. This drug undergoes an extensive first-pass effect and is 
characterized by low and varying bioavailability ranging from 5 to 40% [214, 215]. The 
currently marketed oral ReVia® and Depade® are not well-suited for long-term therapy as 
they produce gastrointestinal side effects and result in poor patient compliance.  On the 
other hand, injectable Vivitrol® affords effective plasma levels for as long as 30 days but 
necessitates in reporting to a healthcare professional upon administration [80]. Also, it 
cannot be easily discontinued, if needed, without painful surgical removal. It would, 
therefore, be advantageous to use the transdermal route of delivery for this drug. A 
transdermal patch would allow eliminating some of the drawbacks related to either oral 
or injectable alternatives. Since naltrexone itself does not possess the physicochemical 
properties that would result in percutaneous transport at therapeutically relevant rates an 
enhancement method is needed [20]. Previous studies showed that a prodrug strategy 
resulted in increased percutaneous transport of NTX, however, observed flux values 
were still below expectations [21, 96, 164]. Alternatively, MN were used to improve the 
delivery of the highly-soluble hydrochloride salt form of NTX. Initial in vitro and in vivo 
animal studies proved the utility of the MN method of enhancement showing 
approximately an order-of-magnitude increase in the transdermal flux over that through 
non-MN treated skin [6]. Subsequently, the first published human MN study 
demonstrated that skin pretreatment with MN and subsequent application of four NTX 
patches afforded drug plasma levels in the lower end of the therapeutic range targeted 
[216]. The results of these studies validated the interest put into the development of MN 
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techniques for increased transport of drugs across skin. Although a large number of 
articles focusing on the engineering aspects of MN use and their effectiveness has been 
published there is little systematic work done in the area of the formulation influence on 
the rate of MN-enhanced transdermal delivery of drugs. Recent publications report the 
efforts to combine liposomes with skin MN pretreatment to further increase drug delivery 
rates [28, 217]. Y. Qiu et al. studied the combined strategy of using conventional and 
elastic liposomes with MN skin pretreatment for the delivery of poorly water-soluble 
docetaxel through porcine skin. The results indicated that this approach afforded 
superior flux values from both liposomal drug formulations as compared to the saturated 
docetaxel solution alone. Additionally, the elastic liposomes produced shorter lag times 
as compared to conventional liposomes. Another study by M.M. Badran et al. focused on 
the effect of the microneedle length and flexible liposomal formulation on the transport of 
a model hydrophilic compound, mannitol, through human skin. It was shown that the 
flexible liposomal formulation delivered a larger fraction of the dose applied in the donor 
compartment as compared with the aqueous mannitol solution. Moreover, the effect of 
MN length on flux values was more pronounced in liposomal formulations. These 
examples illustrate that adequate formulation choice may have a substantial effect on 
the delivery through MN-enhanced skin. 
PG is a very common, generally recognized as safe (GRAS), non-irritating cosolvent 
widely used in topical formulations [218]. It is fully miscible with water and as such is 
often used to increase the solubility of poorly water soluble compounds in formulations. 
Its effect on the transdermal delivery of drugs has been the subject of many studies. In 
the ideal case when the vehicle does not affect the integrity and barrier properties of the 
SC, flux values from saturated solutions of a given drug should be the same as 
suggested by Higuchi [205]. Therefore, the presence of PG in an aqueous formulation of 
a saturated drug solution should not translate into a different flux. However, it rarely is 
96 
 
the case. B.W. Barry examined the PG-human skin interactions and implied that this 
cosolvent can act as a skin permeation enhancer by solvating keratin and occupying 
hydrogen-bonding sites as well as promoting drug partitioning into the skin [219]. 
Similarly, Michael Goodman et al. suggested that the effect of PG on human skin may 
be related to the solvation effects on keratin in the corneocytes [220]. Later, N.A. 
Megrab, A C. Williams and B.W. Barry showed that saturated PG-rich donor solutions 
afforded higher flux values of estradiol through human epidermal membranes as 
compared to their water-rich counterparts [221].  Authors explained the outcome in terms 
of increased solubility of estradiol in SC which was not offset by somewhat decreased 
apparent diffusivity of the drug in the barrier. On the other hand, L. Trottet et al. studied 
the depletion of PG from topical drug-containing formulations in vitro. It was found that 
the permeation enhancement effect on human cadaver skin showed time-dependence 
that correlated with PG levels in the formulation [222]. In another study, Christophe 
Herkenne et al. investigated the effect of PG on ibuprofen absorption on into human skin 
in vivo.  Authors found that PG enters SC increasing ibuprofen‘s solubility in the barrier 
but does not affect the drug‘s diffusivity in the barrier [223]. Moreover, R.M. Watkinson et 
al. studied the influence of the PG concentration on the permeation of ibuprofen in vitro. 
The experiments were analyzed in terms of thermodynamic (partitioning) and kinetic 
(diffusivity) parameters. In accordance with the above studies it was concluded that the 
effect of PG on the human epidermis had little effect on the drug diffusivity in the barrier 
but had a substantial influence on the partitioning from the vehicle into the SC [224]. In 
other words, it seems that the predominant effect on the PG on the human skin is 
reflected in the increased solubility of lipophilic drugs in the PG-altered SC but little 
effect, if any, on the drug diffusivity in this rate-limiting environment. These are a few 
examples illustrating that PG affects and modifies dermal permeation rates of drugs 
through intact skin. 
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No published studies to date have focused on the investigation of the PG effect on the 
MN-enhanced transdermal delivery of drugs.  Since PG is ubiquitous in the area of 
topical formulation, understanding its influence on transport could provide some insights 
into formulation optimization for this new enhanced route of delivery. The present study 
is an evaluation of the effect of different PG-water donor solution compositions on the 
rate of delivery of NTX•HCl through MN-treated skin. 
 
7.2. Materials and methods 
Chemicals 
NTX hydrochloride was purchased from Mallinckrodt (St. Louis, MO, USA). Water was 
purified using NANOpure DiamondTM, Barnstead water filtration system. 1,2-Propanediol, 
Hanks‘ balanced salts modified powder, and sodium bicarbonate were purchased from 
Sigma (St. Louis, MO). 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 
gentamicin sulfate, trifluroacetic acid (TFA), triethylamine (TEA), 1-heptane sulfonic acid 
sodium salt, and acetonitrile (ACN) were obtained from Fisher Scientific (Fairlawn, NJ). 
Reagent-grade chemicals were obtained from Sigma Chemical Company (St. Louis, 
MO). 
 
Donor solution preparation 
Adequate volumes of deionized water and PG (total 5 ml) were pipetted into a 
disposable plastic beaker and stirred magnetically until well-mixed. Seven donor solution 
PG-water binary mixtures with the following compositions were prepared: 0-100, 10-90, 
25-75, 40-60, 75-25, 90-10 and 0-100 % (v/v). To each of these donor solutions 
NTX•HCl was added to obtain the concentration of 110 mg/ml. The solutions were 
placed in glass vials, closed tightly with a plastic cap, sonicated for 15 min and left in the 
shaking water bath at 32 °C overnight before use to ensure all the drug is dissolved. 
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NTX•HCl solubility 
The apparent solubilities of NTX•HCl in different composition PG-water binary mixtures 
were obtained by equilibrating excesses of NTX•HCl with these mixtures. Each slurry 
was continuously shaken in a tightly closed glass vial in a shaking water bath at 32 °C. 
Samples were taken at 24h, 48h, 72h and 96h, filtered using a 32°C prewarmed syringe 
and VWR syringe filter with a 0.2 µm membrane, and diluted with the adequate amount 
of acetonitrile-water 70:30 (v/v) to be analyzed by HPLC. Long equilibration time proved 
to be necessary for PG-rich donor solutions for which the attainment of equilibrium was 
slow. The solubility determination was repeated twice for each sample (n = 2). 
 
Viscosity measurements 
A Brookfield DV-III LV programmable cone/plate rheometer with a CPE-40 spindle was 
used for measuring viscosity of the donor solutions. The sample volume was 0.5 ml. All 
determinations were carried out at 32⁰C using a circulating water bath TC-102. Each 
donor viscosity measurement was taken three times at low, medium and high instrument 
torque value in the range of 10-100% (n = 3). Results are reported as mean and 
standard deviation.  
 
In vitro diffusion studies 
Full-thickness Yucatan minipig skin (approximately 1.8 mm thick) was harvested from 
the dorsal region of a euthanized 6-month-old animal. Animal studies were approved by 
the University of Kentucky IACUC. Subcutaneous fat from skin samples was removed 
with a scalpel and sparse hair shaved. Such skin samples were immediately placed in a 
plastic bag and frozen until use (-20 °C). Before the permeation study, skin samples 
were allowed to thaw for about 30 min. Skin used for MN treatment was placed on a 
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wafer of polydimethylsiloxane polymer, which mimicked the naturally occurring 
mechanical support of underlying tissue because of its comparable structural elasticity. 
MN which were obtained from Dr. Prausnitz‘s laboratory were fabricated by laser cutting 
of stainless steel sheets as reported previously [210]. MN were solid metal, two-
dimensional ―in-plane‖ rows each containing five MN oriented with their axis parallel to 
the steel sheet. This design is characterized by the following MN dimensions: 750 µm 
long, 200 µm wide and 75 µm thick. The insertion of MN into skin was carried out 
manually by applying gentle finger pressure followed by their instantaneous removal. 
The diffusion area of skin (0.95 cm2) was pierced 20 times with a row containing five MN 
(i.e., to make a total of 100 individual and non-overlapping piercings) before mounting 
the skin in the diffusion cell. If any damage to MN was observed a new array was used. 
Untreated skin samples were placed directly into the diffusion cells. Three to four cells 
were used per donor solution composition per case (untreated or MN-treated skin) (n = 
3-4). A PermeGear flow-through (In-Line, Riegelsville, PA) diffusion cell system was 
used for the in vitro diffusion studies. Isotonic HEPES-buffered Hanks‘ balanced salts 
solution (pH 7.4) was used as the receiver solution. The flow rate of the receiver fluid 
was set at 1.5 ml/h to maintain sink conditions. Skin samples in the diffusion cells were 
kept at 32 °C using a circulating water bath. The diffusion experiments were initiated by 
charging the donor compartment with 0.3 ml of the donor solution. Samples were 
collected from the receiver compartment in 6h increments over 48h. All samples were 
stored at 4 °C until processed by HPLC. The permeation data were plotted as the 
cumulative amount of NTX•HCl collected in the receiver compartment as a function of 
time. The flux value for a given run was calculated from the terminal steady-state portion 
of the graph. Permeability coefficients can be calculated from Fick‘s first law of diffusion: 
 
100 
 
1
𝐴
 
𝑑𝑀
𝑑𝑡
 = 𝐽𝑆𝑆 = 𝑃 ∗ 𝛥𝐶        (7.1.) 
 
where, Jss is the steady-state flux, M is the cumulative amount of NTX•HCl permeating 
the skin [nmol], A is the area of the skin [0.95 cm2], P is the effective permeability 
coefficient [cm h-1], and ΔC is the concentration difference [nmol cm-3] of the drug in 
donor and receiver solutions. Since sink conditions prevail under constant flow of the 
receiver solution ΔC is well-approximated by the drug donor concentration alone.  
 
Quantitative analysis 
Quantitative analysis of NTX•HCl concentrations by HPLC was carried out using a 
modification of the assay described by Hussain et al. [225]. The HPLC system consisted 
of a Waters 717 plus autosampler, a Waters 600 quaternary pump, and a Waters 2487 
dual wavelength absorbance detector with Waters Empower™ software. A Brownlee 
(Wellesley, MA, USA) C-8 reversed phase Spheri-5 μm column (220×4.6 mm) with a C-8 
reversed phase guard column of the same type (15×3.2 mm) by Perkin Elmer® was used 
with the UV detector set at a wavelength of 215nm or 278nm. The mobile phase 
consisted of 70:30 (v/v) ACN:(0.1% TFA with 0.065% 1-octane sulfonic acid sodium salt, 
adjusted to pH 3.0 with TEA aqueous phase). Samples were run at a flow rate of 1.5 
ml/min with a run time of 4 min. The injection volume used was 100 µl. The retention 
time of NTX•HCl was 2.3 ± 0.1 min. Samples were analyzed within a linear range of the 
NTX•HCl standard curve from 100 – 10000 ng/ml. The standard solutions exhibited 
excellent linearity over the entire concentration range employed in the assays. 
 
Hydrogel preparation 
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Commercially available AquaSite® (Derma Sciences, Princeton, NJ) hydrogel sheets 
were cut into circular discs, 0.9 cm in diameter. Next, a solution of benzyl alcohol 1%, 
ethanol 5%, propylene glycol 10% and water for injection 84% (v/v) was prepared and 
NTX•HCl was dissolved to obtain a concentration of 110 mg/ml. A four-fold excess of 
NTX•HCl solution, with respect to the weight of the hydrogel, was equilibrated with the 
discs for 48 h. The equilibrium NTX•HCl concentration in the hydrogel discs was 
determined by HPLC to be 90 mg/g. Drug-loaded hydrogel discs were applied on the 
MN-treated skin areas. 
 
Statistical analysis 
The statistical analysis of data was carried out with one-way ANOVA using SIGMA-
STAT (SPSS, Inc., Chicago, IL, USA) software. P < 0.05 was considered statistically 
significant. 
 
7.3. Propylene glycol 
The aim of this study was to investigate the influence of PG-water donor solution 
composition on the MN-enhanced transdermal flux of naltrexone hydrochloride in vitro. 
In order to do so, a series of seven donor solutions containing equal concentrations of 
NTX•HCl 110mg/ml were prepared. This subsaturation concentration was chosen to 
avoid potential problems related with the use of saturated solutions with excess solid 
such as obstruction of microchannel openings or deposition of solid drug in the 
microchannels. These donor solutions consisted of binary mixtures of PG and water. 
One set of in vitro experiments aimed at evaluating transdermal NTX•HCl flux with the 
use of MN, the other employed untreated (no MN) skin. 
Naltrexone pKa values at 32 °C calculated with the help of the Van‘t Hoff‘s equation are 
8.20 and 9.63 [226]. The first pKa corresponds to the dissociation of the protonated 
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aliphatic nitrogen proton and the second to the dissociation of the phenolic proton. The 
pH of a 110 mg/ml aqueous solution of NTX•HCl was found to be 4.95. Hence, in this 
solution NTX is expected to be positively charged. 
Figure 7.1 shows a representative diffusion profile of NTX•HCl through MN-treated skin 
and untreated skin. The steady-state is reached quickly for MN-treated skin but less 
rapidly for untreated skin. This is consistent with a previous report which showed 
decreased lag times upon pretreatment with MN [6]. Transdermal flux values were 
obtained from the slope of the linear, terminal portion of the graph. Individual flux values 
obtained from each donor solution composition were collected and plotted against the 
increasing concentration of PG in the donor solution. Figure 7.2 shows the summary of 
data derived from two sets of experiments. The first set of experiments evaluated the 
permeation of NTX•HCl through MN-enhanced skin. Transdermal flux values varied 
greatly with the highest flux of 30.9 ± 4.4 μg cm−2 h−1 obtained from a pure aqueous 
solution and the lowest flux 0.8 ± 0.3 μg cm−2 h−1 corresponding to a pure PG solution. 
The gradual drop in the transdermal flux was a non-linear function of the PG content in 
the donor solution with the greatest effect seen in water-rich solutions. The magnitude of 
the flux difference obtained from MN-treated skin is as much as ≈40 fold and indicates 
how great the influence of the formulation on this route of delivery can be. Additionally, 
the same set of experiments was repeated with the intact, non-MN-treated skin. The 
results revealed that for all donor solutions tested the flux values were much lower 
ranging from 0.3 ± 0.02 to 3.4 ± 1.0 μg cm−2 h−1. Initially, the increase in the PG content 
in the donor solution resulted in a slight rise in the flux, but between 10% and 40% PG-
water (v/v) the flux values leveled off and finally dropped from PG-rich solutions. The 
maximum flux was measured from a 25% (v/v) PG-water donor solution. Although there 
is a qualitative trend in the data showing that water-rich donor solutions provide higher 
flux over PG-rich donor solutions, this trend doesn‘t mimic the one seen with MN-treated 
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skin. Hence, the effect of donor solution composition is different and had a much more 
pronounced effect on MN-treated skin as compared to the untreated skin. 
The same data can be presented in terms of the flux enhancement calculated as the flux 
through MN-treated skin over that through untreated skin. Figure 7.3 shows such 
enhancement as a function of the donor solution composition. Clearly, the enhancement 
obtained by piercing the skin with MN is not the same for all formulations and equals ≈17 
for the pure aqueous donor but drops to only ≈3 for PG-rich donors. Therefore, it seems 
that the flux enhancement, although providing a quick measure of the efficacy of skin 
MN-treatment, may be of limited practical use as it varies with formulation. 
 
7.4. Viscosity influence on drug diffusivity 
In order to examine in more detail the possible reason for seeing a non-linear rise in the 
MN-enhanced flux with increasing donor solution water content the viscosities of PG-
water binary mixtures were measured and are presented in Table 7.1. The donor 
solutions‘ viscosities seem to be inversely related to the flux obtained from experiments 
with MN-enhanced skin. Such a relationship may be described by the Stokes-Einstein 
equation (Eq. 6.3). To better visualize the interrelation between flux and donor viscosity, 
the original data is plotted as NTX•HCl flux versus its calculated diffusivity in the donor 
solution. The diffusivity of NTX in water was calculated using the Stokes-Einstein 
equation using an experimentally determined viscosity value of 1.03 cP and assuming 
the hydrodynamic molecular radius is 4.6 Å yielding a value of 4.7 10-6 cm2 s-1 [227]. 
Other diffusivity values of NTX in PG-containing donors were obtained by employing the 
experimentally determined viscosity of the relevant donor solution. In Figure 7.4 two 
data sets correspond to the experiments performed with MN-enhanced and untreated 
skin and the third set results from the treatment of data according to Eq. 6.4. The 
experiments carried out with MN-treated skin provided transdermal flux corresponding to 
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JMCP and JISP while those with untreated skin produced flux corresponding to JISP alone. 
By simple subtraction, the value of the microchannel pathway flux is obtained. It is worth 
noting that in Figure 7.4 the data points corresponding to PG-rich solutions are situated 
to the left of the graph, unlike any other table of figure reported here. 
It can be noted that JISP doesn‘t show linear dependence on diffusivity of the donor 
solution. This is not surprising, as in the presence of SC one would expect that it will 
provide a major diffusional resistance. If the drug molecule traverses SC by partitioning 
into intercellular lipids and diffusing along its tortuous route, then in the ideal case, the 
transdermal flux should correlate with percent saturation of the donor solution. The 
apparent solubility of NTX•HCl in donor solutions is summarized in Table 7.2. There is a 
qualitative agreement between percent saturation in donor solution and observed flux. 
Furthermore, PG is known to be a weak permeation enhancer and may affect SC 
characteristics adding additional complexity to the interpretation of data from intact skin 
experiments.  
On the other hand, JMCP correlates with NTX diffusivity in the donor solution. The fact 
that a very good linear correlation (R2 = 0.99) was observed for microchannel pathway 
flux is interesting because it indicates that although the diffusivity calculations in Figure 
7.4 account for the changes of the donor solution exclusively, it seems that they reflect 
drug diffusivity changes in the whole microchannel pathway. A possible explanation for 
this observation is that PG diffuses out of donor solution into MN-treated skin affecting 
its diffusional properties. To test that hypothesis a calculation accounting for changes in 
drug diffusivity in the microchannel and underlying dermis was carried out. In the first 
case (Figure 7.5), it was assumed that PG enters the microchannels, which causes a 
decrease in NTX diffusivity in this region but no changes in NTX diffusivity in the 
underlying dermis are observed. In the second case (Figure 7.6), it was assumed that 
not only PG enters the microchannels, which causes a decrease in NTX diffusivity in this 
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region, but also it decreases NTX diffusivity in the underlying dermis. The calculations 
assumed the changes in diffusivity can be well-described by Stokes-Einstein equation 
(Eq. 6.3), effective fMCP of 2%, and the following NTX diffusivity values for microchannels 
and dermis unaffected by PG: 4.7 10-6 [cm s-1] and 3.4 10-6 [cm s-1], respectively. In the 
first case, the overall diffusional resistance is controlled mainly by the resistance of the 
viable tissue and only in the PG-rich region the diffusional contribution of the 
microchannels comes into play. On the other hand, in the second case, the total 
diffusional resistance is practically equal to the resistance of the viable tissue throughout 
the whole range of vehicle composition tested. When these resistance values are used 
to calculate steady-state microchannel pathway flux, the profiles shown in Figure 7.7 are 
obtained. The experimental data closely follows the pattern outlined by the prediction 
based on the second case calculations. Considering the above, it seems that it is not 
reasonable to assume that by varying the propylene glycol-water composition of the 
donor solution, only the properties of the vehicle and microchannel but not dermis are 
affected. In such case, in water-rich solutions transport through the microchannel 
pathway would likely be controlled by diffusion through viable tissue underlying the 
microchannel. Therefore, transdermal flux would not be expected to correlate with 
viscosity of the donor solution until the viscosity of the donor solution would be high 
enough to produce microchannel resistance that would overcome the resistance of the 
underlying dermis. The prediction based on the first case reveals insensitivity of 
microchannel pathway flux to the changes in composition of water-rich donors, but their 
dependence on the donor composition in the PG-rich region. The experimental data 
obtained in the current study clearly shows that this is not the case. Conversely, the 
experimental profile correlated well with prediction based on the second case and can 
be explained by the influence of propylene glycol on the diffusional properties of both 
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microchannel and underlying dermis through the relationship predicted by the Stokes-
Einstein equation.  
The JTOT obtained from MN-treated skin experiments also seems to follow the linear 
correlation with NTX donor solution diffusivity calculated from viscosity determinations 
(R2 = 0.98). The likely reason for this is that the contribution of JISP to the JTOT in water-
rich donors is minor. As shown in Figure 7.8, the contribution of JISP to the total flux is of 
most importance in the PG-rich donors where it accounts for around 40% of JTOT but 
diminishes to less than 10% in water-rich donors. Figure 7.4 obscures the region 
corresponding to the PG-rich solutions which could reveal difference between behavior 
of JMCP and JTOT as their values diverge in this area. In order to have a closer look at the 
difference between JTOT and JMCP the original data set was transformed by normalization 
of transdermal flux on the basis of viscosity. Since it was observed that viscosity of 
donor solutions seems to affect transdermal flux in MN-treated skin in accordance to the 
Stokes-Einstein equation, viscosity influence on flux can be cancelled out by multiplying 
the observed flux by individual viscosities of donor solutions according to the equation: 
 
𝐽′ = 𝐽 ∗ 𝜂         (7.2) 
 
where: J‘ is the viscosity-normalized flux, J is the flux and η is the viscosity of the donor 
solution. Such viscosity-normalized flux values are presented in Figure 7.9. The 
viscosity-normalized flux values correspond to a donor viscosity of 1 cP which is close to 
the value obtained for aqueous solutions. It can be noted that the viscosity-normalized 
flux values remain relatively constant both for the microchannel pathway alone and for 
the microchannel and intact skin pathways combined (MN-treated skin total flux) 
irrespective of the donor composition used. Statistical analysis (ANOVA) revealed no 
statistically significant difference between viscosity-normalized flux values within either 
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of the two data sets at α = 0.05. Because of large uncertainty in viscosity-normalized flux 
values in PG-rich donor solutions it is impossible to discriminate between JTOT and JMCP. 
Nevertheless, Figure 7.9 suggests that while JMCP flux shows no trend as donor solution 
composition is varied the JTOT shows a slightly decreasing trend with increasing PG 
content in the donors. This observation is in accordance with the expectation that only 
the microchannel pathway resistance closely correlates with donor solution composition. 
Total flux, besides JMCP, also incorporates JISP which doesn‘t depend greatly on the 
viscosity of the donor solution. Overall, the behavior of viscosity-normalized JMCP 
indicates that accounting for viscosity of the donor solution can very well predict the 
microchannel pathway transdermal flux. It is important to note that in the experimental 
set-up used in the present work the concentration of NTX•HCl in all donor solutions was 
maintained at a constant value, and therefore the relationship shown here between flux 
and viscosity is exactly the same for corresponding permeability coefficients and 
viscosity. 
Since from the practical point of view one is often interested in the maximum flux 
attainable it is interesting to look at the apparent solubility of NTX•HCl in different donor 
solutions and their viscosities. As reported in Table 7.2, the addition of PG to an 
aqueous donor gradually increases NTX•HCl solubility up to the donor solution 
composition of PG-water 90-10 after which a sharp drop is observed. Simultaneously, 
higher NTX•HCl concentration causes elevated viscosity of the donors. The data show 
that increased solubility is more than compensated for by elevated viscosity, and 
therefore saturated and PG-containing solutions of NTX•HCl  do not deliver the drug at 
higher rates though MN-treated skin as compared to purely aqueous, saturated donor 
solution (data not shown).  
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7.5. Other common excipients 
At the next stage of investigation, the main question to be addressed was whether the 
apparent viscosity effect on flux seen in the propylene glycol study can be generalized to 
other cosolvents and excipients. This information is valuable from the perspective of 
optimization of formulations designed for MN-enhanced skin. Besides viscosity, some 
other factors that might come into play are the difference in the osmotic pressure 
between the donor and receiver solutions. This could drive the water flow across 
microchannels in the opposite direction and interfere with drug permeation. Other 
possibilities are related to the pH-gradients across skin and possibility of convectional 
flow through microchannels. To address these possibilities collectively in a qualitative 
manner an experiment was designed in which the viscosity of the donor solutions 
containing NTX•HCl and excipients at different concentrations was kept constant. Other 
parameters such as osmotic pressure and pH varied. By comparing the experimental 
results to the viscosity-predicted conclusions were drawn. 
The selection of excipients involved: propylene glycol (PG), poly(ethylene glycol) 400 
(PEG 400), sucrose and hydroxyethylcellulose (HEC). All four were compared to the 
NTX•HCl permeation from an aqueous donor solution alone. For all donor solutions the 
NTX•HCl was kept constant at 90 mg/g. 
Figure 7.10 demonstrates experimental NTX•HCl steady-state flux obtained from five 
different donor solutions. Also, flux is compared to the viscosity-based prediction 
calculated from Stokes-Einstein equation (Eq. 6.3). It is important to realize the flux 
values collected in this study are total flux through MN-treated skin and not microchannel 
pathway flux values since no experiments were performed with untreated skin. It is 
implicitly assumed that the contribution of flux through the intact skin pathway is small at 
all times. Hence, it is expected that some error will be introduced by such simplification. 
For example, for PG based on Figure 7.5, an error of around 20 % can be expected.   
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Table 7.3 summarizes the physicochemical properties of the formulations including 
excipient concentration, solution viscosity, osmotic pressure, and pH. As evident from 
Figure 7.10 flux values obtained from donor solutions containing PG, PEG 400 and 
sucrose agree reasonably well with the predictions based on the viscosity donor solution 
changes (pair-wise t-test between experimental and predicted values show no difference 
at α = 0.05). Flux obtained from donor solution containing HEC does not (the means are 
statistically different at α = 0.05). First, it is interesting to analyze the PG-containing 
donor solution which is characterized by osmotic pressure approximately 4-fold higher 
than either solution containing PEG 400 or sucrose. It could be expected that the flow of 
water in the opposite direction to the drug flux could slow down the apparent permeation 
of NTX•HCl from a high-osmotic-pressure donor solution. However, no evidence of such 
behavior is observed. The flux values obtained from the first three solutions are 
approximately the same and there is no trend corresponding to the varying osmotic 
pressure of the donor solutions. The same holds true for the apparent pH effects. 
However, a major striking feature of Figure 7.10 is the disagreement between the 
experimental and predicted flux value seen for HEC-based donor solution. The 
experimental flux is statistically equal (p > 0.05) to the flux obtained from purely aqueous 
solution. No drop in the transport rate is observed even though the viscosity of the donor 
solution is 2.45 cP. A plausible explanation to this apparent discrepancy is related to the 
fact that HEC is the only high-molecular-weight polymer used in the study. It can be 
envisioned that the diffusion of 720 kDa molecules into the microchannel will be very 
slow due to is low aqueous diffusion coefficient. Moreover, its mobility may be further 
limited in dermis if it ever reaches that skin layer. As a result it could be anticipated that 
the diffusional properties of the skin will not be altered. At the same time the molecular 
mobility of NTX•HCl in the HEC solution is not expected to be lowered as the 
macroviscosity measured experimentally does not mimic microviscosity of the solution. 
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The concept of micro- and macro-viscosity applies to gel systems and the diffusion 
coefficients of low-molecular-weight drugs will be related to the microviscosity only. In 
case of large compounds such as proteins microviscosity may not correlate well with a 
diffusion coefficient as hindrance coming from gel meshwork can no longer be ignored. 
According to Zhao and Chen the discrepancy between the macro- and micro-viscosity 
for a HEC solution at 0.13% (w/w) used in this study is approximately 2.5-fold [228]. In 
consequence, the microviscosity of the HEC solution is close to 1cP, or, the viscosity of 
the aqueous solution. This finding rationalizes the equivalent flux from HEC and 
aqueous donor solutions.  
 
7.6. Gel systems 
The findings of the preceding section are directly applicable to the development of a gel-
based transdermal system. Gels offer the advantage of relatively sturdy structure and 
easy-to-use formulation form. In the following study, the effect of increasing 
concentration of the HEC in the NTX•HCl-containing donor solution was evaluated. HEC 
gellified aqueous donor solutions at the concentration of 1% (w/w) reached a 
macroviscosity of approximately 1000 cP, while the microviscosity only increases to 
about 1.03 cP [228]. Higher HEC concentrations provide gels of even higher 
macroviscosity, which slows down the gel flow and makes their use in vivo more 
convenient. NTX•HCl at 90 mg/ml in aqueous solution, 2% HEC, 3% HEC, and 4% HEC 
were used as donor solutions. The flux through MN-treated skin was recorded and is 
presented in Figure 7.11. As demonstrated experimentally, indeed, the flux drops only 
marginally as a result of the increase of the HEC in the donor solution from 0 to 4%. 
Hence, it was confirmed that for a gel system the macroviscosity does not correlate with 
the flux through MN-treated skin.  
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7.7. Sheet hydrogels and hydrocolloids 
Despite the encouraging results from gel formulations presented in the proceeding 
section additional improvement of the formulation was desired. The main reason for 
further formulation optimization is not related to the rate of NTX•HCl percutaneous 
transport but to the fact that amorphous gels, although a major step forward as 
compared to aqueous solutions, still presented practical challenges when applied in vivo. 
One of the main problems was the containment of the gel in a custom-made covering 
patch over the experimental duration of several days. Amorphous gel had a tendency to 
leak from beneath the prototype patch and out of the MN-treated skin area. Another 
challenge was related to the fact that gels based solely on aqueous solutions with no 
cosolvents present (PG or PEG 400) tended to collapse during in vivo experiments due 
to the water evaporation at elevated skin temperature of 32 °C. To address these two 
major concerns the suitability of commercially available wound dressings as vehicles for 
MN-assisted drug delivery were evaluated. Two distinct classes of dressings: sheet 
hydrogel and hydrocolloids were selected. 
Sheet hydrogels, besides the benefit of providing a vehicle from which NTX•HCl could 
be delivered through MN-enhanced skin at the rate similar to the one obtained from 
aqueous solution, also provided additional benefit of improved formulation sturdiness. As 
the name implies the sheet hydrogels are not amorphous, but rather formed in a disc or 
square-shape and don‘t flow. That allowed full control over the application area and 
addressed the first containment problem. Of three commercially available sheet 
hydrogels tested: AquaFloTM (Kendall), AquaClear® (Hartmann), and AquaSite® (Derma 
Sciences), the latter was found to have the properties that best suited in vivo study 
needs. As for the second problem, the addition of 10% highly-hygroscopic PG to the 
formulation allowed several-day use of hydrogels without collapse or drug precipitation. 
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A price, however, is paid in an approximate 25% decrease in the flux due to the 
microviscosity increase. 
The sheet hydrogel formulations were prepared by 48 h equilibration of the commercial 
product with the excess solution of NTX•HCl at 100 mg/ml in 10% PG aqueous solution. 
The hydrogel absorbs loading solution with the end result of increase in the hydrogel 
mass about 4-fold. Such prepared formulations were tested in an in vitro diffusion 
experiment across MN-treated skin and compared to the loading solution alone, and the 
gel formulation used previously in the first-in-human MN study [216]. The following flux 
values at 48 h were obtained: new AquaSite®-based hydrogel formulation 74.5 ± 6.7 
nmol cm-2 h-1, loading solution 71.6 ± 13.1 nmol cm-2 h-1, and former gel formulation 11.9 
± 0.5 nmol cm-2 h-1 (courtesy of Priyanka Ghosh). In conclusion, formulation optimization 
resulted in a 6-fold increase in in vitro flux and an improved, more user-friendly hydrogel 
sheet form.  
Apart from the sheet hydrogels, another group of wound dressing products that was 
selected for testing were hydrocolloid dressings. These dressings possess lower water 
content than hydrogels, but also absorb aqueous solution to a great degree and 
additionally possess acrylate adhesives which facilitate adhesion to skin. Two 
commercial products were evaluated: TegadermTM hydrocolloid dressing (3MTM), and 
Cutinova Hydro (Smith&Nephew). The experimental procedure involved the preloading 
of hydrocolloid dressing by equilibration with a drug-containing loading solution. 
However, the hydrocolloid performance in in vitro diffusion studies was less than 
satisfactory. The non-steady-state flux at 48 h was only 17.8 ± 3.7 nmol cm-2 h-1 and the 
altered structure of the fully-hydrated dressing made it impossible to provide appropriate 
intimate adhesion to the MN-treated skin surface (courtesy of Priyanka Ghosh).  
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7.8. Conclusions 
Overall, it is possible that factors other than the viscosity of the donor solution can 
influence MN-enhanced percutaneous flux. One example is the case of drugs with lipid 
binding and protein binding potential in dermis. Low binding to immobile cell-membrane 
dermal lipids as well as low-mobility albumins would be expected to elongate lag times, 
but not to affect steady-state flux values. However, in the case of drugs extensively 
bound to albumin the diffusivity of the drug-albumin complex would need to be 
considered and could translate into lower-than-expected permeation rates.  
In conclusion, this work investigated the influence of donor solution composition on the 
rate of transdermal transport of NTX•HCl through MN-enhanced skin. It was found that 
flux correlated well with changes in drug diffusivity caused by donor viscosity variations. 
Also, it is likely that the microchannel pathway flux rather than total flux (combined 
microchannel pathway and intact skin pathway flux) correlates with viscosity changes of 
donor solution through the Stokes-Einstein equation. Moreover, this work indicates that 
percutaneous flux of charged species across intact skin may become important when a 
large skin area is exposed to the drug formulation. In broader context, the findings of this 
work may help improve the design of delivery systems for MN-enhanced skin. In 
classical percutaneous delivery the vehicle plays a critical role in the appearance and 
delivery rates of a drug. Excipients impart the desired rheological character to the 
dosage form. Also, they determine physical properties of the vehicle and its ability to 
modify stratum corneum, the rate-limiting barrier to transport of most drugs. PG, PEGs 
and other viscous cosolvents are common excipients used in topical dosage forms. 
Changes in the physicochemical characteristics may promote drug partitioning from a 
topically applied formulation into the barrier as well as diffusion of drug molecules 
through the barrier. Based on the results from current work it seems reasonable to state 
that when maximum flux through MN-treated skin is sought, then the viscosity of the 
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formulation should be kept as low as possible. However, that restriction does not hold 
with respect to high molecular weight polymeric systems which do not seem to increase 
the diffusional resistance of the microchannel pathway. The selection of a water-rich 
sheet hydrogel formulation proved the most successful in conjunction with MN-assisted 
transdermal drug transport. 
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Table 7.1. Viscosities of NTX•HCl (110 mg/ml) in PG-water binary mixtures (n = 3) 
 
NTX•HCl 110mg/ml 
in PG-water % (v/v) 
0-100 10-90 25-75 40-60 75-25 90-10 100-0 
Viscosity [cP] ± SD 
1.03 ± 
0.01 
1.48 ± 
0.03 
2.47 ± 
0.01 
4.01 ± 
0.01 
14.40 ± 
0.00 
28.43 ± 
0.12 
46.33 ± 
1.01 
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Table 7.2. Apparent NTX•HCl solubility and corresponding viscosity in binary 
mixtures of PG-water (n = 2 for solubility determinations and n = 3 for viscosity 
determinations) 
PG -water %(v/v) 0-100 10-90 25-75 40-60 75-25 90-10 100-0 
 
NTX•HCl solubility 
[mg/ml] ± SD 
121 ± 1 148 ± 24 159 ± 1 189 ± 22 222 ± 12 301 ± 3 130 ± 5 
Viscosity [cP] ± SD 
1.09 ± 
0.00 
1.70 ± 
0.02 
2.94 ± 
0.01 
5.20 ± 
0.01 
20.97 ± 
0.06 
61.00 ± 
0.53 
51.57 ± 
0.25 
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Table 7.3. The summary of physicochemical properties of the donor solutions 
containing NTX•HCl at 90 mg/g and the excipient listed in the first column of the 
table. Concentrations of excipients vary but the donor solution viscosity remains 
approximately constant 2.7 cP. Osmotic pressure (∏) and apparent pH describe 
the characteristics of the donor solutions while the difference in the osmotic 
pressure (Δ∏) and the difference on the apparent pH refer to the difference 
between donor and receiver solutions. 
Donor 
solution 
MW 
[Da] 
Concentration 
[% (w/w)] 
Concentration 
[mol/l] 
Viscosity 
[cP] 
∏ 
[mOsm] 
Δ∏ 
[mOsm] 
pHapp  ΔpH 
 
PG 
 
76 
 
29.7 
 
3.91 
 
2.66 
 
4222  
 
3922  
 
3.35 
 
4.05 
PEG 400 400 22.1 0.55 2.67 1277  977  3.15 4.25 
sucrose 342 27.4 0.80 2.98 1346  1046  5.40 2.00 
HEC  720 000 0.13 1.8 х 10-6  2.45 311  11  5.04 2.36 
DI water  n/a  n/a  n/a  0.98 312  12  5.31 2.09 
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Figure 7.1. 
 
Representative diffusion profile of NTX•HCl through MN-treated Yucatan minipig 
and intact skin (PG-water 25:75 v/v) (n=3). 
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Figure 7.2. 
 
Steady-state flux values of NTX•HCl permeating through untreated and MN-treated 
Yucatan minipig skin as a function of the donor solution composition. The 
concentration of NTX•HCl is constant 110 mg/ml for all donors, while the amount 
of PG increases to the right of the graph (n = 3–4). 
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Figure 7.3. 
 
NTX•HCl flux enhancement as a result of MN-treatment of the Yucatan minipig 
skin (n = 3–4). 
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Figure 7.4. 
 
Steady-state flux values of NTX•HCl for intact skin pathway, microchannel 
pathway, and the sum of both plotted against calculated diffusivity of NTX in the 
donor solution. Low diffusivity on the left of the graph corresponds to the PG-rich 
donors (n = 3–4). 
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Figure 7.5. 
 
Relative contribution of microchannel pathway flux and intact skin pathway flux to 
the total transdermal flux of NTX•HCl. Calculated according to Eq. 6.4. (n = 3–4). 
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Figure 7.6. 
 
Case 1. Propylene glycol assumed to increase the diffusional resistance of the 
microchannel but not the underlying dermis. Dotted line (•••) corresponds to the 
resistance of the microchannel, dashed line (---) corresponds to the resistance to 
the underlying dermis (viable tissue), and solid line (    ) corresponds to the total 
resistance of the microchannel pathway.  
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Figure 7.7. 
 
Case 2. Propylene glycol assumed to increase the diffusional resistance of the 
microchannel and the underlying dermis. Dotted line (•••) corresponds to the 
resistance of the microchannel, dashed line (---) corresponds to the resistance to 
the underlying dermis (viable tissue), and solid line (    ) corresponds to the total 
resistance of the microchannel pathway. 
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Figure 7.8. 
 
 
Microchannel pathway flux predictions based on the Case 1 (dotted line) and Case 
2 (dashed line) assumptions plotted against experimentally obtained flux (unfilled 
boxes). Experimental data presented as mean ± SD (n = 3-4) 
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Figure 7.9. 
 
Viscosity-normalized flux of NTX•HCl through Yucatan minipig MN-treated skin 
calculated according to Eq. 7.2. (n = 3–4) 
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Figure 7.10. 
 
Steady-state flux (black bars) from donor solutions containing NTX•HCl at 90 
mg/g.  The first four donor solutions also contained the following excipients: 
propylene glycol (PG), poly(ethylene glycol) 400 (PEG 400), sucrose, and 
hydroxyethylcellulose (HEC). The concentration of excipients varied and was 
adjusted so that the viscosity of the donor solution equals approximately 2.7 cP. 
The last donor solution contained no excipient and its viscosity was 
approximately 1 cP. Gray bars correspond to the flux predictions calculated based 
on the viscosity change of the donor solution according to Eq. 6.3. All data 
presented as mean ± SD (n = 4). 
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Figure 7.11. 
 
The flux of NTX•HCl across MN-treated Yucatan minipig skin as a function of 
increasing HEC concentration in the donor solution. Data presented as mean ± 
SD, n = 3. 
 
 
 
 
 
 
 
 
 
Copyright © Mikolaj Milewski 2011 
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Chapter 8 
In vitro permeation of naltrexone prodrugs across microneedle treated skin 
 
8.1. Introduction 
The aim of this chapter is to present the potential of naltrexone prodrugs to be used in 
conjunction with MN-treated skin. In order to fulfill the research goal 3.3 a variety of 
naltrexone prodrugs from different chemical classes were synthesized in Dr. Crooks‘ 
laboratory. Prodrug structures underwent rigorous examination with respect to the 
hydrolytic stability (at physiologically-relevant skin surface pH of 5.0 and tissue and 
blood pH of 7.4) as well as solubility. Only a few prodrugs were deemed suitable for in 
vitro permeation testing. First, a PEGylated ester 3-O‘-naltrexone prodrug stability and 
solubility will be described in detail followed by permeation through MN-treated skin. 
Then, other prodrug classes and the challenges associated with them will be outlined. 
The contents of the following chapter besides point 8.7 have been published in Journal 
of Controlled Release [229]. 
The restrictions in percutaneous drug delivery are largely governed by skin anatomy. 
Skin has evolved to provide an adequate interface between the external and internal 
body environment, to minimize water loss, and to impede the penetration of xenobiotics.   
This evolutionary hurdle results in very low skin permeability to most foreign substances 
[55, 57, 230]. The barrier property of the skin for most compounds lies in the stratum 
corneum (SC) extracellular matrix of lipid bilayers [51, 101]. The pool of molecules 
possessing the necessary physicochemical properties to cross this barrier is limited, and 
the number of drugs that can be delivered transdermally at therapeutically relevant rates 
is also low [17]. To overcome this challenge, a variety of different techniques can be 
used [8, 22]. One of the most promising and effective approaches involves the use of 
microneedles (MN).  Micrometer-size needles were shown to be long enough to 
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penetrate the skin effectively breaching the SC barrier, but at the same time being short 
enough to minimize pain sensation. In general, this process results in up to several 
orders-of-magnitude enhancement of drug transdermal transport [8, 152]. 
Naltrexone (NTX) is a potent, competitive opioid receptor antagonist used to treat opioid 
and alcohol addiction [83]. The percutaneous delivery of this agent could bear 
substantial advantages over currently available dosage forms: i.e. oral tablet and 
intramuscular controlled-release injection [20, 231]. Although neither NTX, nor its active 
metabolite, 6-ß-naltrexol, permeate through skin at clinically relevant rates from 
reasonably-sized patches [20, 231], the use of MN proved to significantly improve 
transport [6]. Studies have shown that although the creation of microchannels in the skin 
after MN treatment did not have a substantial effect on the delivery rates of the neutral 
(free-base) form of NTX or 6-ß-naltrexol, an improvement in the delivery of positively 
charged (salt-form) species of these drugs was possible [6]. It was proposed that higher 
NTX and 6-ß-naltrexol water-solubility at the lower pH range, rather than the presence of 
a positive charge, was responsible for the observed increase in the transport rates of the 
salt forms of these drugs [6]. In vitro and in vivo animal studies proved the utility of the 
MN method of enhancement showing approximately an order-of-magnitude increase in 
the transdermal flux of highly water soluble species via MN-assisted delivery over that 
through untreated skin [6, 155]. Subsequently, a first-in-human MN study demonstrated 
that the combination of MN skin pretreatment and application of four NTX•HCl patches 
afforded drug plasma levels in the lower end of the targeted therapeutic range [216]. 
Furthermore, an increase in flux would be expected to translate into higher plasma 
levels, as well as allow a decrease in the number of patches needed.  
It is known that PEGylation, or the process of covalent attachment of polyethylene glycol 
polymer chains to another molecule can substantially increase aqueous solubility of 
hydrophobic drugs and proteins [232, 233]. Besides improved water-solubility, 
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PEGylation is commonly used in the field of pharmaceutics to serve other purposes, 
such as enhancing stability, modifying pharmacokinetics, shielding labile molecules from 
proteolytic enzymes, or eliminating protein immunogenicity [234-236]. In the field of 
transdermal drug delivery, PEGylation has been employed to alter the physicochemical 
properties of prodrugs to enhance delivery across non-MN-treated skin. Overall, these 
attempts translated into limited success for passive transdermal delivery. An elevated 
aqueous solubility was postulated to contribute to a moderate increase in flux observed 
for some derivatives.  All these studies involved drug delivery through non-MN-treated 
skin [64, 167, 237]. 
Based on the experiments by Banks et al. [6], it could be anticipated that an aqueous 
solubility increase achieved through PEGylation of NTX would favorably affect flux 
through MN-enhanced skin. No previous peer-reviewed literature reports have described 
the transdermal potential of PEGylated drug molecules used in conjunction with MN skin 
treatment. The aim of this work was to evaluate the in vitro transport of a PEGylated 
NTX prodrug through MN-treated skin, as a function of concentration in the donor 
solution. 
 
8.2. Materials and methods 
Chemicals 
Naltrexone was purchased from Mallinckrodt (St. Louis, MO, USA). Water was purified 
using a NANOpure DiamondTM Barnstead water filtration system. Hanks‘ balanced salts 
modified powder, and sodium bicarbonate were purchased from Sigma (St. Louis, MO). 
4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), gentamicin sulfate, 
trifluoroacetic acid (TFA), triethylamine (TEA), 1-heptane sulfonic acid sodium salt, and 
acetonitrile (ACN) were obtained from Fisher Scientific (Fairlawn, NJ). 1-Octane sulfonic 
acid sodium salt was obtained from ChromTech (Apple Valley, MN, USA). 
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Synthetic procedure for the preparation of the naltrexone PEGylated prodrug (PEG-
NTX). The following synthetic procedure was carried out by Dr. Reddy Thirupathi from 
Dr. Crooks‘ laboratory. 
The detailed synthetic procedure for the preparation of 3-O-[3-(2-(2-
hydroxyethoxy)ethoxy)propanoyl]naltrexone prodrug has been reported in Bioorganic & 
Medicinal Chemistry Letters [238]. Briefly, to a mixture of naltrexone (0.341 g, 0.001 
mol), DMAP (0.146 g, 0.0012 mol), and dicyclohexylcarbodiimide (DCC, 0.247 g, 0.0012 
mol) in chloroform (30 ml), 3-(2-(2-hydroxyethoxy)ethoxy)propanoic acid (0.178  g, 0.001 
mol) in chloroform (5 ml) solution was added dropwise over a period of 5-10 min under 
an argon atmosphere at ambient temperature.  The solution was stirred at ambient 
temperature for 24 hrs, then it was cooled to 0-5 °C, and the precipitated dicyclohexyl 
urea by-product filtered-off. The filtrate was washed with ice-cold water (20 ml), ice-cold 
brine solution (20 ml), dried over Na2SO4, and the solvent evaporated in vacuo.  The 
resulting residue was purified by column chromatography (silica gel, eluted with 3% v/v 
methanol in chloroform) to obtain pure 3-O-[3-(2-(2-
hydroxyethoxy)ethoxy)propanoyl]naltrexone (0.42 g, 85% yield) as a colorless oil.   
 
Solubility 
The apparent solubilities of the PEG-NTX prodrug and NTX in 0.3M acetate buffer (pH 
5.0) were obtained by equilibration of an excess quantity of prodrug/drug in 6ml of buffer. 
After addition of prodrug/drug, the pH of the resulting slurry was adjusted to pH 5.0, if 
this was found to be necessary. The PEG-NTX prodrug slurry was continuously shaken 
in a tightly closed glass vial in a shaking water-bath at 32°C for 12h. A relatively short 
equilibration time was chosen, due to the hydrolytic instability of the prodrug. The NTX 
slurry was continuously shaken in a tightly closed glass vial in a shaking water bath at 
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32°C for 24h. At the end of the equilibration time, samples were transferred to 
prewarmed plastic centrifuge vials and centrifuged for 10 min at 12000 x g at 32°C. The 
supernatant was sampled, filtered using a 32°C prewarmed syringe containing a 0.2 µm 
membrane syringe filter (VWR 28145-491), diluted with an adequate amount of ACN-
water 70:30 (v/v), and resulting solution analyzed by high pressure liquid 
chromatography (HPLC). Solubility determinations were repeated twice (n = 2).  
 
Prodrug stability 
For the purpose of determining the pH-rate profile, several 20mM buffers were prepared 
and adjusted to the constant ionic strength of I = 0.1 with NaCl: i.e. pH 2.0 (phosphate 
buffer), pH 3.3 (citrate buffer), pH 4.4 (formate buffer), pH 5.4 (acetate buffer), pH 5.9 
(citrate buffer), pH 6.9 (phosphate buffer) and pH 8.7 (ammonium buffer). A stock 
solution of PEG-NTX was obtained by dissolving about 40mg of the prodrug in 2 ml 
ACN. Then, 100µl of the stock solution was transferred to 10ml of buffer thermostated at 
32°C, vortexed and filtered through a 0.45µm nylon syringe filter (Acrodisc® Premium 
25mm Syringe Filter).  Multiple samples were drawn over a period of 140h. Next, 
prodrug stability studies in donor (0.3M acetate buffer pH 5.0) and receiver solutions 
(25mM HEPES-buffered Hanks‘ balanced salt solution pH 7.4) were initiated by charging 
a 10ml volume of hydrolysis media thermostated at 32°C with ≈1mg of prodrug, filtering 
the solution through a 0.45µm nylon syringe filter (Acrodisc® Premium 25mm Syringe 
Filter) and taking samples of the filtrate over a period of 120h. Samples were then 
diluted with ACN-water 70:30 (v/v) for HPLC analysis. All PEG-NTX-prodrug hydrolysis 
studies showed pseudo-first-order kinetic behavior. Apparent pseudo-first-order 
hydrolysis rate constants, kapp, were estimated from the slope of the log-transformed 
amount of PEG-NTX prodrug remaining in the medium. All stability studies were carried 
out in duplicate (n = 2). 
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Donor solution preparation 
Acetate buffer (0.3M, pH 5.0) containing prodrug at saturation (629mM) was diluted with 
0.3M acetate buffer, pH 5.0 to obtain solutions at 10, 20, 40, 70 and 90% solubility. 
Solutions were vortexed and used immediately in in vitro diffusion studies. 
NTX was added to 0.3M acetate buffer, pH 5.0 to obtain concentrations of 25, 50, 75, 
178 and 338mM and the pH of the solutions adjusted to 5.0, if necessary. Solutions were 
vortexed and used immediately in in vitro diffusion studies immediately. 
 
Viscosity measurements 
A Brookfield DV-III LV programmable cone/plate rheometer with a CPE-40 spindle was 
used for measuring the viscosity of the donor solutions. The sample volume was 0.5 ml. 
All determinations were carried out at 32 ⁰C maintained by a circulating water-bath TC-
102. Each donor viscosity measurement was taken three times at low, medium and high 
torque value in the range of 10-100% of the instrument specifications (n = 3).  
 
In vitro diffusion studies 
Full-thickness Yucatan minipig skin was harvested from the dorsal region of a 
euthanized 6-month-old animal. Animal studies were approved by the University of 
Kentucky IACUC. Subcutaneous fat from skin samples was removed with a scalpel and 
sparse hair clipped. Such skin samples were immediately placed in a plastic bag and 
frozen until use (-20°C). The effect of freezing on skin viability [239-241] and 
permeability to xenobiotics [241-244] has been the subject of multiple studies. The 
presence [241-243] or absence [244] of freezing-induced increased skin permeability is 
related to factors such as skin type, nature of the permeant, freezing conditions and time 
of storage. Our experience indicates no major detrimental effect is caused by Yucatan 
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minipig skin freezing up to one year of storage for the purpose of use in in vitro drug 
permeation studies. Before the permeation study, skin samples were allowed to thaw for 
about 30 min. Skin used for MN treatment was first dermatomed to a thickness of about 
1.7mm and then placed on a wafer of polydimethylsiloxane polymer, which mimicked the 
naturally occurring mechanical support of underlying tissue because of its comparable 
structural elasticity. In the context of studies described in this article ―MN‖ refer to 
microneedle rows obtained from Dr. Prausnitz‘s laboratory. They were fabricated by 
laser cutting of stainless steel sheets as reported previously [29]. MN were solid metal, 
two-dimensional ―in-plane‖ rows each containing five microneedles oriented with their 
axis parallel to the steel sheet. This design is characterized by the following microneedle 
dimensions: 750 µm long, 200 µm wide, 75 µm thick and 1.35 mm inter-needle spacing.  
The insertion of MN into skin was carried out manually by applying gentle finger 
pressure followed by their instantaneous removal. The diffusion area of skin (0.95 cm2) 
was pierced 20 times, with a row containing five microneedles, gradually advancing the 
MN application area to obtain 100 non-overlapping piercings before mounting the skin in 
the diffusion cell. If any damage to the MN was observed a new array was used. Three 
to four cells were used per one drug/prodrug concentration (n = 3-4). A PermeGear flow-
through (In-Line, Riegelsville, PA) diffusion cell system was used for the in vitro diffusion 
studies. Isotonic HEPES-buffered Hanks‘ balanced salts solution (25mM, pH 7.4) was 
used as the receiver solution. Additional experiments were carried out to ascertain that 
the receiver flow rate of 1.5 ml/h was sufficient to maintain sink conditions. An increase 
in flow rate to 7.5ml/h did not change the amount of drug permeating over time, and a 
lower 1.5ml/h flow rate was used for all experiments for practical convenience. Skin 
samples in the diffusion cells were maintained at 32°C using a circulating water bath. 
The diffusion experiments were initiated by charging the donor compartment with 0.4 ml 
of the donor solution. Samples were collected from the receiver compartment in 6h 
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increments over 48h. All samples were stored at 4°C until HPLC analysis, which was 
carried out within 24 hours.   
 
Transepidermal water loss (TEWL) measurements 
TEWL was used to assess the integrity of the skin barrier using a DermaLab® TEWL 
probe (CyberDerm Inc.). MN-treatment, by itself, increases TEWL and detection of 
possible barrier compromise due to vehicle alone under such conditions would be 
difficult at best. Therefore, a separate diffusion experiment was carried out to evaluate 
the effect of the drug-free donor solution (0.3M acetate buffer) on the barrier properties 
of the untreated skin. The TEWL values for uncompromised minipig skin are known, and 
are generally equal or less than 10 g m-2 h-1 [245-247]. Measurements were taken after 
30 min. equilibration of the untreated skin with the receiver solution in the diffusion 
apparatus before charging the donor chamber with the drug-free 0.3 M pH 5.0 acetate 
buffer. Another measurement was obtained after removal of the buffer from the donor 
chamber after 48 h, and 30 min equilibration. 
 
Prodrug skin disposition 
After the completion of the diffusion experiment, skin samples were rinsed three times 
with distilled water to remove residual formulation and then dismounted from the 
diffusion cells. A circular section of the skin corresponding to the diffusion area was 
excised with a scalpel and weighed. Next, the skin sample was placed in a glass vial 
containing 10 ml of ACN, the vial closed tightly and left in a shaking water bath 
thermostated at 32°C for 12 h. Solutions were then sampled, diluted with ACN and 
analyzed by HPLC. The PEG-NTX prodrug and NTX content was normalized by skin 
weight and reported as the concentration in the skin. 
 
137 
 
Quantitative analysis 
Quantitative analysis of NTX and the PEG-NTX prodrug by HPLC was carried out using 
a modification of the assay described by Hussain et al. [225]. The HPLC system 
consisted of a Waters 717 plus autosampler, a Waters 600 quaternary pump, and a 
Waters 2487 dual wavelength absorbance detector with Waters Empower™ software. A 
Waters YMCTM CN column (2.0mm × 150mm) with a CN guard column of the same type 
(2.0mm × 20mm) was used with the UV detector set at a wavelength of 278nm. The 
mobile phase consisted of 70:30(v/v) ACN:0.1% TFA containing 0.065% 1-octane 
sulfonic acid sodium salt, adjusted to pH 3.0 with TEA aqueous phase. Samples were 
run at a flow rate of 1.5 ml/min with a run time of 4.5 min. The injection volume was 100 
µl, and the retention times of PEG-NTX and NTX were 3.2 min and 3.5 min, respectively. 
Samples were analyzed within a 100–5000ng/ml linear range of the PEG-NTX prodrug 
and NTX standard curves. Standard solutions exhibited excellent linearity over the entire 
concentration range employed in the assays. 
The permeation data were plotted as the cumulative amount of PEG-NTX and NTX 
collected in the receiver compartment as a function of time. The steady-state flux value 
for a given run was calculated from the terminal slope of the cumulative amount plotted 
against time. The permeability coefficient was obtained from Fick‘s first law of diffusion: 
 
1
A
 
dM
dt
 = JSS = P × ΔC        (8.1) 
 
where, Jss is the steady-state flux, M is the cumulative amount of drug permeating the 
skin [nmol], A is the area of the skin [0.95 cm2], P is the effective permeability coefficient 
[cm h-1], and ΔC is the concentration difference [nmol cm-3] of the drug in donor and 
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receiver solutions. Since sink conditions prevail under constant flow of the receiver 
solution, ΔC is well-approximated by the drug donor concentration alone.  
 
Statistical analysis 
The statistical analysis of the data was carried out by one-way ANOVA with post-hoc 
Bonferroni‘s analysis using SIGMA-STAT software (SPSS, Inc., Chicago, IL, USA). 
  
8.3 Stability and solubility of PEGylated naltrexone prodrug 
The structures of both parent drug (NTX) and its PEGylated prodrug (PEG-NTX) are 
presented in Figure 8.1. A short, two ethylene-glycol unit side chain is attached through 
a hydrolytically labile carboxylate ester linkage to the 3-O position of the NTX molecule. 
Before the in vitro evaluation of the prodrug permeation through the MN-treated skin was 
carried out, its stability was studied at different pH values. A wide pH range was 
investigated with the aim of identifying the pH-dependency for slow and fast chemical 
hydrolysis. The prodrug stability studies at all pH values showed pseudo first-order 
degradation behavior. Apparent pseudo first-order rate constants (kapp) were obtained 
from the slope of the log-transformed amount of prodrug remaining plotted against time. 
Figure 8.2 summarizes the pH stability in the form of a U-shaped pH-rate profile. At pH 
values around 3-5, the PEG-NTX prodrug is most stable. Lower pH values reveal acid-
catalyzed hydrolysis while higher pH values demonstrate base-catalyzed hydrolysis.  
Specifically, in the pH region 7-9, the slope reaches a value of unity, indicating that 
hydroxide ion-catalyzed hydrolysis is the predominant mechanism of hydrolysis in this 
pH range. Since under normal conditions, the surface pH of the skin oscillates around 
4.5 – 6.0, a donor solution of pH 5.0 was chosen for diffusion experiments to closely 
mimic the physiological milieu [248, 249]. This pH value also provides the best stability 
for the PEG-NTX prodrug, as indicated by the pH-rate profile. On the other hand, the 
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receiver solution was buffered to the physiologically relevant pH 7.4, reflecting the 
environment of the deeper layers of skin and bodily fluids [250, 251]. Because the actual 
composition of the donor and receiver solutions differed from buffers used in the stability 
determination, an additional hydrolysis study was carried out to evaluate PEG-NTX 
stability in those media. It was found that the prodrug‘s kapp in the donor solution was 
1.93·10-3 h-1, which translates into a t90 of about 54 h, while in the receiver solution kapp 
equaled 2.88·10-2 h-1 or a t90 of about 4 h. In other words, by chemical hydrolysis alone, 
PEG-NTX would be expected to degrade releasing the parent drug 15 times faster in the 
receiver solution as compared to the donor solution. Overall, the t90 of over 48 h (the 
duration of diffusion experiment) was deemed to be sufficient to ensure that only a small 
portion (<10 %) of NTX coming from prodrug in the donor solution would be formed, and 
would not substantially affect the interpretation of the data.  Besides stability, the second 
key parameter of interest was solubility. The main purpose for designing a PEGylated 
NTX prodrug was to achieve increased water-solubility of the drug in the donor solution. 
The apparent aqueous solubility values for the parent drug and prodrug were 338 mM 
and 629 mM, respectively, showing nearly a 2-fold increase in apparent aqueous 
solubility of the prodrug compared to that of NTX.  
 
8.4. Permeation and simultaneous bioconversion 
The potential detrimental effect of the acetate buffer (present in donor solution) on skin 
was evaluated in a separate experiment involving transepidermal water loss (TEWL) 
measurements before and after charging the donor chamber with the drug-free donor 
solution over 48 h. Typical readings for untreated minipig skin were equal to or less than 
10 g m-2 h-1 [245-247]. The experimental TEWL values for untreated skin remained low 
and increased from 2.2 ± 0.4 to 3.1 ± 0.2 g m-2 h-1 over 48 h, suggesting no damage to 
the barrier had occurred. All in vitro diffusion experiments used MN-pretreated Yucatan 
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minipig skin. Minipig skin is a well-established model for human skin in transdermal drug 
delivery as it possesses the characteristics similar to those of the human skin [34, 35]. 
However, as every model, it has some limitations [36] and results reported here should 
not be extrapolated to human skin without caution. Differences in the structure of the 
dermis may translate into different diffusional resistance of that tissue and, therefore, 
affect the flux values obtained from MN-enhanced permeation experiments.  The 
diagram of the experimental set-up used to investigate the transport of PEG-NTX 
prodrug across MN-treated skin is presented in Figure 8.3.  
The transdermal permeation through MN-enhanced skin was evaluated at 6 
concentrations for PEG-NTX: i.e. 10, 20, 40, 70, 90 and 100 % saturation, or 63, 126, 
252, 440, 566 and 629 mM. The saturated solution did not contain any undissolved 
prodrug to ensure that potential interference between excess prodrug and 
microchannels, such as obstruction of the microchannel opening, presence of the 
undissolved prodrug in the microchannels, etc., would not affect the results. Since the 
prodrug possesses much lower chemical stability at elevated pHs, its diffusion across 
MN-treated skin is accompanied by simultaneous chemical hydrolysis and possibly 
enzymatic bioconversion. As a result, two species, the prodrug itself and NTX generated 
from hydrolysis of the prodrug, are detectable in the receiver solution. Prodrug 
permeation from donor solution at either concentration tested resulted in steady-state 
conditions after a relatively short lag time. A representative permeation profile is 
presented in Figure 8.4 and permeation data is summarized in Table 8.1. The total flux 
was obtained by summation of prodrug flux and NTX-from-prodrug flux, and can be seen 
as a measure of overall performance of the prodrug. Steady-state total flux values 
plotted as a function of PEG-NTX concentration in the donor are shown in Figure 8.5. 
(Note that Table 8.1 reports flux of unhydrolyzed (intact) PEG-NTX prodrug and NTX-
from prodrug separately while Figure 8.5 sums them up to obtain total PEG-NTX 
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prodrug flux (filled circles) which is contrasted with the flux of NTX alone obtained from a 
separate experiment). 
 
8.5. Deviations from ideal behavior 
While in the lower concentration range (63–252 mM) the increase in the flux is roughly 
proportional to the increase in concentration, at higher concentrations (440–629 mM) the 
flux is independent, if not inversely related, to the donor concentration. The behavior in 
the low concentration range can be well predicted by using Fick‘s first law of diffusion 
and a concentration-independent permeability coefficient. However, the deviation from 
ideal behavior is substantial in the higher concentration range. Additionally, Figure 8.5 
illustrates the permeation of the parent drug alone from data obtained from a separate 
experiment. NTX alone provides higher flux as compared to the PEG-NTX prodrug at 
any corresponding concentration. The permeability coefficient of the prodrug is expected 
to be somewhat lower than the permeability coefficient of the parent drug, due to its 
higher molecular weight. In bulk solution (as in microchannels), the Stokes-Einstein 
equation can be used to inversely relate solute diffusivity to the cubic root of the size of a 
molecule, D ~ MW-0.33. On the other hand, in dermis, Kretsos et al. found that the Wilke-
Chang relationship, which predicts a steeper drop in diffusivity as a function of 
increasing molecular weight, D ~ MW-0.6, correlated well with their experimental data 
[59]. However, other functional relationships including that predicted by the Stokes-
Einstein equation were not excluded. In other words an increase in the molecular weight 
from 341 Da (parent drug) to 502 Da (PEG-NTX prodrug) would be expected to 
decrease prodrug diffusivity by about 12% (by the Stokes-Einstein equation) or about 
20% (by the Wilke-Chang relationship). Furthermore, the hydrodynamic radius of the 
PEG-NTX prodrug may be actually larger than that calculated from the molecular weight 
alone due to the association of water molecules with the PEG chain. Overall, superior 
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prodrug solubility, even with a somewhat decreased diffusivity, but in the absence of 
non-ideal behavior, should result in improved transdermal flux through MN-treated skin. 
 
8.6. Viscosity influence on prodrug diffusivity 
It has been suggested that the viscosity of the donor solution may have a vital effect on 
drug delivery rates through MN-treated skin [39]. The relationship between the viscosity 
(η) of the diffusion medium and the diffusion coefficient is given by the Stokes-Einstein 
equation: 
 
D = 
kT
6πηr
          (8.2) 
 
where k is Boltzmann‘s constant, T is absolute temperature, and r is the radius of the 
diffusant (assuming it can be represented by a spherical particle). Specifically, it was 
shown that the NTX•HCl flux through microchannels and underlying dermis correlated 
well with the decrease in the calculated drug diffusivity in the donor solution. Additionally, 
the flux through microchannels using aqueous drug solutions was found to be well 
approximated by the flux through MN-enhanced skin (the contribution of flux through 
skin around microchannels was low). To test the hypothesis that an increase in the 
viscosity of the prodrug-containing donor solution may explain low PEG-NTX flux at high 
concentrations, the donor solution viscosity values were measured. It is known that at 
sufficiently high solute concentration, solvent viscosity can be altered, exerting a 
secondary effect on the solute‘s own diffusivity [54]. Figure 8.6 shows that donor 
solution viscosity increases in an exponential fashion as a function of the prodrug 
concentration, and demonstrates approximately a 3-fold increase between the lowest 
and highest concentrations tested. A simple log-linear empirical equation in the form of: 
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log η = a × C + b         (8.3) 
 
was used to describe this trend for later flux calculations, where C is concentration [mM] 
and a and b are fitted parameters [252].  The experimental data can be transformed by 
normalizing either flux or permeability coefficient for apparent viscosity effect. 
Multiplication by viscosity of a given donor solution affords the viscosity normalized 
parameter, e.g.  
 
J
'
= J × η         (8.4) 
 
or  
 
P
'
= P × η         (8.5) 
 
where J‘ is the viscosity-normalized flux, J is the experimentally measured flux and ŋ is 
the viscosity of the donor solution, and the P‘ is the viscosity-normalized permeability 
coefficient and P is the experimentally determined permeability coefficient. Such 
correction results in flux or permeability coefficient values corresponding to a viscosity 
value of unity. If the hypothesis is valid, it would be expected that the viscosity-
normalized flux will correlate linearly with the prodrug concentration in the donor solution 
over the whole concentration range tested. A plot of viscosity-normalized flux is 
presented in Figure 8.7, which shows a reasonable linear correlation (R2 = 0.96). 
Moreover, from the slope of this graph, an average viscosity-normalized permeability 
coefficient P‘ave of 23.01· 10
-5 ± 2.57 · 10-5 (mean ± 95% CI) was estimated. Individual 
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viscosity-normalized permeability coefficients (P‘) are reported in Table 8.2. Apart from 
the P‘ for the 63 mM concentration which is somewhat higher than the average, the 
normalized permeability coefficients are concentration-independent over the range of 
prodrug concentrations tested (one way ANOVA with post-hoc Bonferroni‘s analysis 
reveals a statistically significant difference at α = 0.05 between the P‘ at 63 mM and P‘ at 
629 mM). In other words, the changes in MN-enhanced percutaneous flux of the PEG-
NTX prodrug can be satisfactorily explained by changes in the viscosity of the donor 
solution.  
Assuming that most prodrug molecules permeate through microchannels and into the 
dermis below, rather than through skin around microchannels, a two-ply membrane 
concept incorporating the microchannel and underlying dermis can be used to rationalize 
the data. In the experimental set-up used in the current study the thickness of the dermis 
below the microchannel exceeds the length of the microchannel, and the diffusion 
coefficients of drugs in the dermis are known to be approximately 3.7-fold lower as 
compared to those in the bulk aqueous solutions [59]. Based on the above, it can be 
expected that the major diffusional resistance lies in the dermis layer. Therefore, flux 
should not depend on the viscosity of the donor solution unless it changes the properties 
of the barrier (dermis). It is possible that the prodrug-containing, elevated-viscosity donor 
solution alters the microenvironment of the dermis by increasing its diffusional 
resistance. Assuming this effect is similar to that seen in the bulk solution, flux through 
microchannels and dermis below would be inversely related to the viscosity of the donor 
solution. In other words, the results from the current study imply that changes in the 
prodrug diffusivity in the donor solution are reflective of prodrug diffusivity changes in the 
whole skin barrier. Using the previously estimated average viscosity-normalized 
permeability coefficient (P‘ave) and the viscosity of the donor solution at any given 
concentration, an expected flux (Jcalc) can be calculated from: 
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 Jcalc= 
P'ave
η
 × C        (8.6) 
 
which, after incorporation of Eq. 3, becomes:  
 
Jcalc= 
P'ave
10
(0.000807×C - 0.097641)
 × C        (8.7) 
 
where C is the prodrug donor concentration [mM]. Figure 8.8 presents experimental 
data and compares it to the predicted total flux for the PEG-NTX prodrug. A reasonable 
agreement between experimental and calculated values lends practical utility to this 
approach. Finally, prodrug skin disposition studies at the end of the diffusion experiment 
were carried out. Both prodrug and NTX-from-prodrug were detected in the skin. Table 
8.3 shows the amount of each as a function of changing concentrations in the donor 
solution. The extent of prodrug metabolism, calculated as fraction of prodrug converted 
to NTX, does not differ substantially and remains constant at 37 ± 10%. This value is 
somewhat higher that its counterpart (29 ± 9%) obtained from flux values (Table 8.1), 
and likely reflects extra degradation that occurred during sample processing time and 
skin extraction procedures. A lack of decline in the fraction of prodrug metabolized with 
an increase in concentration suggests either chemical hydrolysis alone or chemical 
hydrolysis accompanied by non-saturable enzymatic hydrolysis is the primary 
mechanism for PEG-NTX hydrolysis in skin. 
 
8.7. Other prodrugs and codrugs for MN-enhanced drug delivery 
A multitude of other naltrexone and 6β-naltrexol prodrugs and codrugs were synthesized 
by Dr. Crook‘s group. Most of them were evaluated with respect to the hydrolytic stability 
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in the aqueous vehicle at pH 5.0 and with respect to the hydrolytic stability at pH 7.4. A 
list of structures possessing a variety of prodrug moieties and different chemical linkers 
are presented in Table 8.4. It was decided that chemical stability at pH 5.0 should be at 
least enough to provide less than 10% prodrug degradation over the duration of the in 
vitro diffusion experiment. This translated into a pseudo first-order hydrolytic rate 
constant of less than 2.2x10-3 h-1. As evident from a stability summary in Figure 8.9 
many prodrugs did not fulfill this requirement. The lack of adequate formulation stability 
was the single major issue related to prodrug use. Some of the comparisons, among the 
tested compounds, are instructive. The hydrolytic stability between compounds of the 
same chemical linker containing minor modification at the side chain situated far from 
the reaction center is similar (YTR-NTX-20 vs. YTR-NTX-43 and YTR-NTX-28 vs. YTR-
NTX-63). Everything else being the same, carbamate esters hydrolyzed 2-fold slower 
than carboxylate esters (YTR-NTX-20 vs. YTR-NTX-28 and YTR-NTX-43 vs. YTR-NTX-
63). NTX prodrugs containing an electron-withdrawing oxygen atom situated close, β, to 
the reaction center hydrolyzed about 16–fold faster as compared to the structures 
possessing an oxygen atom in the farther γ position (YTR-NTX-29 or YTR-NTX-31 vs. 
YTR-NTX-43), which can be rationalized on the basis of facilitating the nucleophilic 
attack at the carbonyl. A carboxylate carbohydrate prodrug hydrolyzed much faster than 
its PEGylated counterparts (YTR-NTX-69 vs. YTR-NTX-29 or YTR-NTX-31). A cholyl 
carbonate prodrug of NTX hydrolyzed at a similar rate to the PEGylated carboxylate 
prodrugs of NTX with oxygen in the β position (YTR-NTX-100 vs. YTR-NTX-29 or YTR-
NTX-31). The NTX-cytisine codrug (JAE-1) is characterized by very high chemical 
stability (no hydrolysis observed over the stability study duration) as can be expected 
from a disubstituted carbamate linker [253]. Finally, with respect to the reactivity of the 
3O‘ and 6O‘ hydroxide groups of NTX and NTXol; the reactivity of the phenolic –OH is 
much greater as can be expected from a better leaving group character. The pKa of a 
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phenolic group is around 10 while the pKa of an aliphatic hydroxide group is around 14. 
This difference is readily observed while comparing the hydrolytic rates of 3O‘ NTX and 
6O‘ NTXol amino acid prodrugs (Val-3O‘-NTX and Leu-3O‘-NTX vs. Val-6O‘-NTXol and 
Leu-6O‘-NTXol). Also, the duplex carbonate NTXol codrug (YTR-NTXol-89) hydrolyzed 
slowly as could be expected based on the lower reactivity of the 6O‘ hydroxyl group and 
steric hindrance provided by two bulky NTXol molecules in the direct vicinity of the 
reaction center. In order to increase the stability of some prodrugs the change in 
aqueous vehicle composition was investigated. The addition of a cosolvent, such as PG, 
to unbuffered water was found to dramatically influence the rate of hydrolysis. The 
increase in the abundance of PG caused a decrease in the hydrolysis rate. The 
magnitude of this effect was different for carboxylate and carbamate esters as shown in 
Figure 8.10 and Figure 8.11. However, the practical utility of this approach is limited 
due to the effect that a cosolvent exerts on flux through MN-treated skin as described in 
Chapter 7. 
The stability at pH 7.4, was typically at least one order of magnitude lower as compared 
to pH 5.0, which was expected and advantageous from the perspective of systemic drug 
delivery. The notable exception was the JAE-1 codrug, which was very stable under both 
pH values. This observation is in agreement with a different, and extremely slow, 
mechanism which is involved in the hydrolysis of disubstituted carbamates [253]. 
The fulfillment of the stability prerequisites was not interpreted as a warrant for 
progressing to the in vitro diffusion studies. In addition to the adequate stability a 
produg/codrug must possess high solubility so that the driving force for diffusion is high. 
An example of a codrug which possessed desired stability but failed to demonstrate high 
solubility is YTR-NTXol-89. Despite promising formulation stability the solubility at 
relevant pH of 5.0 was very low (Figure 8.12) and no permeation studies were carried 
out with this molecule. 
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8.8. Conclusions 
The current study explored the in vitro permeation of a PEGylated NTX prodrug across 
MN-treated skin as a function of its concentration in the donor solution. It has been found 
that the flux did not proportionally increase when high concentrations of the prodrug in 
the donor solution were utilized. In other words, the apparent permeability coefficient 
(calculated as a ratio of flux over drug concentration in the donor solution) is not a 
concentration-independent proportionality constant between flux and drug concentration. 
It was hypothesized that this non-linearity was caused by elevated viscosity of the donor 
media. Calculations based on the Stokes-Einstein equation afford a reasonable 
explanation of the experimental data. Interestingly, if this reasoning is correct, a clear 
decline in flux would be expected with further increases in prodrug concentrations in the 
donor solution. It was not possible to investigate this with the present PEG-NTX prodrug, 
due to its limited solubility. Overall, it cannot be excluded that other formulation 
characteristics besides viscosity of the donor solution may also alter transport rates 
through MN-treated skin. Apart from kinetics considerations, a decrease in the 
thermodynamic chemical potential of the diffusant at high concentrations may also 
contribute to deviation from ideal behavior. Nevertheless, in the present study, 
accounting for changes in viscosity alone provided a rational interpretation for the data 
obtained. Obviously, the generalization of the results obtained from the current study will 
require further investigation. It is not expected that the type of behavior seen in the 
present study will be universal for all MN-involving transport experiments as different 
methods of MN application, MN design and formulation characteristics play a significant 
role in the drug transport across MN-treated skin [254]. In consequence, the generality of 
the present in vitro findings may be limited to the studies involving, among others, water-
based formulations, MN-pretreated skin with microchannels having similar nature to 
those obtained in this study and permeants which cross the skin mainly through 
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microchannels and underlying dermis, rather than through the intact skin around 
microchannels. Overall, it is very likely that the prodrug approach to increase aqueous 
solubility of a poorly soluble lipophilic parent drug could be successful in increasing flux 
across microchannel pathway. However, in the present study, charged NTX possesses 
already high water solubility and further increase seems not to translate into any 
practical benefit due to deviations from ideal behavior. If the above reasoning is correct, 
the maximum flux for a compound permeating across microchannel pathway would 
occur where the ratio of donor solution concentration to donor solution viscosity is the 
highest. 
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Table 8.1. Summary of the in vitro permeation of the PEG-NTX prodrug through 
MN-treated Yucatan minipig skin from donor solutions containing prodrug at 
different concentrations. Simultaneous diffusion and hydrolysis of the prodrug 
resulted in the detection of both: prodrug itself and NTX-from-prodrug in the 
receiver phase. Each value represents the mean ± SD (n = 3-4). 
 
Prodrug 
concentration in 
donor solution 
[mM] 
 
 
Prodrug   
NTX-
from-
prodrug 
 
Fraction of 
prodrug 
converted ± SD 
[%] 
n 
Flux ± SD 
[nmol cm-2 h-1] 
Lag time 
± SD [h] 
 
Flux ± SD 
[nmol cm-2 h-1] 
Lag time 
± SD [h] 
    
           
63  17.9 ± 5.3 5.8 ± 0.7  6.8 ± 2.5 10.5 ± 1.1  28 ± 12  3 
126  22.9 ± 5.7 8.4 ± 2.6  9.0 ± 2.5 9.5 ± 2.2  28 ± 10  4 
252  37.9 ± 7.3 7.8 ± 1.0  14.1 ± 2.8 8.6 ± 1.1  27 ± 7  4 
440  45.0 ± 4.1 7.7 ± 0.6  20.5 ± 2.3 12.0 ± 1.7  31 ± 4  3 
566  40.8 ± 13.8 4.2 ± 2.3  17.0 ± 4.8 8.6 ± 1.5  29 ± 11  4 
629  35.5 ± 10.1 3.5 ± 2.7  14.6 ± 3.6 7.8 ± 2.9  29 ± 9  4 
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Table 8.2.  Summary of individual permeability coefficients (P) and viscosity-
normalized permeability coefficients (P’) as a function of the prodrug 
concentration in the donor solution. Permeability coefficients were normalized per 
viscosity according to Eq. 5. Each value represents the mean ± SD (n = 3-4). 
 
Prodrug donor 
concentration [mM] 
63 126 252 440 566 629 
n 3 4 4 3 4 4 
P x 105 ± SD [cm h-1] 39.3 ± 9.3 25.4 ± 4.9 20.7 ± 3.1 14.9 ± 1.1 10.2 ± 2.6 8.0 ± 1.7 
P’ x 105 ± SD [cm h-1] 36.1 ± 8.6 25.4 ± 4.9 25.9 ± 3.9 26.5 ± 1.9 23.2 ± 5.9 21.0 ± 4.5 
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Table 8.3. Summary of the drug skin disposition at the end of the 48 h diffusion 
experiment involving MN-treated Yucatan minipig skin. Both the PEG-NTX prodrug 
and NTX-from-prodrug were detected in the skin. Each value represents the mean 
± SD (n = 3-4). 
 
Prodrug donor 
concentration [mM] 
63 126 252 440 566 629 
n 3 4 4 3 4 4 
Prodrug amount ±  SD 
[nmol/g skin] 
367 ± 127 597 ± 214 850 ± 306 1445 ± 123 1352 ± 125 1459 ± 236 
NTX from prodrug 
amount ±  SD  
[nmol/g skin] 
253 ± 54 404 ± 129 504 ± 189 752 ± 68 749 ± 68 784 ± 87 
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Table 8.4. A list of prodrug and codrug structures of naltrexone and 6β-naltrexol 
tested for hydrolytic stability at pH 5.0 and pH 7.4. Name, molecular weight, 
estimated log Ko/w (ChemDraw
® 8.0), and chemical structure are reported. 
CARBOXYLATE PEGYLATED PRODRUGS 
Name MW logKo/w Structure 
YTR-NTX-20 502 0.08 
 
YTR-NTX-21 606 2.21 
 
YTR-NTX-29 502 0.15 
 
YTR-NTX-31 458 0.30 
 
YTR-NTX-43 516 0.44 
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CARBAMATE PEGYLATED PRODRUGS 
Name MW logKo/w Structure 
YTR-NTX-28 517 -0.12 
 
 
 
 
 
 
 
YTR-NTX-63 530 0.24 
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CARBOXYLATE CARBOHYDRATE PRODRUGS 
Name MW logKo/w Structure 
YTR-NTX-69 685 -0.4 
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CARBOXYLATE AMINO ACID PRODRUG PRECURSORS 
Name MW logKo/w Structure 
JAE-2 647 2.82 
 
O
N
OH
OO
O
HN
O
O
O
O
 
CARBAMATE CODRUGS 
Name MW logKo/w Structure 
JAE-1 558 0.19 
 
O
N
OH
O
O
O
N
N
O
 
 
CARBONATE DUPLEX PRODRUGS OF 6-β-NALTREXOL 
Name MW logKo/w Structure 
YTR-NTXol-89 712 N/A 
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CHOLYL CARBONATE PRODRUG OF NALTREXONE 
Name MW logKo/w Structure 
YTR-NTX-100 507 N/A 
HO
N
O
O
O
O
O
N Cl
  
AMINO ACID ESTER PRODRUGS OF 6β-NALTREXOL 
Name MW logKo/w Structure 
6-O-valinyl-
naltrexol ester 
443 2.04 
 
6-O-β-alanyl-
naltrexol ester 
414 1.15 
 
6-O-prolinyl-
naltrexol ester 
441 1.82 
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6-O-alanyl-
naltrexol ester 
414 0.81 
 
 
 
 
6-O-leucinyl-
naltrexol ester 
456 2.04 
 
 
 
 
6-O-isoleucinyl-
naltrexol ester 
457 2.11 
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AMINO ACID ESTER PRODRUGS OF NALTREXONE 
Name MW logKo/w Structure 
3-O-alanyl-
naltrexone ester 
412 0.21 
 
 
 
3-O-leucinyl-
naltrexone ester 
454 1.44 
 
 
 
3-O-valinyl-
naltrexone ester 
440 1.09 
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DUPLEX CARBAMATE PRODRUGS 
Name MW logKo/w Structure 
AVR-11 851 - 
 
AVR-13 823 - 
 
AVR-15 879 - 
 
AMINO PRODRUG 
Name MW logKo/w Structure 
AVR-14 456 0.37 
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Figure 8.1. 
 
 
 
Structures of (a) naltrexone and (b) its PEGylated prodrug. 
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Figure 8.2. 
 
pH-rate profile for the hydrolysis of the PEG-NTX prodrug ester bond in 20mM 
buffers, I = 0.1 at 32°C. Points indicate apparent rate constants for the degradation 
of the prodrug (n = 2). 
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Figure 8.3. 
 
Diagram of the in vitro experimental set-up used to study the permeation of the 
PEG-NTX prodrug. Yucatan minipig skin was treated with MN to obtain 100 
microchannels and mounted into a diffusion cell. Six different concentrations of 
the prodrug solution (pH 5.0) were prepared and placed in diffusion cell donor 
compartments to initiate the permeation experiment. Fractions of the receiver 
solution composed of the isotonic HEPES-buffered Hanks’ balanced salts solution 
(pH 7.4) were collected every 6h over the 48h duration of the experiment. They 
were analyzed by HPLC for the presence of the PEG-NTX prodrug (intact prodrug) 
and the NTX-from-prodrug (parent drug generated from prodrug). 
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Figure 8.4. 
 
Representative in vitro permeation profile of the PEG-NTX prodrug through MN-
treated Yucatan minipig skin. The cumulative amount of PEG-NTX prodrug itself 
(♦) and NTX generated from the prodrug (■) detected in the receiver phase are 
plotted against time. Each point represents the mean ± SD (n = 4). 
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Figure 8.5. 
 
Summary of the drug permeation data presented as a total flux plotted against 
drug concentration in the donor solution. Two independent plots correspond to 
two separate experiments which used either: PEG-NTX prodrug (●) or NTX (▲) as 
the permeant in the donor solution. MN-treated Yucatan minipig skin was 
employed. Each point represents the mean ± SD (n = 3-4). 
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Figure 8.6. 
 
Viscosity of the prodrug-containing donor solutions as a function of PEG-NTX 
prodrug concentration. Points indicate experimentally measured viscosity values 
while dashed line represents the least-squares fit to the log-linear empirical Eq. 3. 
Each point represents the mean of three determinations (n = 3), standard deviation 
is smaller than the size of the symbols. 
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Figure 8.7. 
 
Total flux of the PEG-NTX prodrug through MN-treated Yucatan minipig skin 
normalized per viscosity of the donor solution according to Eq. 4. Points indicate 
calculated viscosity-normalized total flux values and solid line represent the least-
square fit to a linear equation with zero Y-intercept. Each point represents the 
mean ± SD (n = 3-4). 
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Figure 8.8. 
 
Comparison of the experimental total prodrug flux through MN-treated Yucatan 
minipig skin to the flux calculated according to the Eq. 7. Points indicate 
experimentally measured mean flux values ± 95% CI (n = 3-4) and dashed line 
denotes the calculated mean flux value ± 95% CI as outlined by dotted lines. 
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Figure 8.9. 
 
The pseudo first-order hydrolytic rate constants (k) for NTX and NTXol prodrugs 
and codrugs at pH 5.0. Additionally, Ala-3O'-NTX and Leu-3O'-NTX, which are not 
included in the graph, degraded extremely fast giving k values of 4.74 and 2.32 h-1, 
respectively. 
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Figure 8.10. 
 
YTR-NTX-20 carboxylate prodrug hydrolysis as a function of PG concentration in 
the aqueous medium. Higher PG content corresponds to lower prodrug 
degradation rates. Circles – 25% PG, crosses – 50% PG, triangles – 75% PG, 
rhomboids – 90% PG and squares – 100% PG.  
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Figure 8.11. 
 
YTR-NTX-28 carbamate prodrug hydrolysis as a function of PG concentration in 
the aqueous medium. Higher PG content corresponds to lower prodrug 
degradation rates. Circles – 25% PG, crosses – 50% PG, triangles – 75% PG, 
rhomboids – 90% PG and squares – 100% PG.  
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Figure 8.12. 
 
The pH-solubility profile of the YTR-NTXol-89 codrug. Even at the high solubility 
range at low pH values, the absolute solubility is low as compared to NTX and 
NTXol.  
 
 
 
 
 
 
 
 
 
Copyright © Mikolaj Milewski 2011 
172 
 
Chapter 9 
In vitro permeation of naltrexone salts across microneedle treated skin 
 
9.1. Introduction 
The goal of this chapter is to present the potential of using naltrexone salts in 
conjunction with MN-treated skin. In order to fulfill the research goal 3.4 several 
naltrexone salts were synthesized by Dr. Reddy Pinninti. First, pH-solubility profiles were 
established. Next, permeation of highest water-soluble salt – NTX glycolate – across 
MN-treated skin was evaluated. Finally, the skin irritation potential of NTX glycolate, 
lactate and hydrochloride were assessed in hairless guinea pig model. The contents of 
the following chapter have been submitted for publication to Journal Investigative 
Dermatology. 
The effectiveness of transdermal drug delivery depends on the ability of transporting a 
drug across skin in a quantity sufficient to elicit a therapeutic effect. A single major 
challenge in the percutaneous drug delivery field is low permeability of the human skin. 
For most xenobiotics, it is the very high diffusional resistance of the stratum corneum 
(SC) that imparts barrier properties to the whole skin and results in low drug transport 
rates [55, 57]. The spectrum of drugs possessing the necessary physicochemical 
properties to cross this barrier at a relevant rate is limited, and the number of drugs that 
are successfully delivered percutaneously is relatively low [17]. To address this 
challenge, a variety of skin permeability enhancement techniques are used [8, 22]. 
Microneedles (MN) represent one of the physical enhancement methods that have been 
shown to produce substantial increase in the transdermal drug flux. Physically, 
microneedles typically refer to the arrays of micrometer-size protrusions long enough to 
penetrate and breach the SC barrier, but at the same time short enough to minimize pain 
173 
 
sensation [25, 30, 31]. Transient microchannels created by the application of MN provide 
a path of the least diffusional resistance for permeating drug. 
Naltrexone (NTX) is a potent, competitive opioid receptor antagonist approved for 
treatment of opioid and alcohol addiction [83]. Its transdermal delivery could bear 
substantial advantages over currently available dosage forms: e.g. oral tablet and 
intramuscular controlled-release injection [20]. The percutaneous rates of passive 
transport of NTX and its active metabolite, 6-ß-naltrexol, from reasonably-sized patches 
are therapeutically insufficient. However, the use of MN proved to significantly improve 
transport. In vitro diffusion studies have shown that the creation of microchannels in the 
skin had limited effect on the delivery rates of the neutral (free-base) form of NTX and 6-
ß-naltrexol, but an improvement in the rate of delivery of positively charged (salt-form) 
species of these drugs was observed [6]. It was hypothesized that elevated NTX and 6-
ß-naltrexol water-solubility, rather than the presence of a positive charge, was 
responsible for the observed increase in the transport rates of the salt forms of these 
drugs [6]. As an extension of this thought, a study evaluating a highly-soluble PEGylated 
prodrug form of naltrexone was carried out [229]. However, it was observed that the 
improved solubility of the prodrug did not translate into superior flux as compared to the 
parent drug. Besides increased molecular size, a highly non-linear relationship between 
prodrug donor solution concentration and percutaneous flux was noted and rationalized 
based on the accompanying vehicle viscosity changes [229].  
Generally, for NTX•HCl, in vitro and in vivo animal studies showed that MN use resulted 
in an approximate 10-fold enhancement in the transdermal flux over that through 
untreated (no MN) skin [6, 155]. Importantly, a first-in-human pharmacokinetic MN study 
demonstrated that the combination of MN skin pretreatment and application of four 
NTX•HCl patches afforded drug plasma levels in the lower end of the targeted 
therapeutic range [32]. To improve this prototype drug delivery system an increase in the 
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flux is desired. An enhanced transport rate through MN-treated skin would allow higher 
plasma levels and a decrease in the number of patches needed.  
In the absence of non-ideal behavior, and in accordance with Fick‘s first law of diffusion, 
an increase in the drug concentration translates directly into augmented transdermal 
flux. We have observed a substantial deviation from the ideal behavior while evaluating 
the permeation of a highly water-soluble PEGylated naltrexone prodrug across MN-
treated skin [229]. As a result, a prodrug approach produced no enhancement in the 
transport rates of naltrexone species. In the present work, another approach involving 
naltrexone salt selection is investigated. The aim of this study was to identify a 
naltrexone salt that would a) provide an elevated in vitro percutaneous drug transport 
rate across microneedle-treated skin as compared to that of naltrexone hydrochloride 
and b) prove non-irritating to the skin in vivo. 
 
9.2. Materials and methods 
Chemicals 
Naltrexone and naltrexone hydrochloride was purchased from Covidien Mallinckrodt (St. 
Louis, MO, USA). Hanks‘ balanced salts modified powder, and sodium bicarbonate were 
purchased from Sigma (St. Louis, MO). 4-(2 Hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES), gentamicin sulfate, trifluoroacetic acid (TFA), triethylamine (TEA), 1-
heptane sulfonic acid sodium salt, and acetonitrile (ACN) were obtained from Fisher 
Scientific (Fairlawn, NJ). 1-Octane sulfonic acid sodium salt was obtained from 
ChromTech (Apple Valley, MN, USA). Hydroxyethyl cellulose (HEC) Naltrosol® grade 
250MR was purchased from Aqualon (Wilmington, DE, USA) and propylene glycol (1,2-
propanediol) from Sigma-Aldrich. Water was purified using a NANOpure DiamondTM 
Barnstead water filtration system.  
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Synthesis procedure of naltrexone salts 
The synthesis was carried out by Dr. Reddy Pinninti. 
Naltrexone free base was dissolved in about 10 volumes of anhydrous acetonitrile. An 
equimolar amount of acid (acetic, glycolic, lactic, fumaric or citric) was added and the 
reaction mixture was heated until the salt precipitated out. The crystals obtained were 
filtered and washed three times with dichloromethane to remove the unreacted free 
base. The resulting salt was dried under vacuum to give white crystals of salts (acetate, 
glycolate, lactate, fumarate and citrate). 
Chemical identity of NTX salts was confirmed by NMR analysis. All the 1HNMR and 13C 
NMR spectra were recorded as δ values in CDCl3 with reference to tetramethylsilane 
(TMS) as internal standard on Varian mercury instrument (300 MHZ). 
Naltrexone Acetate: 
1H NMR (300 CDCl3) δ 0.13 (m,2H), 0.47-0.49 (m,2H), 1.28-1.32 (d,1H), 1.41-1.50 
(t,1H), 1.73-1.82 (m,2H), 1.89-2.12 (m,2H), 2.32-2.37(m,4H),2.62-2.66 (d,1H), 2.86-3.00 
(m,3H), 3.12-3.13 (d,1H), 3.44 (bs,3H), 4.75-4.76 (d,1H), 6.48-6.59 (m,2H) 
13C NMR (300 CDCl3) δ 4.41, 4.60, 10.03, 21.92, 22.97,26.80, 31.02, 31.96, 36.62, 
41.13, 44.09, 51.02, 59.14, 62.12, 70.46, 90.09, 117.85, 119.66, 123.98, 130.06, 139.97, 
144.03, 172.61,209.22 
Naltrexone Glycolate: 
1H NMR (300 CDCl3) δ 0.15 (m, 2H), 0.47-0.51 ( 2H), 0.88 (m,1H), 1.30-1.34 (d,1H), 
1.46-1.51 (t,1H), 1.76-1.79(d,1H), 2.20-2.11 (m,2H), 2.37-2.56 (m,5H), 2.66-2.70 (d,2H), 
2.89-3.03 (m,2H), 3.18-3.20 (d,1H), 3.85 (d,1H), 4.76 (d,1H), 4.87 (bs, 3H), 6.49-6.58 
(m,2H) 
13C NMR (300 CDCl3) δ 4.37, 4.72, 9.74, 23.05, 30.78, 31.93, 36.56, 44.34, 50.90, 
59.02, 60.49, 62.12, 70.47, 90.01, 117.94, 119.75, 123.76, 129.94, 140.08, 144.06, 
174.81, 209.14 
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Naltrexone Citrate: 
1H NMR (300 CDCl3) δ 0.33 (m,2H), 0.60 (m,2H), 1.06 (m,2H), 1.47-1.50 (m,2H), 1.90 
(m,1H), 2.11-2.15 (d,1H), 2.31 (m2H), 2.59-2.74 (m,7H), 2.90 (m,5H), 3.35 (bs,1H), 3.67 
(m,1H), 4.46-4.87 (d,1H), 6.56-6.64 (m,2H), 9.36 ( bs,1H) 
13C NMR (300 CDCl3) δ 3.87, 5.48, 7.77, 19.39, 23.49, 29.11, 31.52, 35.95, 43.70, 
44.63, 45.86, 49.93, 56.80, 58.13, 62.04, 70.49, 72.29, 89.50, 118.44, 120.26, 122.19, 
128.96, 140.49, 144.10, 171.83, 176.75, 208.38 
Naltrexone Fumarate: 
1H NMR (300 CDCl3) δ 0.20 (m,2H), 0.50-0.53 (m,2H), 0.91 (m,1H), 1.32-1.36 (d,1H), 
1.47 (m,1H), 1.79 (d,1H), 2.08-2.13 (m,2H), 2.37-2.44 (m,3H ), 2.57-2.73 (m,3H), 2.91 
(m,1H), 3.02-3. 08 (d, 1H), 3.31 (1H, m), 4.10 (bs, 3H), 4.79-4.83 (d, 1H), 6.54-6.62 (m, 
4H) 
13C NMR (300 CDCl3) δ 4.20, 4.96, 9.00, 23.21, 30.14, 31.79, 36.33, 44.85, 50.53, 
58.70, 62.09, 70.46, 89.83, 118.12, 119.93, 123.16, 129.59, 135.02, 140.23, 144.07, 
167.19, 208.90 
 
Thermal Analysis 
Differential scanning calorimetry (DSC) was used to characterize natrexone salts. All 
thermal analysis were carried out using a TA Instruments DSC 2920 (TA Instruments, 
New Castle, DE) differential scanning calorimeter. Around 5 mg of each sample was 
placed in a flat crimped aluminum pan and heated at a rate of 5 °C/min under N2 purge 
(50 ml/min). Potential changes in drug substance, such as hydration state and melting 
were monitored. Additionally, all melting points were confirmed by MelTemp® model 
1201D (Barnstead International, IA, USA) (n = 3).  
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pH-solubility profile determination 
pH-Solubility profiles of naltrexone salts were determined at 25 °C. At first, excess solids 
(NTX salts) were added to glass vials containing 2 ml of water. Solubility at different pH 
values were determined by stepwise titration with HCl or NaOH solutions. At each 
addition of HCl or NaOH, the suspension was equilibrated for 24 h, the pH value was 
recorded, and an aliquot was removed and spin-filtered for 1 min in VWR centrifugal 
filters (0.2 µm membrane) at 25 °C. The filtrate was diluted with an adequate amount of 
acetonitrile (ACN):water 70:30 (v/v), and resulting solution analyzed by high pressure 
liquid chromatography (HPLC). The number of samples obtained for each salt solubility 
determination is as follows: NTX•HCl (n = 19), NTX acetate (n = 18), NTX glycolate (n = 
12), NTX lactate (n = 18), NTX fumarate (n = 10), and NTX citrate (n = 17). 
 
Donor solution preparation 
Eleven donor solution concentrations for in vitro permeation experiments were prepared. 
NTX•HCl was dissolved in water at 32 °C to obtain the following concentrations: 40, 80, 
119, 159, 212, 265 and 291 mM. NTX glycolate was dissolved in water at 32 °C to obtain 
the following concentrations: 365, 645, 946 and 1272 mM. The pH of all donor solutions 
was adjusted to 5.0 with a 3M HCl solution. 291 mM is the saturation solubility of the 
NTX•HCL at pH 5.0 at 32 °C while 1272 mM is the saturation solubility of the NTX 
glycolate at pH 5.0 at 32 °C. All donor solutions were prepared immediately before 
launching in vitro permeation experiments. Three to four cells were used per single 
naltrexone salt concentration (n = 3-4). 
 
Viscosity measurements 
A Brookfield DV-III LV programmable cone/plate rheometer with a CPE-40 spindle was 
used for measuring the viscosity of the donor solutions. The sample volume was 0.5 ml. 
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All determinations were carried out at 32 ⁰C maintained by a circulating water-bath TC-
102. Each donor viscosity measurement was taken three times at low, medium and high 
torque value in the range of 10-100% of the instrument specifications (n = 3).  
 
In vitro diffusion studies 
Full-thickness Yucatan minipig skin was harvested from the dorsal region of a 
euthanized 6-month-old animal. Animal studies were approved by the University of 
Kentucky IACUC. Subcutaneous fat from skin samples was removed with a scalpel and 
sparse hair clipped. Skin samples were immediately placed in a plastic bag and frozen 
until use (-20 °C). Before each permeation study, skin samples were allowed to thaw for 
about 30 min. Skin used for MN treatment was first dermatomed to a thickness of about 
1.9 mm and then placed on a wafer of polydimethylsiloxane polymer, which mimicked 
the naturally occurring mechanical support of underlying tissue because of its 
comparable structural elasticity. In the context of in vitro studies described in this article 
―MN‖ refer to microneedle rows obtained from Dr. Prausnitz‘s laboratory. They were 
fabricated by laser cutting of stainless steel sheets as reported previously [210]. MN 
were solid metal, two-dimensional ―in-plane‖ rows each containing five microneedles 
oriented with their axis parallel to the steel sheet. This design is characterized by the 
following microneedle dimensions: 750 µm long, 200 µm wide, 75 µm thick and 1.35 mm 
inter-needle spacing.  The insertion of MN into skin was carried out manually by applying 
gentle finger pressure followed by their instantaneous removal. The diffusion area of skin 
(0.95 cm2) was pierced 20 times, with a row containing five microneedles, gradually 
advancing the MN application area to obtain 100 non-overlapping piercings before 
mounting the skin in the diffusion cell. If any damage to the MN was observed a new 
array was used. Three to four cells were used per each naltrexone salt concentration (n 
= 3-4). A PermeGear flow-through (In-Line, Riegelsville, PA) diffusion cell system was 
179 
 
used for the in vitro diffusion studies. Isotonic HEPES-buffered Hanks‘ balanced salts 
solution (25 mM, pH 7.4) was used as the receiver solution. Skin samples in the diffusion 
cells were maintained at 32 °C using a circulating water bath. The diffusion experiments 
were initiated by charging the donor compartment with 0.4 ml of the donor solution. 
Samples were collected from the receiver compartment in 6 h increments over 48 h. All 
samples were stored at 4 °C until HPLC analysis, which was carried out within 24 hours.   
 
Quantitative analysis 
Quantitative analysis of NTX salts by HPLC was carried out using a modification of the 
assay described by Hussain et al. [225]. The HPLC system consisted of a Waters 717 
Plus autosampler, a Waters 600 quaternary pump, and a Waters 2487 dual wavelength 
absorbance detector with Waters Empower™ software. A Perkin Elmer® Brownlee 
Spheri-5 VL 5 µm (220 x 4.6 mm) C18 column with a guard column of the same type 
was used with the UV detector set at a wavelength of 278 nm. The mobile phase 
consisted of 70:30 (v/v) ACN:0.1% TFA containing 0.065% 1-octane sulfonic acid 
sodium salt, adjusted to pH 3.0 with TEA aqueous phase. Samples were run at a flow 
rate of 1.5 ml/min with a run time of 4.5 min. The injection volume was 100 µl, and the 
retention times of all NTX salts were 2.2 min. Samples were analyzed within a linear 
range of NTX salts concentrations 100 – 10,000 ng/ml.  
The permeation data were plotted as the cumulative amount of NTX collected in the 
receiver compartment against time. The steady-state flux value for a given run was 
calculated from the slope of the terminal portion of the graph, according to: 
 
𝑄/𝐴 = 𝐽𝑠𝑠(𝑡 − 𝑡𝑙𝑎𝑔 )          (9.1) 
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where Q is the cumulative amount of permeant, A is the area of diffusion, Jss is the 
steady-state flux defined as mass transport per area, t is time, and tlag is the lag time for 
diffusion.  
 
In vivo NTX salts skin irritation potential study  
Three Charles River hairless guinea pigs were used in the skin irritation studies (n = 3). 
Five treatment sites were assigned to each guinea pig dorsal region. Four of them 
corresponded to the formulations under scrutiny and the fifth one was a negative control. 
The following treatments were employed:  
 placebo gel: sterile water:PG 90:10 (v/v) and 3% hydroxyethylcellulose (HEC) 
(w/v), pH 6.5 
 NTX•HCl gel: 250 mM NTX•HCl in sterile water:PG 90:10 (v/v) and 3% 
hydroxyethylcellulose (HEC) (w/v) , pH 5 
 NTX lactate gel: 700 mM NTX lactate in sterile water:PG 90:10 (v/v) and 3% 
hydroxyethylcellulose (HEC) (w/v), pH 5 
 NTX glycolate gel: 700 mM NTX glycolate in sterile water:PG 90:10 (v/v) and 3% 
hydroxyethylcellulose (HEC) (w/v), pH 5 
 Control: no gel 
The formulation composition selection was based on former and present findings about 
the percutaneous transport of the NTX species and skin irritation potential of the 
excipients. PG and HEC are common, generally recognized as safe (GRAS) excipients 
widely used in topical formulations and are not skin-irritating [218]. HEC has been 
successfully used in earlier studies as a thickening agent. The inclusion of 10% PG in 
the formulation is dictated by its beneficial influence on the physical stability of the gel 
under in vivo conditions where, as a strongly hygroscopic excipient, it prevents water 
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evaporation and collapse of the gel (unpublished observations). The concentrations of 
NTX species in gels were selected to approximate the concentrations that provided 
highest in vitro NTX flux through MN-treated skin. 
 
Protective patch fabrication 
The occlusive protective patches were fabricated by sandwiching a rubber ring (inner 
diameter 2 cm) between an ARcare® 7396 adhesive and an impermeable backing 
laminate (Scotchpak™ #1109 SPAK 1.34 MIL Heat Sealable Polyester Film) fixed on 
one side of the rubber ring creating a reservoir able to contain a gel formulation. The 
protective patch was placed on a release liner composed of Scotchpak™ 9742 until the 
application on animals. 
 
Application of treatments 
For in vivo studies ―MN‖ refer to two-dimensional ―out of plane‖ 50 MN arrays. The 
arrays were manufactured with needles cut into the plane of the stainless steel sheet 
and subsequently bent at 90° out of the plane [210]. MN arrays were obtained from Dr. 
Prausnitz‘s laboratory. In each guinea pig, four treatment sites (about 2 cm in diameter) 
were treated with MN arrays twice to obtain the total of 100 microchannels per site. Next 
0.3 g of the gel (placebo, NTX•HCl, NTX lactate or NTX glycolate) was applied to each 
of the treated sites once and covered with a protective patch. The fifth site (control) was 
not treated with MN, nor was the gel or protective patch applied. Protective patches were 
secured on the guinea pig dorsal region by the use of a Bioclusive transparent dressing 
for the 4-day duration of the experiment. The length of the experiment was chosen 
based on the in vivo drug delivery goals. After 4 days the protective patches and gels 
were removed. 
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Biophysical skin assessment 
Colorimetry and TEWL measurements were carried out immediately prior to the 
application of the treatments and 45 min, 3 h, 6 h, 24 h and 48 h after the removal of the 
treatments. 
 
Colorimetry (a* parameter) 
The inflammation of the skin can be evaluated by assessing the degree of erythema. 
Skin color was measured by the use of a Minolta colorimeter (Chroma Meter CR-400, 
Konica Minolta, Japan). The instrument  records color reflectance in three-dimensional 
scale L*a*b, where L* value (luminance) expresses the relative brightness; a* 
corresponds to the red-green axis with +100 expressing full red and -100 full green; and 
b* corresponds to the yellow-blue axis. The colorimeter was calibrated before use 
against a white plate provided by Konica Minolta in the study environment. To perform a 
measurement the head of the instrument was gently placed on the skin treatment area. 
 
Transepidermal water loss (TEWL)  
The skin barrier integrity was evaluated by TEWL. The head of a DermaLab® TEWL 
probe (CyberDerm Inc.) was gently placed on the skin treatment area to perform a 
measurement. Besides skin barrier compromise, skin hydration and MN-treatment are 
both known to contribute to increased TEWL values. The detection of possible barrier 
compromise due to a given NTX salt alone under such conditions would be difficult. 
However, the inclusion of the treatments with MN and placebo gel allows for examination 
of these two factors independently.  
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Statistical analysis 
Linear least-square fitting of viscosity-normalized data was performed using Scientist® 
software (MicroMath). The statistical analysis of the skin irritation data was carried out by 
step-wise t-test at α = 0.05 using SIGMA-STAT software (SPSS, Inc., Chicago, IL, USA).  
 
9.3. pH-solubility profiles 
Former studies focused on the skin permeation potential of NTX and 6-β-naltrexol in 
conjunction with MN [6, 155, 255]. The maximum transdermal flux of NTX was found to 
be limited by the saturation solubility of NTX•HCl in the donor solution [229, 255]. In this 
work, five naltrexone salts: acetate, glycolate, lactate, fumarate (1:1) and citrate (1:1) 
were synthesized and their pH-solubility profiles were evaluated. An increased solubility 
at the physiologically-relevant skin surface pH of 5.0 gives the theoretical basis for 
expecting improved transport rates through MN-enhanced skin.  
Naltrexone possesses two pKa values; one basic corresponding to the protonation of the 
tertiary aliphatic nitrogen atom (pKa1 = 8.30), and the other acidic corresponding to the 
dissociation of the phenolic proton (pKa2 = 9.80) [226]. Thus, depending on the pH, it can 
act as a base or as an acid. At low pH values, naltrexone is positively charged and can 
form salts with acids, while at high pH values it is negatively charged and can form salts 
with bases. At the intermediate pH values the naltrexone molecule exists predominantly 
as an uncharged species. Figure 9.1 shows the distribution of the naltrexone species as 
a function of pH. 
The total solubility (Stot) of naltrexone at any pH is the sum of solubilities of the unionized 
and ionized forms: 
 
𝑆𝑡𝑜𝑡 =  𝑁
− +  𝑁𝐻 + [𝑁𝐻2
+]       (9.2) 
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where the [N-], [NH] and [NH2
+] correspond to the negative, neutral and positive species 
of naltrexone, respectively. When the neutral naltrexone species is in equilibrium with 
the solid, the solubility in the aqueous solution can be written as: 
 
𝑆𝑡𝑜𝑡 = [𝑁𝐻]𝑠(1 + 10
𝑝𝐾𝑎1−𝑝𝐻 + 10𝑝𝐻−𝑝𝐾𝑎2 )     (9.3) 
 
where the subscript ―s‖ refers to the saturation species. This equation describes the pH-
solubility profile at the intermediate pH values. Of note, since two pKa‘s are numerically 
close to each other there is no pH value at which the intrinsic solubility of the uncharged 
NTX species could be determined directly. On the other hand, at low pH values where 
the salt form is the equilibrium species, and the amount of the negatively charged NTX 
species is negligible, the total solubility can be described by the following equation: 
 
𝑆𝑡𝑜𝑡 = [𝑁𝐻2
+]𝑠(1 + 10
𝑝𝐻−𝑝𝐾𝑎1 )      (9.4) 
 
where the subscript ―s‖ refers to the saturation species. The maximum solubility for any 
NTX salt occurs at the pHmax, or the pH at which the two curves described by Eq. 9.3 
and Eq. 9.4 intersect [256]. For all salts tested the pH-solubility curve portion described 
by Eq. 9.3 is the same as the unionized form of NTX and is identical for all NTX salts. 
However, at lower pH values individual salt solubility profiles diverge and plateau at 
different levels in the cases of NTX•HCl, acetate, glycolate and lactate; or demonstrate 
more complicated behavior in the cases of NTX fumarate and citrate. Figure 9.2 
presents the pH-solubility profiles of NTX•HCl, acetate, glycolate and lactate. At pH 5.0, 
relevant for percutaneous drug delivery, the solubility of the NTX salts ranks as follows: 
NTX glycolate ≥ NTX lactate ≥ NTX acetate >> NTX•HCl. Therefore, all three NTX salts 
under scrutiny demonstrate superior solubility as compared to the NTX•HCl reference. 
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(Noteworthy, at pH values less than 4, the addition of hydrochloric acid for pH control 
converts all three naltrexone salts back to the hydrochloride salt. This was inferred by 
the converging solubility profiles converge in this region, which cannot be accounted for 
by Eq. 9.4). The intrinsic solubilities of the ionized and nonionized NTX forms are 
summarized in Table 9.1 together with experimentally determined melting points and 
calculated pHmax values. Figure 9.3 shows the pH-solubility profiles of NTX•HCl, 
fumarate and citrate. The non-plateau region observed for fumarate and citrate salts at 
the lower pH values may be a consequence of formation of multiple equilibrium species 
as a result of the use of di- and tri-carboxylic acids and cannot be described by E. 9.4). 
Since the solubility of NTX fumarate and citrate around pH 5.0 did not show a substantial 
improvement over NTX•HCl these two salts were excluded from further examination. 
 
9.4. Permeation across MN-treated skin 
Next, in vitro permeation studies were carried out with the most water-soluble NTX salt – 
NTX glycolate. While the saturation solubility of NTX•HCl at pH 5.0 (32 °C) is below 300 
mM, NTX glycolate saturation solubility approaches 1300 mM. Several donor solutions 
containing either NTX•HCl (<300mM) or NTX glycolate (>300 mM) were prepared. The 
saturated donor solutions did not contain any excess solid to ensure that potential 
interference between excess NTX salt and the microchannels would not affect the 
results, such as obstruction of the microchannel opening, or presence of the undissolved 
drug in the microchannels, etc. The drug permeation from all donor solutions resulted in 
steady-state conditions after a relatively short lag time. A representative permeation 
profile is presented in Figure 9.4. Permeation of the two NTX salts as a function of the 
donor solution concentration is summarized in Figure 9.5.  
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9.5. Deviations from ideal behavior 
For NTX•HCl, the increase in the donor solution concentration corresponded to the 
increase in the flux through MN-enhanced skin. This increase, however, was not linear. 
For NTX glycolate, further increase in the drug concentration produced a parabolic 
relationship between the flux and drug donor solution concentration, with a maximum 
corresponding to a concentration of ≈700 mM. The maximum flux obtained with the use 
of NTX•HCl was 121 ± 16 nmol cm-2 h-1 (291 mM donor solution), while the maximum 
flux obtained with the use of NTX glycolate was 178 ± 43 nmol cm-2 h-1 (645 mM donor 
solution). In other words, at the cost of roughly doubling the drug concentration and 
switching from NTX•HCl to NTX glycolate a 50% increase in the percutaneous flux can 
be achieved. The behavior in the lower concentration range can be well described by 
Fick‘s first law of diffusion and a concentration-independent permeability coefficient. 
However, the deviation from ideal behavior is substantial at the intermediate and high 
concentration ranges. Noteworthy, there is no discontinuity in the flux-concentration 
profile at the NTX concentration where the counterion is swapped from HCl to glycolate. 
This suggests lack of major counterion effect on the diffusivity of NTX as could be 
expected given the MW of counterions is substantially smaller than that of NTX. 
 
9.6. Viscosity influence on drug diffusivity 
It has been suggested that the viscosity of the donor solution may have a vital effect on 
drug delivery rates through MN-treated skin [229, 255]. The relationship between the 
viscosity (η) of the diffusion medium and the solute diffusion coefficient is given by the 
Stokes-Einstein equation: 
 
𝐷 =  
𝑘𝑇
6𝜋𝜂𝑟
         (9.5) 
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where k is Boltzmann‘s constant, T is absolute temperature, and r is the radius of the 
diffusant (assuming it can be represented by a spherical particle). Specifically, it was 
shown that the NTX•HCl flux through microchannels and underlying dermis correlated 
well with the decrease in the calculated drug diffusivity in the donor solution. The 
viscosity of the donor solution was controlled by addition of propylene glycol to the 
aqueous vehicle. Also, the flux through microchannels alone was found to be well-
approximated by the total flux through MN-enhanced skin for the aqueous donor 
solution. In other words, the contribution of flux through intact skin around microchannels 
was low as shown in Chapter 7. Herein, it will be assumed that the contribution of NTX 
glycolate flux through intact skin pathway was also very low (e.g. <5%) as compared to 
the microchannel pathway. It seems a reasonable approximation given the experimental 
results obtained from NTX•HCl studies. It is also corroborated by the fact that neither 
NTX•HCl or NTX glycolate salts caused skin irritation, which could be indicative of 
increased flux through skin around microchannels. Furthermore, the permeation of a 
PEGylated NTX prodrug correlated with the viscosity changes of the prodrug-containing 
donor solution as shown in Chapter 8 [229]. In that study, viscosity changes in the donor 
solution were caused by the prodrug itself. It is known that at sufficiently high solute 
concentration, solvent viscosity can be altered, exerting a secondary effect on the 
solute‘s own diffusivity [54]. Hence, although the donor solution viscosity changes in the 
above two studies were caused by different mechanisms the end result was the same – 
increased viscosity of the donor solution correlated with decreased transdermal flux 
through MN-treated skin. 
In the current study the lowest concentration of NTX•HCl (40 mM) produced a donor 
solution viscosity of 0.81 cP while the highest NTX glycolate concentration (1272 mM) 
produced a donor solution viscosity of 6.46 cP. Hence, there is almost an 8-fold 
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difference between these extreme values. The experimental data can be transformed by 
normalizing flux by the apparent viscosity effect. According to Fick‘s first law of diffusion: 
 
𝐽𝑠𝑠 = 𝑃𝐶 =
𝐷
𝑕
         (9.6) 
 
where Jss is the steady-state flux, P is permeability coefficient and C is the permeant 
concentration in the donor solution when sink conditions in the receiver solution prevail. 
For solute transport through microchannels the permeability coefficient, P, is defined as 
the ratio of solute diffusivity (D) in the barrier to the barrier thickness (h) [39]. The 
substitution of Eq. 9.5 into Eq. 9.6 demonstrates the inverse relationship between 
steady-state flux and viscosity of the barrier. Hence, the ratio of two flux values, 
uncorrected (J) and corrected (J‘) for viscosity effect, is given by: 
 
𝐽
𝐽 ′
=
𝜂′
𝜂
          (9.7) 
 
where J‘ is flux obtained from a donor solution having viscosity ŋ‘ while J is the flux 
obtained from a donor solution having viscosity ŋ. Assuming that ŋ‘ represents a low-
viscosity donor solution and ŋ represents a high-viscosity donor solution, an expected 
flux at elevated viscosity can be calculated by: 
 
𝐽 = 𝐽′
𝜂′
𝜂
         (9.8) 
 
Alternatively, having an experimental flux value available from a high-viscosity donor 
solution, the expected flux value for a low-viscosity solution would be: 
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𝐽′ = 𝐽
𝜂
𝜂′
         (9.9) 
 
If it is further assumed that ŋ‘ equals 1 cP, which is a fair approximation for low drug 
concentration donor solutions, the viscosity-normalized flux (J‘) is the product of the 
experimental flux (J) and the corresponding viscosity (ŋ) of the donor solution. Such 
normalization yields flux values that correspond to a viscosity value of unity. The above 
discussion equates the viscosity of the donor solution with the microviscosity of the 
diffusion barrier – dermis underlying the microchannels. It had been hypothesized that 
donor solution composition can directly alter the properties of the dermis, thus, affecting 
the diffusion of drugs through this barrier [229, 255]. If the hypothesis is valid, it would be 
expected that the viscosity-normalized flux will correlate linearly with the drug 
concentration in the donor solution over the whole concentration range tested. A plot of 
viscosity-normalized flux is presented in Figure 9.6, which shows a reasonable linear 
correlation (1/Y2 weighted R2 = 0.93). Therefore, the results seem to support the 
hypothesis.  
To gain more insight about the diffusion process across MN-treated skin a two-ply 
membrane concept incorporating the microchannel and underlying dermis can be used. 
In the experimental set-up used in the current study the thickness of the dermis below 
the microchannel exceeds the length of the microchannel, and the diffusion coefficients 
of drugs in the dermis are known to be typically 3-10 times lower as compared to those 
in the bulk aqueous solutions [18, 59]. Based on the above, it can be expected that the 
major diffusional resistance lies in the dermis layer. Therefore, flux should not depend on 
the viscosity of the donor solution unless donor solution changes the properties of the 
dermis barrier. It is possible that the naltrexone salt containing, elevated-viscosity donor 
solution alters the microenvironment of the dermis by increasing its diffusional 
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resistance. Assuming this effect is similar to that seen in the bulk solution, flux through 
microchannels and dermis below would be inversely related to the viscosity of the donor 
solution. In other words, the results from the current study imply that changes in the drug 
diffusivity in the donor solution are reflective of drug diffusivity changes in the whole skin 
barrier.  
By analogy to Eq. 9.9, permeability coefficients can also be normalized by viscosity. The 
slope of the line in Figure 9.6 corresponds to the average viscosity-normalized 
permeability coefficient P‘ave. Applying 1/Y
2 weighting to the viscosity-normalized flux 
values (Scientist®), the least-square estimate of P‘ave is 47.8 x 10
-5 cm h-1, 95% 
confidence interval (41.1, 54.5) x 10-5 cm h-1.   This average value, in combination with 
individual donor solution viscosity, ŋ, and drug concentration in the donor solution, C, 
can be used to calculate the expected transdermal flux, Jcalc, across MN-treated skin: 
 
𝐽𝑐𝑎𝑙𝑐 = 𝑃𝐶 = 𝑃′𝑎𝑣𝑒
𝜂′
𝜂
𝐶        (9.10) 
 
Figure 9.5 presents flux calculated according to Eq. 9.10 as compared to the 
experimental data. A reasonable agreement between experimental and calculated 
values lends practical utility to this approach. Overall, the selection of NTX glycolate over 
NTX•HCl permits augmented flux through the MN-treated skin. At the cost of roughly 
doubling the saturation solubility of NTX•HCl in the aqueous formulation, by means of 
using NTX glycolate, a 50% increase in the percutaneous flux can be achieved. 
 
9.7. Guinea pig skin irritation study 
Finally, a prerequisite for any successful transdermal drug is the lack of or minimal skin 
irritation potential. Of the three NTX salts that showed increased solubility as compared 
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to NTX•HCl, NTX glycolate and lactate were further tested for skin irritation potential. α-
hydroxy acids, such as glycolic acid and lactic acid, have a long history of being used in 
cosmetology. Their use typically relates to counteracting skin aging and reduction of 
wrinkles through increased skin exfoliation [257]. Also, Lac-Hydrin® is a prescription 
medicine containing 12% lactic acid neutralized with ammonium hydroxide employed for 
treatment of ichthyosis vulgaris and xerosis. Hence, it was anticipated that NTX salts of 
these two α-hydroxy acids may have a safe, non-irritating profile. The skin irritation 
potential of NTX glycolate, NTX lactate and NTX•HCl (as a reference), was evaluated in 
vivo in a hairless guinea pig model. Skin irritation is defined as a reversible damage to 
the skin following the application of a test substance. It can manifest itself through local 
inflammation, edema and compromised skin barrier function. Hairless guinea pigs are 
commonly employed for this type of testing because of their histo-anatomical similarities 
to the human skin [258-260]. It has been shown that this model ranks skin irritation 
potential of chemicals in the same order as human studies do, although it is more 
sensitive. As a consequence, the negative skin irritation results obtained from the 
hairless guinea pig model imply no irritation to the human skin; however, positive results 
do not necessarily predict intolerability in humans [259]. The current study protocol 
involved MN treatment of the designated dorsal sites and application of drug-containing 
and drug-free gels. Also, one control site with no MN treatment and no gel application 
was included. After 4 days the gels were removed and skin irritation potential of NTX 
salts was evaluated by transepidermal water loss (TEWL) and colorimetry 
measurements (Chroma Meter CR-400, Konica Minolta, Japan).  Figure 9.7 shows the 
change in the a* value with time in different treatments applied to hairless guinea pigs. 
The increase in the a* colorimetric value is indicative of erythema, which in turn 
correlates with local inflammation. Before the application of the treatments, a* values 
oscillated in the range of 9-10. After the completion of the 4-day experiment and the 
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removal of gels the a* value was somewhat elevated (up to 12.6) for all the gel 
treatments, over that of the control, but dropped back to baseline levels over the next 48 
hours. The fact that the augmented a* value was observed in naltrexone-containing gels, 
as well as in the placebo gel suggests that the MN treatments and gel application 
themselves caused a mild redness. Literature reports indicate that a* values of around 
16 [259] are observed following the application 1% sodium lauryl sulfate as a positive 
control for skin irritation. Our experience (unpublished data) indicates a rise to a value of 
18 and higher with sodium lauryl sulfate treatment. Hence, the magnitude of increase in 
the a* value seen in the current study is not of considerable practical importance. The 
inclusion of the NTX species in the gels did not produce any additional increase in the 
erythema. This was also corroborated by visual inspection of the treatment sites. 
Complimentary to the colorimetry data, Figure 9.8 presents the treatment-induced 
TEWL changes as a function of time. The baseline water loss ranged from 3 to 6 g m-2 h-
1 in accordance with typical literature reports [259]. Shortly after the removal of the gels, 
at 45 min, TEWL values were elevated (up to about 20 g m-2 h-1) only to drop back to the 
baseline values within a few hours. The initial increase in the water loss was due to the 
hydration of the skin resulting from prolonged occlusion. However, an additional 
contribution coming from the potential existence of the microchannels at that time cannot 
be ruled out. The lack of augmented TEWL readings at later time points implies no 
severe reaction to the NTX salts species and maintenance of proper barrier function of 
the skin.  
A previous first-in-human MN study by Wermeling et al. showed that a 3-day application 
of NTX•HCl formulated in a topical gel ranked from non-irritating to mildly-irritating to the 
human skin [32]. The present skin irritation study findings suggest that both naltrexone 
lactate and glycolate performed similarly to NTX•HCl. Consequently, both salts are 
viable candidates for further in vivo investigation. Moreover, in vitro diffusion studies 
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demonstrated that NTX glycolate (and possibly NTX lactate and acetate) increased 
aqueous solubility can be translated into elevated transdermal flux through MN-treated 
skin. That increase, although modest, is of practical importance for maximizing the 
delivery of NTX species through the MN-enhanced skin. 
  
9.8. Conclusions 
The present study evaluated permeation and skin irritation potential of several NTX 
salts. Three NTX salts (acetate, lactate and glycolate) demonstrated improved aqueous 
solubility that of NTX•HCl at a relevant skin surface pH of 5.0 over. Increased solubility 
of NTX glycolate, despite the non-ideal flux behavior, can be used to achieve increased 
permeation across MN-treated skin. Moreover, the skin irritation-potential of naltrexone 
glycolate and lactate were found to be not greater than that of NTX•HCl or placebo gel in 
the guinea pig model. Overall, a new naltrexone glycolate (and possibly lactate) salt 
appears to be a promising candidate for further testing and inclusion in an in vivo 
transdermal drug delivery system in conjunction with microneedle skin treatment.  
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Table 9.1. Summary of physicochemical properties of naltrexone salts. [NH]s is the 
saturation solubility of the neutral naltrexone species in equilibrium with the solid. 
[NH2
+]s is the saturation solubility of the positive naltrexone species in equilibrium 
with the solid. pHmax is the pH corresponding to maximum salt solubility. MP is 
experimentally determined melting point. 
Naltrexone salt 
[NH]s 
1 
mean (95% CI) 
[NH2
+]s 
1 
mean (95% CI) 
pHmax MP [°C] 
hydrochloride 1.23 (0.95, 1.51) 221 (210, 232) 6.05 275 
acetate 1.23 (0.95, 1.51) 804 (746, 861) 5.48 196 
lactate 1.23 (0.95, 1.51) 927 (842, 1011) 5.42 221 
glycolate 1.23 (0.95, 1.51) 1125 (885, 1365) 5.34 223 
fumarate 1.23 (0.95, 1.51) n/a n/a 231 
citrate 1.23 (0.95, 1.51) n/a n/a 208 
1 The concentration units are [mM] 
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Figure 9.1. 
 
Naltrexone speciation as a function of pH. Dashed line (---) corresponds to 
positive NTX species [NH2
+], solid line (    ) corresponds to the neutral NTX species 
[NH], and dotted line (•••) corresponds to the negative naltrexone species [N-].  
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Figure 9.2. 
 
pH-solubility profiles of the hydrochloride (), acetate (), lactate (∆), and glycolate 
() naltrexone salts. Solid line represents a least-square fit to Eq. 9.3 and Eq. 9.4 
for NTX•HCl. 
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Figure 9.3. 
 
pH-solubility profiles of the hydrochloride (), fumarate (x), and citrate (○) 
naltrexone salts. Solid line represents a least-square fit to Eq. 9.3 and Eq. 9.4 for 
NTX•HCl. 
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Figure 9.4. 
 
Representative in vitro permeation profile of naltrexone glycolate through MN-
treated Yucatan minipig skin. The cumulative drug amount is plotted against time. 
Each point represents the mean ± SD (n=4). 
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Figure 9.5. 
 
Comparison of the experimental flux of naltrexone hydrochloride (●) and 
naltrexone glycolate () through MN-treated Yucatan minipig skin to the flux 
calculated according to the Eq. 9.10.  Points indicate experimentally measured 
mean flux values ± SD (n = 3-4) and the solid line denotes the calculated mean flux 
value according to Eq. 10.9. 
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Figure 9.6. 
 
Flux of naltrexone hydrochloride (●) and naltrexone glycolate () normalized per 
viscosity of the donor solution according to Eq. 9.9. Points indicate calculated 
viscosity-normalized flux values and solid line represent the 1/Y2 weighted least-
square fit to a linear equation with zero Y-intercept. Each point represents the 
mean ± SD (n = 3-4). 
 
 
 
 
 
 
 
 
R2 = 0.93 
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Figure 9.7. 
 
In vivo skin redness, reported as a* value, in guinea pigs after application of the 
following treatments: placebo gel (gray filling), NTX•HCl gel (black filling), NTX 
lactate gel (dotted filling), NTX glycolate gel (checked filling), and control (white 
filling). All results are mean ± SD (n = 3). Of note, readings indicate the time after 
removal of the treatments. * denotes statistically significant difference (p < 0.05) 
between the mean control reading as compared to individual treatment mean. 
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Figure 9.8. 
 
In vivo transepidermal water loss in guinea pigs after application of the following 
treatments: placebo gel (gray filling), NTC HCl gel (black filling), NTX lactate gel 
(dotted filling), NTX glycolate gel (checked filling), and control (white filling). All 
results are mean ± SD (n=3). Of note, readings indicate the time after removal of 
the treatments. * denotes statistically significant difference (p < 0.05) between the 
mean control reading as compared to individual treatment mean. 
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Chapter 10 
In vivo MN-assisted permeation and pharmacokinetics of naltrexone 
hydrochloride in Yucatan minipig 
 
10.1. Introduction 
The purpose of this chapter is to fulfill the research goals specified under points 3.5 and 
3.6. All the studies reported so far in previous chapters related to in vitro drug delivery 
with special emphasis on maximization of NTX flux across MN-treated skin. The key 
question the present chapter attempts to address is: ―how can the knowledge obtained 
so far be used to predict in vivo drug delivery with a ‗poke and patch method‘‖? Besides 
all the topics covered earlier, in vivo drug delivery requires the discussion of at least a 
few additional subjects: microchannel closure and its effect on drug transport, drug 
disposition in the body and elimination from the body. Only the simultaneous 
consideration of all the above factors can provide some insight into the behavior of 
plasma concentration profiles of NTX in vivo after MN-assisted transdermal delivery.  
There is an abundance of publications related to drug delivery through MN-enhanced 
skin in vitro [6, 24, 213, 217, 229, 255, 261-263]. The number of literature reports on the 
in vivo drug delivery with a ―poke and patch‖ method is limited. A few examples include 
naltrexol base and hydrochloride delivery in hairless guinea pigs [155], naltrexone 
hydrochloride delivery in hairless guinea pigs [264], naltrexone hydrochloride delivery in 
humans [216], ketoprofen delivery in rats [265], and nicardipine hydrochloride delivery in 
hairless rats [212]. The outcomes of the above studies showed differences in 
effectiveness of MN skin treatment, and shapes of drug plasma profiles, depending on 
specific experimental conditions. Additionally, the microchannel closure process was the 
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topic of several literature reports [23, 155, 211, 266, 267]. The conclusions with respect 
to the timeframe of microchannel closure varied according to experimental conditions 
and methods used for making the assessment. However, there is no study that 
incorporated the concepts of MN-enhanced transdermal drug transport, the 
microchannel closure process, drug disposition, and elimination in vivo in a quantitative 
manner. In the present study, the delivery of naltrexone hydrochloride in Yucatan minipig 
using a ―poke and patch‖ method, and the disposition and elimination after IV bolus 
administration are investigated.  The purpose of this work is to develop a mathematical 
model for description of drug transport across MN-treated skin in vivo, and to establish 
an in vitro-in vivo correlation. Previous studies provided some insight into MN-enhanced 
percutaneous in vitro NTX transport [39], which will be used and expanded upon to 
accommodate the rate of microchannel closure, drug disposition and elimination in vivo.  
 
10.2. Materials and methods 
Chemicals 
NTX hydrochloride was purchased from Mallinckrodt (St. Louis, MO, USA). Water was 
purified using NANOpure DiamondTM, Barnstead water filtration system. 1,2-Propanediol, 
Hanks‘ balanced salts modified powder, and sodium bicarbonate were purchased from 
Sigma (St. Louis, MO). 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 
gentamicin sulfate, trifluroacetic acid (TFA), triethylamine (TEA), 1-heptane sulfonic acid 
sodium salt, and acetonitrile (ACN) were obtained from Fisher Scientific (Fairlawn, NJ). 
Reagent-grade chemicals were obtained from Sigma Chemical Company (St. Louis, 
MO). 
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In vitro diffusion study – estimation of naltrexone diffusivity in dermis 
NTX•HCl was added to water to obtain the concentration of 110 mg/ml. The solutions 
were placed in glass vials, closed tightly with a plastic cap, sonicated for 15 min and left 
in the shaking water bath at 32°C overnight before use to ensure all the drug is 
dissolved. 
Full-thickness Yucatan minipig skin was harvested from the dorsal region of a 
euthanized 6-month-old animal. Animal studies were approved by the University of 
Kentucky IACUC. Subcutaneous fat from skin samples was removed with a scalpel and 
sparse hair shaved. Such skin samples were immediately placed in a plastic bag and 
frozen (-20°C) until use. Before each permeation study, skin samples were allowed to 
thaw for about 30 min. Skin was dermatomed by removing whole epidermis and varying 
thickness of dermis so that a range of dermis thicknesses were obtained from 0.8 – 2.2 
mm. Dermis thickness was evaluated with calipers. A PermeGear flow-through (In-Line, 
Riegelsville, PA) diffusion cell system was used for the in vitro diffusion studies. Isotonic 
HEPES-buffered Hanks‘ balanced salts solution (pH 7.4) was used as the receiver 
solution. The flow rate of the receiver fluid was set at 1.5 ml/h to maintain sink 
conditions. Skin samples in the diffusion cells were kept at 32°C using a circulating water 
bath. The diffusion experiments were initiated by charging the donor compartment with 
0.7 ml of the donor solution. Samples were collected from the receiver compartment in 6 
h increments over 48 h. All samples were stored at 4 °C until processed by HPLC. The 
permeation data were plotted as the cumulative amount of NTX•HCl collected in the 
receiver compartment as a function of time. Fourteen diffusions cells were employed (n 
= 14). 
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IV bolus injection preparation 
NTX•HCl was dissolved in sterile saline to obtain a drug concentration of 40 mg/ml. 
Solution for IV injection was filtered through a sterile 0.22 µm filter into a sterile 
scintillation vial under a laminar biosafety hood. Syringes were prefilled to deliver a 
desired dose: 1 mg/kg, 9 mg/kg or 10 mg/kg. 
 
Transdermal patch preparation 
Commercially available AquaSite® (Derma Sciences, Princeton, NJ) hydrogel sheets 
were cut into circular discs, 4 cm in diameter. Next, a solution of benzyl alcohol 1%, 
ethanol 5%, propylene glycol 10% and water for injection 84% (v/v) was prepared and 
NTX•HCl was dissolved to obtain a concentration of 110 mg/ml. A four-fold excess of 
NTX•HCl solution, with respect to the weight of the hydrogel, was equilibrated with the 
discs for 48 h. The equilibrium NTX•HCl concentration in the hydrogel discs was 
determined by HPLC to be 90 mg/g. Next, the transdermal formulation was autoclaved 
at high pressure saturated steam at 121°C for 15 min (verified for chemical stability by 
HPLC). Sterile and drug-loaded hydrogel discs were applied on the MN-treated skin 
areas and covered with protective patches to prevent dislocation throughout the duration 
of the experiment. The protective patches (4 cm internal diameter) were prepared by 
sandwiching a rubber ring to create a reservoir between a drug-impermeable backing 
membrane and an adhesive around the edge of a rubber spacer.  After application to 
Yucatan minipig back treatment sites patches were further secured in place by applying 
Bioclusive® tape over prototype patches. 
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Animal Studies 
Male and female Yucatan minipigs (Sinclair Bio-Resources; Columbia, MO) weighing 
approximately 40 kg were used for in vivo studies. These animals underwent surgical 
procedure at Sinclair Bio-Resources to cannulate the jugular veins and implant Vascular 
Access Ports (VAPs) (Access Technologies; Skokie, IL). All animal studies were in 
accordance with institutional guidelines approved by the University of Kentucky IACUC. 
IV bolus injections: NTX•HCl bolus was administered via VAP through a controlled 
infusion over 3.5-5 min. Three independent experiments (n=3) were carried out with 
three different NTX•HCl doses of 1 mg/kg, 9 mg/kg or 10 mg/kg. Blood samples were 
collected prior to drug treatment (baseline). After dosing, VAP was flushed with sterile 
heparinized saline. Blood samples (2 ml) were drawn from VAP at scheduled time 
intervals for 55 h after the intravenous dose. The blood samples were immediately 
centrifuged at 10 000 g for 3 min; plasma was separated and stored at -70 °C until 
analyzed. 
Transdermal studies: For transdermal delivery studies, 4 sites were designated on the 
dorsal region of Yucatan miniature pig and treated with MN (400 
each). NTX•HCl hydrogels were applied to the sites and covered with patches and 
Bioclusive® transparent dressing. A jacket was placed on the pig to protect the patches.  
Three independent experiments (n=3) were carried out. Blood samples were collected 
prior to drug treatment (baseline). After application of patches, blood samples were 
obtained over 72 h followed by patch removal and blood sampling for another 24 h. The 
blood samples were immediately centrifuged at 10 000 g for 3 min. Plasma was 
separated and stored at -70 °C until analyzed. 
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Quantitative analysis - HPLC 
Quantitative analysis of NTX•HCl concentrations from in vitro study was carried out by 
HPLC using a modification of the assay described by Hussain et al. [225]. The HPLC 
system consisted of a Waters 717 plus autosampler, a Waters 600 quaternary pump, 
and a Waters 2487 dual wavelength absorbance detector with Waters Empower™ 
software. A Brownlee (Wellesley, MA, USA) C-8 reversed phase Spheri-5 μm column 
(220×4.6 mm) with a C-8 reversed phase guard column of the same type (15×3.2 mm) 
by Perkin Elmer® was used with the UV detector set at a wavelength of 215 nm or 278 
nm. The mobile phase consisted of 70:30 (v/v) ACN:(0.1% TFA with 0.065% 1-octane 
sulfonic acid sodium salt, adjusted to pH 3.0 with TEA aqueous phase). Samples were 
run at a flow rate of 1.5 ml/min with a run time of 4 min. The injection volume used was 
100 µl. The retention time of NTX•HCl was 2.1 ± 0.1 min. Samples were analyzed within 
a linear range of the NTX•HCl standard curve from 100 – 10000ng/ml. The standard 
solutions exhibited excellent linearity over the entire concentration range employed in 
the assays. 
 
Quantitative analysis – LC-MS-MS 
Plasma samples obtained from in vivo Yucatan minipig studies were quantified by a LC-
MS-MS method.  
Calibration standards: Stock solutions of naltrexone hydrochloride (NTX•HCl) and 6-ß-
naltrexol hydrochloride (NTXol•HCl) in acetonitrile were prepared at 100 ng/ml 
concentration. Working solutions were prepared by serial dilution of the stock solutions. 
Calibration standards of NTX•HCl and NTXol•HCl at concentrations 1, 2, 3, 5, and 10 
ng/ml in Yucatan minipig plasma were prepared fresh daily by spiking Yucatan pig 
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plasma with 20 µl of NTX•HCl and NTXol•HCl working solutions at adequate 
concentrations.  
Sample extraction procedure: All standards and samples of volume 200 µl were 
extracted with 1ml of acetonitrile:ethyl acetate (1:1, v/v), resulting in protein precipitation. 
The mixture was vortexed for 15 s and centrifuged at 12000 g for 20 min. The 
supernatant was transferred to a glass tube and evaporated under nitrogen. Then, the 
residue was reconstituted in 100 µl acetonitrile, sonicated for 10 min and vortexed for 15 
s. Samples were transferred into low volume inserts into HPLC vials and injected onto 
the LC-MS/MS system. 
LC-MS-MS conditions: Waters Atlantis Hilic Silica 5 µm, 2.1x150 was used as the 
chromatographic column with a mobile phase consisting of methanol with 0.1% acetic 
acid:buffer 95:05 (v/v). The aqueous buffer consisted of 20 mM ammonium acetate and 
5% methanol. The injection volume was 40 µl. Liquid chromatography was carried out in 
the isocratic mode at the flow rate of 0.5 ml/min with a total run time of 4 min. The 
retention times for NTX•HCl and NTXol•HCl were as follows: 2.2 and 2.1 min, 
respectively. The LC-MS/MS system consisted of a HPLC Waters Alliance 2695 
Separations Module, Waters Micromass® Quattro MicroTM API Tandem Mass 
Spectrometer and Masslynx Chromatography software with Waters Quanlynx (V. 4.1) 
analysis software. Positive mode atmospheric pressure chemical ionization was used for 
detection of both compounds (APCI+). Multiple reaction monitoring (MRM) was carried 
out with the following parent to daughter ion transitions for NTX•HCl and NTXol•HCl: m/z 
341.8→323.8, m/z 343.8→325.8, respectively. The corona voltage was 3.5 µA, cone 
voltage 25 V, extractor 2 V, RF lens 0.3 V, source temp 130 °C, APCI probe temperature 
575 °C. The collision gas was 20 eV. Nitrogen gas was used as a nebulization and 
drying gas at flow rates of 50 and 350 l/h, respectively. Calibration plots were prepared 
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by the linear regression analysis of the standard peak areas versus nominal drug 
concentration.  
Lower quantification limits (LLOQ): based on the coefficient of variation (CV) < 20 % 
criterion the following limits of quantification were estimated: NTX•HCl 0.5 ng/ml, 
NTXol•HCl 0.5 ng/ml. 
 
Statistical analysis 
The statistical analysis of data (95% confidence intervals determination) was carried out 
with the use of Scientist® software (Micromath). 
 
10.3. Model development 
The aim of this work was to develop a mathematical model that would adequately 
describe in vivo NTX•HCl plasma profile after a ―poke and patch‖ method application. 
This was approached through the use of a combined diffusion-compartmental model. 
The critical elements incorporated into the model are as follows: recognition of two 
parallel pathways for drug permeation after MN skin treatment (intact skin pathway and 
microchannel pathway), the barrier thickness-dependant diffusional resistance of 
microchannel pathway, direct relationship between electrical admittance of the 
microchannels and their permeability to drugs, and pharmacokinetic compartmental 
module for description of drug disposition and elimination from the body. The schematic 
diagram of the model is shown in Figure 10.1, and can be divided into 3 modules: 
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Module 1 – Skin diffusion  
One-dimensional diffusion model accounts for diffusion of drug molecules from a 
formulation across skin to a certain hypothetical skin depth where an absolute clearance 
exists (sink conditions). The drug concentration on surface of the skin is assumed to 
remain constant at all times. This is typically true for skin controlled-diffusion where flux 
is not sufficiently high to deplete drug from the formulation over study duration. In the 
present study it was confirmed experimentally by observing no change in NTX•HCl 
concentration from beginning to the end of the in vivo transdermal study (data not 
shown). For untreated skin only one permeation pathway – intact skin pathway – is 
recognized. The barrier nature of intact skin pathway is well-approximated by the barrier 
properties of the mono-layered stratum corneum alone. This was experimentally 
confirmed in vitro by comparing the rate of NTX•HCl permeation through untreated skin 
against skin devoid of stratum corneum, which resulted in hundreds-fold increase in 
transport rate (data not shown). After MN-treatment another permeation pathway – 
microchannel pathway – is formed. The barrier nature of this pathway is bi-layered, the 
first layer corresponds directly to the microchannel and the second to the viable tissue 
(dermis) between microchannel and hypothetical skin depth at which an absolute 
clearance exists (sink conditions). However, since NTX diffusivity in the dermis is much 
lower, as compared the microchannel interior, it is assumed that all diffusional resistance 
will come primarily from the viable tissue. Thus, a mono-layered membrane model is 
used for simplicity. Fractional skin surface area is assigned to each pathway which 
describes relative contribution of each flux to the total flux through MN-treated skin. At 
any time the total flux, JTOT, equals: 
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𝐽𝑇𝑂𝑇 = 𝑓𝐼𝑆𝑃𝐽𝐼𝑆𝑃 + 𝑓𝑀𝐶𝑃 𝐽𝑀𝐶𝑃        (10.1) 
 
where fISP is the fractional skin surface area of intact skin pathway, JISP is the flux through 
intact skin pathway, fMCP is the fractional skin surface area of microchannel pathway, and 
JMCP is the flux through microchannel pathway. Assuming homogenous nature of skin 
layers: stratum corneum and viable tissue, the cumulative amount-time profiles can be 
derived by solving Fick‘s second law of diffusion: 
 
𝜕𝐶𝑚
𝜕𝑥
= 𝐷𝑚
𝜕𝐶𝑚
𝜕𝑥2
         (10.2) 
 
where Cm is drug concentration in the membrane, Dm is drug diffusion coefficient in the 
membrane, and x is spatial coordinate. After imposing the following initial conditions: 
 
𝐶𝑚  𝑥, 0 = 0         (10.3) 
 
and boundary conditions: 
 
𝐶𝑚  0, 𝑡 = 𝐶𝑣         (10.4) 
𝐶𝑚  𝑕𝑚 , 𝑡 = 0         (10.5) 
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it was shown [78] that the solution is terms of cumulative amount of drug exiting the 
membrane is: 
 
𝑄 𝑡 = −𝐷𝑚𝐴   
𝜕𝐶𝑚
𝜕𝑥
𝑡
0
 
𝑥=𝑕𝑚
𝑑𝑡 = 𝐴𝐶𝑣𝑕𝑚  
𝑡
𝑡𝑑
−
1
6
−
2
𝜋2
 
(−1)𝑛
𝑛2
∞
𝑛=1 ∙ 𝑒
(−
𝑡
𝑡𝑑
𝜋2𝑛2)
  (10.6) 
 
where the diffusion time, td is: 
 
𝑡𝑑 =
𝑕𝑚
2
𝐷𝑚
         (10.7) 
 
Hence, for intact skin pathway (stratum corneum as a membrane) the flux per unit area 
as a function of time is given by: 
 
𝐽𝐼𝑆𝑃 = −𝐷𝑆𝐶  
𝑑𝐶𝑆𝐶
𝑑𝑥
 
𝑥=𝑕𝑆𝐶
=
𝐷𝑆𝐶
𝑕𝑆𝐶
𝐶𝑣  1 + 2  (−1)
𝑛∞
𝑛=1 ∙ 𝑒
(−
𝑡
𝑡𝑑
𝜋2𝑛2)
   (10.8) 
 
and for microchannel pathway (dermis as a membrane) the analogous solution is: 
 
𝐽𝑀𝐶𝑃 = −𝐷𝑉𝑇  
𝑑𝐶𝑉𝑇
𝑑𝑥
 
𝑥=𝑕𝑉𝑇 ′
=
𝐷𝑉𝑇
𝑕𝑉𝑇
𝐶𝑣  1 + 2  (−1)
𝑛∞
𝑛=1 ∙ 𝑒
(−
𝑡
𝑡𝑑
𝜋2𝑛2)
   (10.9) 
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The above solutions are assumed to adequately describe drug transport through MN-
treated skin in in vitro conditions. In the in vivo case an additional factor that needs to be 
considered is the microchannel closure process. 
 
Module 2 – Microchannel closure  
Upon formation of microchannels in the skin in vivo, the tissue repair process initiates. 
The fundamental assumption of this module about in vitro and in vivo microchannel 
pathway permeability is the following: in vitro microchannel pathway permeability is a 
constant and remains high indefinitely, while in vivo microchannel pathway permeability 
decreases as a function of time. Multiple studies demonstrated that after MN treatment 
of skin in vitro the permeability of microchannel pathway remains constant as manifested 
by achievement and maintenance of steady-state flux [6, 28, 255]. For simplicity, the 
permeability of the microchannel pathway can be interpreted in terms of the fractional 
skin surface area of microchannels that remains open. Such treatment is an obvious 
generalization, as behind the decreasing permeability of the microchannel pathway in 
vivo lays a cascade of biological processes related to wound healing, which ultimately 
leads to the complete repair of the injured skin [43, 44, 268]. These processes will affect 
both the drug diffusivity in the microchannel pathway and skin surface opening of 
microchannels. However, for the sake of drug delivery discussion, it is a compelling 
simplification. Another crucial assumption is that the skin electrical impedance 
measurements employed herein to study the time-dependent microchannel closure 
provide valuable information with respect to NTX•HCl permeability through the 
microchannel pathway. A report by P. Karande et al. demonstrated that even for non-
MN-treated skin, in presence of chemical enhancers, the inverse correlation between 
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electrical impedance and permeability of hydrophilic solutes was good (R2 = 0.8) [269]. 
Authors stated that permeability can be related to skin impedance through the porous 
pathway theory with the fundamental underlying hypothesis that polar uncharged solutes 
and ions (carrying current) migrate through the SC via identical pathways. With respect 
to drug transport through MN-treated skin, G. Yan et al. found a good linear correlation 
(R2 = 0.94) between acyclovir flux and skin conductance [263]. This is not surprising 
since the presence of microchannels in the skin undoubtedly establishes the pathway of 
least electrical and diffusional resistance. Hence, the electrical impedance 
measurements can be expected to reliably probe the barrier domain for transport of 
NTX•HCl across MN-enhanced skin. The inverse of electrical impedance is electrical 
admittance, which is assumed herein to be directly proportional to permeability of the 
microchannel pathway. Hence, the equation that can adequately describe the total flux in 
in vivo situation is as follows: 
 
𝐽𝑇𝑂𝑇 ,𝐶 = 𝑓𝐼𝑆𝑃𝐽𝐼𝑆𝑃 + 𝑓𝑂𝑀𝐹𝑓𝑀𝐶𝑃 𝐽𝑀𝐶𝑃       (10.10) 
 
where JTOT,C is total flux corrected for microchannel closure, fOMF stands for open 
microchannel surface area fraction, or more precisely for fraction of initial permeability of 
the microchannel pathway. It was found experimentally that the decrease in the 
admittance of the microchannel pathway follows an apparent exponential decrease in 
time (unpublished human results by Nicole Brogden). The apparent first-order rate 
constant, kY, obtained from in vivo electrical impedance measurements was used 
directly as an estimate of kOMF to describe the drop in time-dependant permeability of the 
microchannel pathway: 
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𝑓𝑂𝑀𝐹 = 𝑓𝑂𝑀𝐹
0 𝑒−𝑘𝑂𝑀𝐹 𝑡         (10.11) 
 
where f0OMF numerically equals the value of unity and corresponds to the initial open 
microchannel surface area fraction, or more precisely the initial permeability of the 
microchannel pathway obtained immediately after skin MN treatment. Implicitly it is 
assumed that in in vitro situation f0OMF holds the value of unity and Eq. 10.10 collapses to 
Eq. 10.1. Of note, in the strict sense the microchannel healing process causes time-
dependant drop in the microchannel skin surface area which is accompanied by the 
same area increase in the intact skin around the microchannels. However, since fMCP is 
typically very small (e.g. 0.025) as compared to fISP (e.g. 0.975), the time-dependant 
increase in fISP is minute and ignored in Eq. 10.10, as shown by lack of a time-dependant 
term in front of the fISP•JISP term. This simplification reduces the calculation work and 
does not negatively affect the results. Once drug has crossed viable skin tissue and 
reaches local microvasculature it is swept away by blood flow to find itself in the central 
pharmacokinetic compartment. 
 
Module 3 – pharmacokinetic compartments 
Through viable tissue drug is absorbed into systemic circulation, or central 
pharmacokinetic compartment. The experimental data reported herein demonstrated an 
apparent 3-exponential decrease in NTX•HCl concentration as a function of time after a 
bolus IV administration. In consequence, a 3-compartment mammillary model was 
chosen to describe NTX•HCl distribution and elimination from the body. The differential 
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equations that describe drug delivery to the central compartment, its distribution and 
elimination are as follows: 
 
𝑑𝐶1
𝑑𝑡
=
𝐴∙𝐽𝑇𝑂𝑇 ,𝐶
𝑉𝑑
+
𝑘21𝑋2
𝑉𝑑
+
𝑘31𝑋3
𝑉𝑑
− 𝑘12𝐶1 − 𝑘13𝐶1 − 𝑘10𝐶1   (10.12) 
𝑑𝑋2
𝑑𝑡
= 𝑘12𝐶1𝑉𝑑 − 𝑘21𝑋2      (10.13) 
𝑑𝑋3
𝑑𝑡
= 𝑘13𝐶1𝑉𝑑 − 𝑘31𝑋2      (10.14) 
 
where A is the total skin area of hydrogel application, Vd is the initial volume of 
distribution; k12, k13, k21, k31 are micro rate constants describing drug transport between 
central (#1) and peripheral (#2 and #3) compartments; and k10 is the elimination 
constant. The drug plasma concentration (central compartment) is a single major 
variable of interest.  
 
10.4. Method of solution 
Scientist® software (Micromath, Saint Louis, MO) was used to numerically solve model 
equations (Eq. 10.8 - 10.14) transformed into LaPlace domain. The inverse 
transformation was performed by software using Piessens and Weeks algorithms. 
Scientist® initially uses fast Weeks algorithm; however, in situation when this method is 
not applicable it automatically detects it and employs to a slower but more reliable 
Piessens algorithm. The accuracy of numerical solutions obtained from equations written 
in LaPlace domain was compared with those written in time domain for a case where 
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diffusion equations describing drug transport through MN-treated skin were replaced 
with true zero-order delivery. The agreement between two methods was excellent. 
 
10.5. Parameter estimation 
 
Estimation of naltrexone diffusion coefficient in water 
The estimate of the NTX diffusion coefficient in water was obtained by the use of Stokes-
Einstein equation: 
 
𝐷 =
𝑘𝑇
6𝜋𝜂𝑟
         (10.15) 
 
where k is the Boltzmann constant, T is the absolute temperature, η is the viscosity and r 
is the hydrodynamic radius of the solute. Using experimentally determined viscosity 
value of 1.03 cP determined at 32 °C [39] and assuming the hydrodynamic molecular 
radius of 4.6 Å [227] a diffusion coefficient value of 4.7•10-6 cm2 s-1 was calculated. This 
value is assumed to approximate well the diffusivity of naltrexone in microchannels filled 
with interstitial fluid. It has been formerly shown by McAllister et al. that MN-enhanced 
transdermal flux values for a variety of compounds of different sizes correlated well with 
prediction based on the Stokes-Einstein eq. [27]. It suggests that diffusivity of drug 
molecules in the microchannels resembles that seen in the bulk solution. 
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Estimation of naltrexone diffusion coefficient in the dermis 
For the purpose of experimental assessment of drug diffusivity in the dermis, a study 
involving NTX•HCl permeation across skin devoid of epidermis was carried out. Figure 
10.2 demonstrates a representative graph of cumulative amount of naltrexone HCl 
plotted against time. As evident from the plot, the flux is very high, which caused 
depletion of drug in the donor solution. At the end of the 48 h study, experimentally 
measured NTX•HCl concentration in the donor solution dropped, on average, by 50 ± 18 
%. Due to this fact, the plot lacks late steady-state portion and flux was estimated not 
from the terminal, but rather, early graph section. The slope of the plot in 6-12 h 
timeframe better approximates stead-state flux, in this case, as it allows for lag time but 
minimizes the effect of drug depletion in the donor solution. Flux values obtained by this 
method were plotted against the thickness of the dermis employed in the diffusion study. 
Figure 10.3 summarizes data from all 14 cells. A clear trend is visible with thicker dermis 
corresponding to higher diffusional resistance of the barrier and decreased flux. The 
reciprocal relationship between flux and the thickness of the barrier (dermis) can be 
described by Eq. 10.16: 
 
𝐽 =
𝐶
𝑕𝑉𝑇
𝐷𝑉𝑇
          (10.16) 
 
where J is steady-state flux, C is donor solution concentration of NTX•HCl, hVT is 
thickness of the dermis (viable tissue) and DVT is diffusion coefficient of NTX in the 
dermis. Since the values of all the above terms are known with exception of the NTX 
diffusion coefficient in dermis, it can be estimated by non-linear regression of flux on 
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dermis thickness by means of Eq. 10.16. The mean estimated value was found to be 
3.46 10-7 cm2 s-1, 95 % confidence interval of (3.28 10-7, 3.65 10-7). This value is 
approximately 14-fold lower than the diffusion coefficient of NTX in water estimated in 
the former paragraph. 
 
Estimation of effective microchannel diameter 
Effective microchannel diameter was estimated from in vitro diffusion data. Former 
studies employed in vitro diffusion set-up consisting of 0.95 cm2 of 1.8 mm-thick Yucatan 
minipig skin possessing 100 microchannels and donor solution of NTX•HCl in water at 
110 mg/ml. The length of the microchannels in the skin was assessed to be 
approximately 650 µm (unpublished data). The steady-state flux through microchannel 
pathway alone (JMCP-EXP) was measured to be 76.8 ± 11.7 nmol h
-1 [39]. By comparison 
of this experimental flux value (JMCP-EXP) to the calculated flux value (JMCP-CAL), which 
corresponds to the same experimental conditions but with fractional skin surface area of 
microchannel pathway of unity (fMCP-CAL = 1), the estimate of the effective microchannel 
pathway skin fractional surface area (fMCP-EXP) can be obtained. The value of JMCP-CAL was 
estimated by use of the following parameter values: DMC = 4.70 10
-6 cm2 s-1, hMC = 0.65 
mm, DVT = 3.46 10
-7 cm2 s-1, hVT‘ = 0.115 mm, C = 290 mM, and fMCP-CAL = 1 according to 
Eq. 10.17: 
 
𝐽𝑀𝐶𝑃−𝐶𝐴𝐿 = 𝑓𝑀𝐶𝑃−𝐶𝐴𝐿
𝐶
𝑕𝑀𝐶
𝐷𝑀𝐶
+
𝑕𝑉𝑇 ′
𝐷𝑉𝑇
       (10.17) 
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where fMCP-CAL is the microchannel pathway skin fractional surface area, C is NTX•HCl 
donor solution concentration, DMC is NTX diffusivity in microchannels approximated by 
NTX diffusivity in water, hMC is thickness of the microchannel layer, DVT is NTX diffusivity 
in the dermis, and hVT‘ is the thickness of the underlying dermis layer. Numerically, JMCP-
CAL was found to equal 3017 nmol cm
-2 h-1. 
On the other hand, the JMCP-EXP of 76.8 nmol cm
-2 h-1 corresponds to the following Eq. 
10.18: 
 
𝐽𝑀𝐶𝑃−𝐸𝑋𝑃 = 𝑓𝑀𝐶𝑃−𝐸𝑋𝑃
𝐶
𝑕𝑀𝐶
𝐷𝑀𝐶
+
𝑕𝑉𝑇 ′
𝐷𝑉𝑇
       (10.18) 
 
where fMPC-EXP is unknown. Since the numerical value of the ratio of drug donor solution 
concentration to the total microchannel pathway resistance is the same in Eq. 10.17 and 
Eq. 10.18, the solution for JMCP-EXP can be simplified to Eq. 10.19: 
 
𝑓𝑀𝐶𝑃−𝐸𝑋𝑃 =
𝐽𝑀𝐶𝑃 −𝐶𝐴𝐿 ∙𝑓𝑀𝐶𝑃 −𝐸𝑋𝑃
𝐽𝑀𝐶𝑃 −𝐶𝐴𝐿
       (10.19) 
 
which yields the fMCP-EXP value of 0.025 or 2.5 %. This fractional skin surface area 
translates into an effective microchannel opening diameter of 176 µm. Noteworthy, this 
effective opening diameter is larger than the actual skin surface opening of the 
microchannel that is around 50-100 µm wide [270]. The likely reason for this difference is 
the inclusion of lateral diffusion within the ―effective‖ microchannel diameter. While all the 
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equations presented herein are one-dimensional, in reality lateral diffusion will contribute 
to the overall flux, and it can be expected that ―actual‖ microchannel diameter will not 
suffice to account for the flux obtained through microchannel pathway. Therefore, it will 
be the effective microchannel diameter that will be used for further calculations. 
 
Estimation of microchannel pathway fractional skin area in vivo 
The in vivo Yucatan minipig transdermal experiment involved application of 4 patches. 
Each patch had a diameter of 4 cm and covered 400 microchannels. Therefore, the total 
skin surface area involved in diffusion was 50.24 cm2 and skin surface area of all 
microchannel openings was 0.39 cm2, which gives the microchannel pathway fractional 
skin area fMCP = 0.0077 or 0.77 % in vivo. 
 
Estimation of the microchannel closure rate in vivo 
The electrical impedance was used to evaluate the permeability of microchannel 
pathway in vivo. Skin impedance in the context of this study is understood as electrical 
resistance measured in presence of an AC signal. It measures the difficulty of electrical 
current (ionic) transport across skin. In the current experimental set-up, after MN 
treatment, three parallel and independent pathways for electric current transport can be 
distinguished: resistor box, skin around the microchannels and microchannels 
themselves. Alternatively, in the absence of microchannels in the skin, only two parallel 
pathways are available: resistor box and untreated skin. The latter case represents 
either a situation before MN treatment or a situation when microchannels are fully 
closed/healed after MN treatment. The resistor box and skin, with or without 
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microchannels, are truly unrelated pathways. However, in the strict sense, 
microchannels and skin are not since upon MN treatment microchannels take over a 
minute skin surface area. Practically, the drop in the intact skin surface area is negligible 
as a result of microchannel formation and the fractional area of skin before and after MN 
treatment remains close to unity fMCP ≈ 1. Based on earlier in vitro effective microchannel 
diameter estimates (167 µm), density of MN treatment (100/cm2), and electrode surface 
area (0.95 cm2) the fraction of microchannel pathway skin surface area fMCP in in vivo 
microchannel closure studies also equals 2.5 %. Of note, the intact skin impedance 
value corrected for fMCP establishes the upper limit for microchannel pathway. In other 
words, when the microchannel closure process is complete the microchannel pathway 
impedance values come back to the value corresponding to the intact skin. Overall, 
experimental electrical impedance measurements after skin MN-treatment provide a 
total impedance value ZTOT that is a function of ZRB (resistor box), ZISP (intact skin 
pathway) and ZMCP (microchannel pathway) according to Eq. 10.20: 
 
𝑍𝑡𝑜𝑡 =
1
1
𝑍𝑅𝐵
+
1
𝑍𝐼𝑆𝑃
+
0.025
𝑍𝑀𝐶𝑃
        (10.20) 
 
where the implicit assumption about a negligible drop in fISP as a result of MN-treatment 
is built in. In the absence of MN-treatment the total electrical impedance equals: 
 
𝑍𝑡𝑜𝑡 =
1
1
𝑍𝑅𝐵
+
1
𝑍𝐼𝑆𝑃
         (10.21) 
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Since ZTOT and ZRB are known, and ZISP can be independently estimated from an 
experiment employing untreated skin under occlusion, the electrical impedance of the 
microchannel pathway can be calculated. This approach allows elimination of the 
confounding variables, such as the influence of the resistor box settings and the 
hydration state of the skin. Moreover, to evaluate microchannel closure kinetics it is 
more intuitive to use inverse of the electrical impedance (Z), the electrical admittance 
(Y), which directly correlates with permeability or fractional skin surface area of open 
microchannels. The interpretation of electrical admittance values resembles another 
popular method – transepidermal water loss (TEWL) in the sense that high values signify 
compromise in the barrier integrity, while low, baseline values are typical under normal 
physiological conditions. Since no impedance microchannel closure data is available for 
Yucatan minipig at present, human impedance microchannel closure data (collected by 
Nicole Brogden, unpublished), were used instead. It is believed that human impedance 
microchannel closure data will provide an acceptable surrogate for its Yucatan minipig 
counterpart. The time-dependent changes of the microchannel pathway admittance 
values (normalized per initial admittance values obtained after microneedle treatment 
and after subtraction of baseline intact skin pathway value) followed an apparent 
exponential decrease. The subtraction of baseline intact skin pathway value from 
microchannel pathway admittance is necessary to assure that at long times the signal 
drops to zero as required by Eq. 10.22. To estimate the rate of microchannel closure the 
data was logarithmically transformed to obtain the apparent first-order microchannel 
closure rate constants (kY‘s) according to the following empirical model: 
 
𝑌𝑀𝐶𝑃 = 𝑌𝑀𝐶𝑃
0 ∙ 𝑒−𝑘𝑌 𝑡         (10.22) 
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where Y0MCP stands for the initial microchannel pathway admittance after microneedle 
treatment. The average estimate for kY obtained from human studies (data collected by 
Nicole Brogden, unpublished, n = 9) equaled 0.041 h-1, corresponding to t1/2 of 17 h, and 
was adopted as a surrogate kY value for Yucatan minipigs. 
 
Adjustment of naltrexone diffusivity per formulation microviscosity 
In Chapter 7 the influence of propylene glycol on the MN-assisted NTX•HCl flux was 
discussed. It was demonstrated that the inclusion of PG in the aqueous donor solution 
caused a marked decrease in the transport rates in vitro. Hence, NTX diffusivity values 
corrected for the presence of 10 % propylene glycol in the formulation used in the 
current in vivo study are the following: DMC =  3.34 10
-6 cm s-1 and DVT = 2.46 10
-7 cm s-1. 
 
Estimation of naltrexone pharmacokinetic parameters 
In order to assess parameter values related to NTX•HCl distribution and elimination from 
the body, IV bolus drug administration was carried out. The plasma levels of NTX•HCl in 
Yucatan minipig was observed to follow an apparent three-exponential decrease and 
can be adequately described by a three-compartmental model as shown in Figure 10.4. 
To obtain the pharmacokinetic parameter values the experimental data from three 
independent experiments with the following doses 1 mg/kg, 10 mg/kg, and 9 mg/kg were 
fitted simultaneously to the following differential equations: 
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𝑑𝐶1
𝑑𝑡
=
𝑘21𝑋2
𝑉𝑑
+
𝑘31𝑋3
𝑉𝑑
− 𝑘12𝐶1 − 𝑘13𝐶1 − 𝑘10𝐶1    (10.23) 
𝑑𝑋2
𝑑𝑡
= 𝑘12𝐶1𝑉𝑑 − 𝑘21𝑋2      (10.24) 
𝑑𝑋3
𝑑𝑡
= 𝑘13𝐶1𝑉𝑑 − 𝑘31𝑋2      (10.25) 
 
where at time zero the initial drug concentration in the central compartment (C1) was 
calculated as dose/Vd. Such analysis resulted in parameter values summarized in Table 
1. Given the preliminary nature of the IV bolus studies and limited number of repetitions 
the estimate values are to be taken with caution. Further studies will provide more 
certainty in the estimated parameter values. Systemic clearance of NTX•HCl defined as 
k10•Vd equals 1.9 l min
-1 or 47 ml min-1 kg-1. Hence, weight-normalized systemic NTX•HCl 
clearance value is practically equivalent to its human counterpart of around 50 ml min-1 
kg-1. 
 
10.6. Microneedle-enhanced naltrexone delivery in Yucatan minipig  
Experimental data demonstrating NTX•HCl plasma levels in Yucatan minipig after a 
―poke and patch‖ method use are shown in Figure 10.5. No steady-state NTX•HCl 
plasma level is observed. Initially, the drug concentration increases quickly to reach Cmax 
of approximately 2.5 ng/ml at 4 h. A sharp drop in the drug plasma level follows and 
within approximately 24 h NTX•HCl concentration becomes only half of Cmax. Finally, at 
late 48-72 h timeframe the level seems to plateau at 0.6 ng/ml. After removal of the 
transdermal patches at 72 h NTX•HCl level drops rapidly below lower limit of 
quantification. No naltrexol was detected in the transdermal drug delivery study. The 
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overall goal of employing the mathematical model to describe the in vivo NTX•HCl 
plasma levels was to evaluate if recognition of two parallel flux and microchannel closure 
process would suffice to adequately describe plasma NTX•HCl profile, and obtain a 
reliable value of hVT‘ parameter. This estimate can be interpreted as a hypothetical 
thickness of the dermis that separates the microchannel from a dermis level at which an 
absolute clearance into the blood compartment exists (sink conditions). The knowledge 
of hVT‘ parameter can help better design in vitro experiments to reflect in vivo conditions 
as closely as possible. All the other parameter values are known from independent 
studies and summarized in Table 10.1. Of those, two parameter estimates are to be 
taken with caution: kOMF and DSC. The first was obtained through investigation of 
microchannel closure process in humans (Nicole Brogden‘s unpublished data) and is 
employed as a surrogate for its Yucatan minipig counterpart, which is lacking at present. 
The second, DSC, obtained through a in vitro permeation study [39] turned out to be an 
overestimate. If its value held true in in vivo conditions a plateau observed at late times 
(48-72 h) in Figure 10.5 would need to equal approximately 1.1 - 1.5 ng/ml. A possible 
reason for this mismatch is the negative effect of storage and freeze-thaw process on 
Yucatan minipig skin used in in vitro experiments. Transport of ionized species is 
expected to be very sensitive to even slightest defects in the skin which can cause a 
significant overestimate of permeation [66]. Such defects are not anticipated to play a 
major role in the transport of unionized and moderately lipophilic species for which SC 
lipid domain is the preferred route of permeation. Hence, the in vivo value of DSC was re-
estimated through regression analysis. Two parameter values hVT‘ and DSC were fitted 
simultaneously through regression of NTX•HCl plasma concentration on time, while 
keeping all other parameter values, obtained independently, constant. The least-squares 
fit of the model equations to experimental data is denoted as solid line in Figure 10.5. In 
general, a good correlation indicates that the model presented herein can dependably 
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represent in vivo drug delivery conditions with a ―poke and patch‖ method. The 
regression estimate of in vivo DSC was found to be 4.02 10
-12 cm2 s-1, or 95% CI (4.99 10-
13, 7.54 10-12), suggesting a point estimate value about 3-fold lower as compared to the 
estimate obtained from the in vitro studies [39] but within a large confidence interval 
range. More importantly, though, the estimate for hVT‘ was found to be 0.74 mm, or 95% 
CI (0.64, 0.84). The accuracy of the hVT‘ estimate depends on the method of its 
estimation. Herein, as mentioned before, point estimates of all other parameters were 
fixed while performing the least-square fit. This approach assumes that these estimates 
were accurate and no uncertainty from their estimation was included in the fitting 
process. An alternative, more conservative, approach would include simultaneous fitting 
of individual parameters from independent experiments together with the herein 
described model, which would  lead to a larger confidence interval for hVT‘. This 
approach was not used in the present analysis given the preliminary nature of the 
findings and the emphasis put on the recognition of the critical factors involved in the 
drug transport though closing microchannels in vivo. Yet another approach could involve 
simultaneous fitting of several parameters besides hVT‘ based on the transdermal data 
alone. However, such method was abandoned due to high correlation between 
parameters of interest and, hence, low credibility of the findings. The value of 0.74 mm 
may seem large, especially in the light of the fact that skin microvasculature is located in 
direct vicinity of the microchannel. For untreated skin, the distance that a permeating 
drug molecule needs to cross to reach cutaneous microcirculation is often assumed to 
be approximately 200 µm which anatomically corresponds to the thickness of avascular 
epidermis. Such approximation has been successfully used for a variety of cases. It 
could be expected then that the hVT‘ would be numerically even less than 200 µm; 
however, this is clearly not the case. There are at least a couple of factors that may 
rationalize this observation. Firstly, the assumption of an absolute clearance at a certain 
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depth of the dermis, although appealing by simplicity, may not be adequate to represent 
the drug transport process from a microchannel to the cutaneous blood vessels. It can 
be expected that a more complicated clearance distribution within the dermis would 
more realistically describe diffusion-clearance processes [271, 272]. Secondly, drug 
concentration in the microchannels is anticipated to be very high and it is likely that 
surrounding blood vessels do not provide true sink conditions. The existence of either 
the above phenomena would translate into a greater-than-expected hVT‘ value. In vitro, 
the hVT‘ value can be interpreted as an effective dermis thickness between a 
microchannel and a receiver solution, which provides true sink conditions. In vivo, this 
value can be understood as effective dermis thickness between a microchannel and a 
hypothetical dermis level at which an absolute clearance exists. It should be noted that a 
simple modeling approach used herein does not accommodate several other factors that 
may affect drug transport in vivo, such as microchannel shape, length, non-first order 
kinetics of microchannel closure, microvasculature spatial distribution, local blood flow, 
and others. More elaborate model would be required to address the above factors. For 
example, microneedle geometry may not only affect the fractional skin surface area of 
microchannel pathway but also the apparent value of hVT‘. This is due to the fact that the 
use one-dimensional diffusion modeling in in vivo situation may be an oversimplification. 
It can be anticipated that the area of the microchannel interior would better correlate with 
permeability rather than skin surface area of the opening. Such approach would be also 
robust enough to accommodate different length and shape of the microchannels. At this 
time, it was judged that the present approach was sufficient to elucidate key factors 
related to NTX•HCl delivery in vivo. The data analysis suggest that a single major 
obstacle for obtaining long-term, near steady-state drug profiles in vivo after the use of a 
―poke and patch‖ method is the relatively rapid closure of microchannels. Delaying the 
onset of microchannel closure or decreasing the rate of microchannel closure could 
230 
 
potentially greatly extend the timeframe of drug delivery via this route. All of the above 
discussion applies to a ―poke and patch‖ method where the formulation is non-rate-
limiting. Other uses of MN, e.g. inclusion of drug in polymeric dissolvable MN, would 
require a different treatment and optimization. An interesting discussion of the rate of 
drug release from drug-in-MN system was presented by Park et al. [273]. Authors 
presented biodegradable polymer microneedles that encapsulate drug for controlled 
release in skin. The rate of drug release was found to be determined by drug diffusivity 
in the polymeric matrix and could be controlled by selection of adequate polymer type. 
The release of the drug from polymeric MN showed an initial burst effect followed by 
gradual decrease in the rate of release. This represents a formulation-release-rate-
limited drug delivery. Another option could involve polymeric MN that biodegrade very 
quickly, which would imply MN-erosion-rate-limited release of drug. The recognition of 
the rate-limiting step is critical. Within a broad notion of ―MN drug delivery‖ several 
different delivery types may be distinguished with various rate-determining steps in drug 
transport. 
Working under assumption that the present model is adequate, and employing 
parameter estimates obtained from the current study, a few meaningful simulations can 
be performed. First, it is instructive to compare the microchannel pathway flux JMCP 
uncorrected (in vitro conditions) and corrected for microchannel closure process (in vivo 
conditions) through experimental skin surface area. Figure 10.6 demonstrates how 
drastic the difference between in vitro and in vivo conditions is. Not only in vivo flux 
decreases sharply over time but also never quite reaches the steady-state flux level of 
almost 0.5 g of NTX•HCl per hour in absence of microchannel healing. The more 
advanced healing process is the greater limitation is drug transport via microchannel 
pathway exists. It is sometimes attempted to assign a ―lifetime‖ to microchannels which 
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could be then employed to determine the time window for MN-assisted drug delivery. 
While this approach provides some very basic information with respect to timescale of 
the events it fails to recognize the time-dependent changes in permeability of the 
microchannels. The recognition of ―open/close‖ microchannel state depends either on 
arbitrary assumptions (e.g. 5-10% ―open‖ microchannel is considered ―closed‖) or 
statistical difference in signal between MN-treated and untreated skin which, in turn, 
depends on the sensitivity and precision of the measurement technique (TEWL, 
electrical impedance, dye staining). Even more importantly, though, the consequence of 
microchannel transition between arbitrary ―open‖ and ―close‖ states seems to have little 
bearing on the drug transport. Adopting a 10% ―open‖ mark as borderline between   
―open/close‖ state in the present study gives microchannels ―lifetime‖ of around 56 h. 
However, it is evident from the graph that while the JMCP keeps decreasing at 56 h there 
is no discontinuity in the flux at that time. The drop in JMCP between 55 and 57 h is of 
lesser practical significance than at any time before 56 h, say, 12 and 14 h. What is of 
major importance is the apparent exponential decrease in permeability of the 
microchannels implying that, after achieving a maximum, flux will continue to decrease 
by half every 17 h. In the current study, within an ―open‖ microchannel timeframe of 56 h, 
JMCP will diminish as much as 8.6 times. Hence, the microchannel closure process 
cannot be successfully described by an on-off approach assigning either ―open‖ or 
―closed‖ state, but rather gradual changes in the permeability must be recognized. 
Secondly, it can be visualized what are the contributions of intact skin pathway and 
microchannel pathway to the total flux in vivo across 50.24 cm2 of skin area employed in 
the study. In the experiment reported herein JISP was so low that it could not be detected 
directly with analytical methods available (below LLOQ) and its value was inferred 
indirectly through least-squares fit to the model. Figure 10.7 demonstrates that the total 
flux is almost synonymous with JMCP, except for late times when microchannels are 
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almost completely healed and low JISP value comes into play. It is also evident from the 
comparison of Figure 10.6 and Figure 10.7 that the time needed to reach JISP steady-
state is much longer as compared the time needed to reach JMCP steady-state. Next, an 
interesting comparison can be made by allowing for changes in the microchannel 
closure half-life (t1/2). Experimental t1/2 was evaluated to be around 17 h, and is too short 
to provide a sustained delivery of drug over the period of several days. However, if the 
rate of microchannel healing can be slowed four times (t1/2 of 69 h), a substantial 
improvement in the flux and drug plasma concentration can be anticipated as 
demonstrated in Figure 10.8. In such case, a drop of NTX•HCl plasma concentration 
from around 3 to 2 ng/ml can be expected instead of experimentally observed drop from 
2.7 to 0.4 ng/ml during 72 h. Alternative solution could involve the delay in the onset of 
the healing process rather than the decrease in the rate of healing. The approaches that 
can be utilized to achieve these goals are beyond the scope of the present work. It 
should be noted, however; that attempts have been made to elongate lifetime of the 
microchannels. A recent publication by Banks et al. [264] and unpublished results of 
Nicole Brogden suggest that a topical use of diclofenac, a COX enzyme inhibitor, can 
slow down the microchannel healing process, possibly through reduction in the 
inflammatory response to the micro-injury. Other options are also being explored in our 
laboratory. Generally, the use of methods that can delay the onset or/and slow down 
rate of microchannel closure can have a vital effect on the delivery of therapeutic agents. 
It seems that besides suppression of local inflammation or lipid SC barrier synthesis, 
other approaches that could help extend microchannel lifetime include the agents that 
would interfere ad slow down the migration of keratinocytes and reepithalization of the 
micro-injury. Finally, Figure 10.8 also presents the delivery profile of NTX•HCl 
anticipated in the absence of the microchannel closure process. This profile establishes 
the upper limit of in vivo drug delivery. As a result of the microchannel closure half-lives 
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extension from 17 h to 69 h to infinity (no healing) the shape of the drug delivery profile 
changes. While in the absence of the healing process the profile resembles a familiar 
shape of near 0-order delivery typically observed in classical transdermal drug delivery, 
with the microchannel closure process on, the shape gradually changes to resemble an 
oral delivery profile. Although the underlying processes behind the oral absorption 
processes and MN-enhanced percutaneous drug transport are different they manifest 
themselves in drug plasma concentration in a similar way. Depending on the overall goal 
of the delivery system this phenomenon can be desired or unwanted. When a sustained 
drug delivery over several days is sought for, the decrease in the rate of microchannel 
healing could provide an extended time window of high-flux NTX•HCl delivery. 
 
10.7. Conclusions 
In the present chapter NTX•HCl delivery in Yucatan minipig with a ―poke and patch‖ 
method was investigated. After an initial spike in plasma drug concentration, a rapid drop 
and plateau followed. A mathematical model, which incorporated the concepts of two-
pathway parallel drug transport, microchannel closure process, and drug disposition and 
elimination in vivo, was developed. With majority of the model parameters estimated 
independently, the overall fit of the model to experimental data was good implying that it 
accounted for key processes related to MN-enhanced drug delivery in vivo. Additionally, 
an estimate for hypothetical dermis thickness separating a microchannel from dermis 
level at which an absolute clearance exists, was obtained. Its relatively large value 
suggests that the effect of diffusional resistance of the dermis in vivo should not be 
ignored and must be accounted for in order to obtain a good in vitro-in vivo correlation. 
Based on the current study, it seems that the relatively fast rate of microchannel closure 
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is the single major hurdle for obtaining a sustained-delivery drug profiles in vivo after a 
―poke and patch‖ method. The application of the present model to other drugs delivered 
by MN-enhanced skin could shed some light on the generality of present findings. While 
the overall structure of the model should easily accommodate different diffusion 
coefficients of drugs, density of MN treatment, microchannel closure times and 
pharmacokinetic parameters, it would be very interesting to see if the value of the hVT‘ 
parameter remains approximately constant. The limitations of the present model include 
lack of explicit recognition of the microchannel length effect on the transport, ignorance 
of the possible dermal metabolism, protein binding, local blood flow, and 
microvasculature spatial distribution. A future project could address the above factors by 
expansion of the current model. 
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Table 10.1. Model parameters. All the parameters values (except for two which are 
denoted by asterisks) were obtained through independent experiments and were 
kept constant during performing a least-squares fit of the model to the in vivo 
transdermal data. The two fitted parameters (denoted by asterisks) are DSC (in 
vivo) and hVT’. 
Parameter Point estimate 95% CI Unit 
DSC (in vitro) 4.02 10
-12 n/a [cm2 s-1] 
DSC (in vivo)* 1.45 10
-12 (4.99 10-13, 7.54 10-12) [cm2 s-1] 
hSC 20 n/a  [µm] 
DVT 2.46 10
-7 n/a  [cm2 s-1] 
hVT’* 740 (640, 840) [µm] 
A 50.24 n/a  [cm2] 
fISP 1 n/a  [-] 
fMCP 0.0077 n/a  [-] 
kOMF = kY 0.041 n/a  [h
-1] 
Vd 43.86 n/a  [l] 
k12 3.192 n/a  [h
-1] 
k21 2.002 n/a  [h
-1] 
k13 0.098 n/a  [h
-1] 
k31 0.050 n/a  [h
-1] 
k10 2.596 n/a  [h
-1] 
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Figure 10.1. 
 
 
A schematic diagram of the model used to analyze the MN-assisted transdermal 
delivery of NTX•HCl in Yucatan minipig. Hydrogel drug formulation is placed on 
the MN-treated skin area. Skin allows drug transport through two parallel 
pathways. Drug is distributed amongst central and two peripheral compartments, 
and eliminated from the central compartment. 
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Figure 10.2. 
 
An individual (n = 1), representative permeation profile of NTX•HCl across dermis. 
Filled squares (■) denote experimental data points while solid line shows linear 
approximation of flux at 6-12 h timeframe extrapolated over the whole experiment 
duration. High flux resulted in approximately 50% drug depletion in the donor 
solution by the end of the 48 h study which manifests itself as a drop in flux at 
later time points. 
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Figure 10.3. 
 
NTX•HCl flux across dermis. Fourteen (n = 14) individual flux values denoted as 
filled squares (■) are plotted against increasing thickness of the dermis. The solid 
line represents the least square fit to Eq. 10.3.  
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Figure 10.4. 
 
Yucatan minipig plasma NTX•HCl levels after IV bolus administration of 1 mg/kg 
dose (♦), 10 mg/kg dose (), and 9 mg/kg dose (▲). Solid lines represent a least-
squares fit according to Eq. 10.23-10.25. 
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Figure 10.5. 
 
Yucatan minipig plasma NTX•HCl levels after a “poke and patch” method. At 72 h 
transdermal patches were removed. Points (♦) represent mean of three (n = 3) 
determinations, while solid line represent a least-squares fit according to Eq. 10.8-
10.14 in the 0-72 h timeframe. 
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Figure 10.6. 
 
Simulation demonstrating time-dependent changes in microchannel pathway flux 
under in vitro (dotted line) and in vivo (solid line) conditions. Microchannel 
closure causes the drop in flux in vivo. 
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Figure 10.7. 
 
Simulation demonstrating contributions of intact skin pathway flux (gray line) and 
microchannel pathway flux (dotted line) to the total flux (solid black line) in vivo.  
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Figure 10.8. 
 
Simulation demonstrating an effect of the change in the microchannel closure 
time on the plasma concentration of NTX•HCl. Solid line corresponds to 
microchannel closure t1/2 of 17 h (experimental), dotted line - t1/2 of 69 h, and gray 
line - t1/2 of infinity (no microchannel closure).  
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Chapter 11 
Conclusions and future directions 
 
The thesis project was based on two major objectives. The first, narrower in scope, was 
to increase the transdermal delivery rate of naltrexone from a transdermal patch through 
microneedle-enhanced skin. The second, wider in scope, is to gain better understanding 
of microneedle-enhanced transdermal drug delivery in terms of critical parameters 
governing the transport. Work reported herein can be seen as a continuation of 
pioneering NTX•HCl microneedle studies performed by Dr. S. Banks [274]. Naltrexone is 
a drug used primarily in the management of alcohol dependence and opioid 
dependence. Our interest in delivering naltrexone transdermally is well-founded and 
based on several drawbacks associated with the oral and injectable intramuscular 
dosage forms of naltrexone currently available on the market including significant first-
pass effect, gastrointestinal side effects and poor patience compliance. Although NTX 
does not permeate skin at the rate sufficient to reach therapeutic concentrations in 
human plasma, novel flux enhancement methods such as microneedles can address 
this problem. The use of MN offers substantial increase in the rates of drug delivery 
though skin. 
In fulfillment of the research goals, first, a simple mathematical model was developed for 
analysis of steady-state permeation data through MN-treated skin. The distinct feature of 
the model is that it recognizes the microchannels as a separate permeation pathway in 
parallel to the intact skin permeation pathway. Since the fractional skin surface area 
taken by the microchannel openings is very small the formation of microchannels 
practically does not affect the intact skin pathway. Hence, MN-treatment can be seen as 
a method of providing an additional permeation pathway through skin without affecting 
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an already existing one. In vitro diffusion studies with indomethacin demonstrated that 
the formation of microchannels increases percutaneous drug transport. The magnitude 
of flux enhancement depends on the donor solution solubility and permeability through 
both: intact skin pathway and microchannels pathway. The interplay between these 
factors determines the overall benefit of using MN. Former studies carried out with 
naltrexone and 6β-naltrexol provided similar results.  
Secondly, the effect of formulation on the rate of transdermal transport of NTX•HCl 
through MN-enhanced skin in vitro was investigated. It was found that flux correlated 
well with changes in drug diffusivity caused by donor viscosity variations. Also, it is likely 
that the microchannel pathway flux rather than total flux (combined microchannel 
pathway and intact skin pathway flux) correlates with viscosity changes of donor solution 
through the Stokes-Einstein equation. Moreover, this work indicated that percutaneous 
flux of charged species across intact skin may become important when large skin area is 
exposed to the drug formulation. These findings suggested that when maximum flux 
through MN-treated skin is sought then the viscosity of the formulation should be kept as 
low as possible. However, that restriction does not hold with respect to high molecular 
weight polymeric systems which don‘t seem to increase the diffusional resistance of the 
microchannel pathway. The selection of water-rich sheet hydrogel formulation proved 
the most successful in conjunction with MN-assisted transdermal drug transport. 
Approximately 5-fold increase in the transdermal flux was achieved as compared to the 
formerly employed formulation in the first-in-human MN study [216]. 
Next, in vitro permeation of a PEGylated NTX prodrug across MN-treated skin was 
investigated. It has been found that the flux did not proportionally increase when high 
concentrations of the prodrug in the donor solution were utilized. In other words, the 
apparent permeability coefficient was not a concentration-independent proportionality 
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constant between flux and drug concentration. It was hypothesized that this non-linearity 
was caused, again, by elevated viscosity of the donor media. Calculations based on the 
Stokes-Einstein equation afford a reasonable explanation of the experimental data. The 
generalization of the results obtained from the current study will require further 
investigation. It is not expected that the type of behavior seen in the present study will be 
universal for all MN-involving transport experiments as different methods of MN 
application, MN design and formulation characteristics play a significant role in the drug 
transport across MN-treated skin. In consequence, the generality of the present in vitro 
findings may be limited to the studies involving, among others, water-based 
formulations, MN-pretreated skin with microchannels having similar nature to those 
obtained in this study and permeants which cross the skin mainly through microchannels 
and underlying dermis, rather than through the intact skin around microchannels.  A 
great variety of other NTX prodrugs were tested in stability and solubility studies. The 
use of prodrugs to modify permeant physicochemical properties has been known to be a 
successful strategy to improve flux in a variety of cases. However, in the current project 
this goal was not achieved. Three major factors that have contributed to this result are 
the lack of adequate formulation stability, pronounced deviation from ideal behavior 
causing a non-linear flux increase as function of permeant concentration, and insufficient 
aqueous solubility. 
In the following step, the permeation and skin irritation potential of several NTX salts was 
studied. Three NTX salts (acetate, lactate and glycolate) demonstrated improved 
aqueous solubility at practically-relevant skin surface pH of 5.0 over that of NTX•HCl. 
Increased solubility of NTX glycolate, despite the non-ideal behavior, can be used to 
achieve approximately 50% increase in permeation across MN-treated skin. Moreover, 
the skin irritation-potential of naltrexone glycolate and lactate were found to be not 
greater than that of NTX•HCl in the guinea pig model implying that they can be safely 
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used on human skin. Overall, a new NTX glycolate salt was demonstrated to be a 
promising candidate for further testing and inclusion in a in vivo transdermal drug 
delivery system in conjunction with microneedle skin treatment.  
Finally, a mathematical model that would described in vivo NTX•HCl plasma profile after 
a ―poke and patch‖ method application was developed. This was achieved through the 
use of a combined diffusion-compartmental model. The critical elements incorporated 
into the model were the recognition of two parallel pathways for drug permeation after 
MN skin treatment (intact skin pathway and microchannel pathway), the barrier 
thickness-dependant diffusional resistance of microchannel pathway, direct relationship 
between electrical admittance of the microchannels and their permeability to drugs, and 
classic pharmacokinetic compartmental module for description of drug disposition and 
elimination from the body. Experimentally, NTX•HCl delivery in Yucatan minipig with a 
―poke and patch‖ method was studied and demonstrated an initial spike in drug plasma 
concentration followed by a rapid drop and a plateau. With majority of the model 
parameters estimated independently, the overall fit of the model to experimental data 
was good implying that it accounted for key processes related to MN-enhanced drug 
delivery in vivo. A 0.74 mm estimate for hypothetical dermis thickness separating a 
microchannel from dermis level at which an absolute clearance exists was obtained. Its 
relatively large value suggests that the effect of diffusional resistance of the dermis in 
vivo should not be ignored and must be accounted for in order to obtain a good in vitro-in 
vivo correlation. Based on the current study, it seems that the relatively fast rate of 
microchannel closure is the single major hurdle for obtaining a sustained-delivery drug 
profiles in vivo after a ―poke and patch‖ method. 
From a practical perspective, it is envisioned that future research efforts will primarily 
focus on the extension of microchannel lifetime so that a wider time window for NTX•HCl 
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delivery becomes available. A method that would enable the delay of the healing 
process and/or substantially decrease the rate of the microchannel closure has a great 
potential to add more value to the sustained delivery of drugs via microchannel pathway. 
Based on the present study, the rate of microchannel closure in vivo makes the use of 
the MN skin enhancement to attain high, sustained drug delivery over the period of 
several days difficult. However, a more optimistic human study is also known, which 
demonstrated a milder drop in the NTX•HCl concentration over time after MN-treatment 
[32]. It is anticipated that future research efforts will ultimately lead to longer sustained 
delivery of NTX•HCl, which is the end therapeutic goal. Moreover, it should be 
emphasized that the time window for drug delivery through microchannels, available at 
present, may be sufficient for other therapeutic indications without any further 
modifications. In various instances including: delivery of bolus-like dose of drug, shorter 
drug delivery time, or permeation of large-molecular-weight drugs (proteins) that are 
impermeable to untreated skin, microneedles present a distinct advantage and major 
delivery option. Apart from the ―poke and patch‖ method other modes of MN application 
have been described in details [7] and include MN coating, drug in MN, and injections 
through hollow MN. There is an array of clinical options for MN use [97]. For example, 
one of the most promising therapeutic areas employing MN, is vaccination [22, 23, 29, 
210, 275]. Due to the high potency of vaccines and presence of immunologically-
relevant Langerhans cells in skin microneedles provide a very convenient and 
hypodermic-needle-free medium for effective inoculation process. Likely, as research 
progress is made, even more clinical options will be unveiled. On the other hand, it is 
recognized that a more advanced mathematical model can further improve the 
understanding of the critical factors involved in the drug transport via ‖poke and patch‖ 
method. Overall, this work has introduced several concepts that may facilitate analysis of 
drug transport through MN-treated skin: parallel permeation pathways, relative 
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contributions of diffusional resistance of individual skin layers, influence of formulation 
viscosity on the rate of transport, recognition of link between electrical admittance and 
permeability of skin, and combination of the above factors with compartmental 
pharmacokinetic modeling to describe in vivo drug plasma levels. It is believed that 
these concepts can be further expanded and build upon to gain additional insight and 
increase the predictive power of the current model. 
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